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The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) 
signaling pathway is activated by numerous cytokines. JAK-STAT pathways involve 
in regulation of cell growth, proliferation, differentiation, apoptosis, angiogenesis, 
immunity and inflammatory response. Because of their significance in immune 
response, they are often targeted by pathogens, including porcine reproductive and 
respiratory syndrome virus (PRRSV). PRRSV causes reproductive failure in sows 
and severe respiratory disease in pigs of all ages. A typical feature of the immune 
response to PRRSV infection in pigs is delayed production and low titer of virus 
neutralizing antibodies, and weak cell-mediated immune response. One possible 
reason for the weak protective immune response is that PRRSV interferes with innate 
immunity and modulates cytokine signaling, including JAK-STAT pathways. The 
objective of this project was to elucidate the mechanisms of PRRSV interference with 
JAK-STAT2 and JAK-STAT3 signaling. This study demonstrates that PRRSV 
  
antagonizes interferon (IFN)-activated JAK-STAT2 signaling and oncostatin M 
(OSM)-activated JAK-STAT3 pathway via inducing STAT2 and STAT3 degradation. 
Mechanistically, PRRSV non-structural protein 11 (nsp11) and nsp5 induce the 
degradation of STAT2 and STAT3, respectively, via the ubiquitin-proteasome 
pathway. Notably, PRRSV manipulates karyopherin alpha 6 (KPNA6), an importin 
that is responsible for STAT3 nuclear translocation in the JAK-STAT signaling, to 
facilitate viral replication. Knockdown of KPNA6 expression led to significant 
reduction in PRRSV replication. These data demonstrate that PRRSV interferes with 
different JAK-STAT pathways to evade host antiviral response while harnessing 
cellular factors for its own replication. These findings provide new insights into 
PRRSV-cell interactions and its molecular pathogenesis in interference with the host 
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This dissertation is original and based on independent work conducted by the 
author Liping Yang under the supervision of Dr. Yanjin Zhang at the University of 
Maryland, College Park, MD from 2013 to 2018.  
There are seven chapters in the dissertation. The first three chapters focus on 
literature review of PRRSV, JAK-STAT signaling and nucleocytoplasmic trafficking 
system, respectively. The next three chapters present research results on PRRSV 
interference with JAK-STAT signaling and manipulation of KPNA6 for its own 
replication. The last chapter is conclusion and future perspectives. Other research has 
also been done during my Ph.D. studies but not included in this dissertation due to 
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Chapter 1: Porcine reproductive and respiratory syndrome virus 
Introduction 
Porcine reproductive and respiratory syndrome (PPRS) is a contagious disease, which leads to 
severe respiratory disorder, poor growth condition with weight loss in pigs of all ages, and reproductive 
failure in sows (1). PRRS has been the most costly viral disease for swine industry with an estimated 
annual loss of $664 million in the United States (2), and an average loss of 126 €/sow in Europe (3). The 
disease was first reported in 1987 in North America and soon recognized in Europe and other regions. 
The causative agent, PRRS virus (PRRSV), was first isolated and characterized in Europe in 1991, 
recently reclassified as species PRRSV-1, followed by successful isolation of a PRRSV-2 strain in the 
United States (4, 5). PRRSV remains highly prevalent in swine farms across the globe with a few 
exceptions like Australia and New Zealand, although PRRS vaccines have been widely used since the 
mid-1990s. Highly effective vaccines or antiviral drugs against PRRSV are still not available due to the 
meager protective immune response induced by PRRSV infection and the large genetic and antigenic 
variations among PRRSV strains. Therefore, more studies are needed to further characterize PRRSV 
biology, virus-cell interactions, pathogenesis and mechanisms of PRRSV evasion of the host immune 
response as well as interference with cell signaling to facilitate the development of improved vaccines or 
therapeutics for PRRS control.  
PRRSV classification 
PRRSV is a small, enveloped single-stranded positive-sense RNA virus with a particle size 
ranging from 50-80 nm. It belongs to the genus Porartevirus, the family Arteriviridae, the order 
Nidovirales (6). The Arteriviridae is composed of five genera: Dipartevirus, Equartevirus, Nesartevirus, 





hemorrhagic fever virus (SHFV, a member of Simartevirus), equine viral arteritis (EAV, a member of 
Equartevirus), and lactate dehydrogenase elevating virus (LDV, a member of Porartevirus). PRRSV 
strains are highly divergent. PRRSV has been well known to have two genotypes: Type 1 (European 
PRRSV, the prototype is Lelystad virus) and Type 2 (North American PRRSV, the prototype is VR-
2332). Recently, the two genotypes are reclassified into two species: PRRSV-1 and PRRSV-2 in the 
genus Porartevirus. The overall clinical signs, disease phenotype, virion structure, genomic 
organization, genetic elements, and replication cycle of PRRSV-1 and PRRSV-2 strains are all similar 
though they only share less than 60% genomic nucleotide identity (8). 
PRRSV morphology 
Electron microscopic (EM) studies show that purified extracellular PRRSV virions are mostly 
spherical or oval-shaped particles with smooth outer appearance, which are similar to other arteriviruses 
(9). The virion contains an isometric core with a mean diameter of 39 nm. Inside the core is PRRSV 
genomic RNA capsulated by nucleocapsid proteins with asymmetric and linear arrangement (10). Cryo- 
 
Fig. 1.1 Schematic illustration of PRRSV virion. Seven virion-associated proteins and genomic RNA in 
PRRSV are depicted: E, minor non-glycosylated membrane protein; GP2, GP3, and GP4, minor envelope 
glycoproteins; N: nucleocapsid protein; M: matrix protein; GP5, major envelope glycoprotein. 
 
EM displays the visible lipid bilayer of the envelope and shows its thickness is 4.5 nm, which may 





proteins. Moreover, there are 10-15 nm protrusions on the envelope. Based on the shape and size, the 
heterotrimer formed by GP2, GP3, and GP4 may account for the protrusions. The heterotrimer complex 
in the virion may play a critical role in the PRRSV binding and entry of target cells. The structure of 
PRRSV virion is schematically illustrated in Fig. 1.1. 
PRRSV genome 
PRRSV virion contains a linear, non-segmented single-stranded positive-sense RNA genome 
with a size of approximately 15 kb. The RNA genome carries a methylated cap at the 5’ end and a 
polyadenylated tail at the 3’ end. Over ten open reading frames (ORFs) have been identified in the 
PRRSV genome, illustrated in Fig. 1.2. About 80% of the PRRSV genome is composed of ORF1a and  
 
Fig. 1.2 Schematic illustration of PRRSV genome, transcription and translation. The open reading frames 
(ORFs), 5′ UTR, 3′ poly A tail (An), programmed ribosomal frameshift (PRF) of the ORF1a/1b are indicated on 
top row. Replicase polyproteins pp1a and pp1ab are translated from ORF1a and 1ab, respectively. The pp1a-
nsp2N and pp1a-nsp2TF are generated transcripts by -1 and -2 PRF, respectively. These polyproteins are cleaved 
to generate at least 14 nonstructural proteins (indicated by arrows) by viral proteinases. Structural proteins and 
subgenomic RNAs are also depicted.  
 





frameshift (PRF) signal in the ORF1a/ORF1b overlap area. Then they are proteolytically cleaved into 14 
nonstructural proteins (nsps) from nsp1α to nsp12 by viral proteases (11). Nsp1, nsp2, and nsp4 are three 
different proteases. Both nsp1 and nsp2 contain a papain-like cysteine protease domain, and nsp4 is a 
3C-like serine protease. Nsp3 and nsp5 are transmembrane proteins. It has been demonstrated that nsp9 
encodes the viral RNA-dependent RNA polymerase (RdRp) and nsp10 is a helicase, which are 
responsible for the viral genome replication and transcription (11). Nsp11 has been shown to play a 
critical role in the replication cycle of all arteriviruses due to its endoribonuclease domain (12). In 
addition, nsp1β is a transactivator to induce -2/-1 PRF in nsp2, leading to the expression of two novel 
proteins: nsp2TF and nsp2N (13, 14). These two proteins have been demonstrated to be important in 
inhibiting the host innate immune response (15). 
Structural proteins are encoded by ORFs 2-7 located at the 3’ end of the PRRSV genome (16-
18). ORFs 2, 3, and 4 encode minor membrane-associated proteins GP2, GP3, and GP4, respectively. 
These proteins interact with each other to assemble as a heterotrimeric complex, which plays a role in 
viral entry (19). ORF2b, a small ORF embedded in ORF2 sequence in a different reading frame, 
encodes a 10-kDa, non-glycosylated protein named E (18). ORF5 encodes the major envelope 
glycoprotein (GP5), which interacts with the matrix protein (M) encoded by ORF6, forming a 
heterodimer. It is believed that the heterodimer is critical in PRRSV attachment and internalization (11). 
ORF7 encodes N protein that is associated with PRRSV genomic RNA to form the nucleocapsid (16). 
GP5, M, and N are the major components of the viral particles. Furthermore, a polypeptide of 51 amino 
acids encoded by ORF5a is referred as the ORF5a protein, which is highly conserved among diverse 
PRRSV strains (20). 
PRRSV tropism 
Pig is the only known natural host for PRRSV infection. PRRSV has a very restricted cell 





monocyte/macrophage lineage, mainly pulmonary alveolar macrophages (PAMs) (21). PAMs are 
important effector immune cells of the innate immune system against invading pathogens in lung (22).  
Some studies show that monocyte-derived dendritic cells (MDDCs) and bone marrow-derived 
immature dendritic cells (BM-imDCs) are susceptible to PRRSV infection (23, 24). However, the 
primary lung dendritic cells (L-DCs) are not permissive to PRRSV (25). Even though MDDCs share 
many common features of primary DCs, they still preserve certain original characteristics of monocytes 
which contribute to their susceptibility to PRRSV (26). Therefore, further studies are required to 
investigate the permissibility of DCs on PRRSV infection. Moreover, during the persistence of PRRSV 
infection, tonsils, lungs, and lymphoid organs are the major source of viral RNA in pigs (27). 
In vitro, the African green monkey kidney cell MA-104 and its derivatives MARC-145, CL-
2621, and CRL11171 are used to propagate PRRSV and explore the interaction between PRRSV and 
host cells (5, 28, 29). Immortalized PAMs and other porcine-derived cells such as PK15 with 
overexpression of CD163, the main PRRSV receptor, have been used for PRRSV propagation. BHK21 
with overexpression of CD163 has been used for PRRSV proliferation and vaccine production (30).  
PRRSV replication cycle 
PRRSV entry 
The restricted cell tropism of PRRSV is attributed to some entry factors in the host cells, because 
some non-permissive cell lines could support the replication of PRRSV once they are transfected with 
the infectious cDNA clone (31). Several cellular proteins that play roles in PRRSV entry have been 
identified. 
The first identified entry factor for PRRSV is heparin-like molecules (32). Incubation of PRRSV 
with heparin prior to infecting the cells inhibits the viral infection. Moreover, treating the host cells with 





role of heparin-like molecules on PRRSV entry. In 2002, heparan sulfate proteoglycans were identified 
in binding with M/GP5 protein complex of PRRSV to mediate PRRSV entry into PAM cells (33). 
However, heparan sulfate proteoglycans are present on the surface of most mammalian cells, 
including monocytes/macrophages. Moreover, incubation of PRRSV with heparin or heparan sulphate 
could not completely block PRRSV infection. These findings indicate that other host factors are 
associated with facilitating PRRSV attachment and entry into the host cells (34). 
Sialoadhesin (CD169) was then identified by immunoprecipitation using the antibody that could 
block PRRSV infection (35-37). Sialoadhesin is a transmembrane glycoprotein on the surface of 
macrophages, and belongs to the siglecs family of sialic acid-binding lectins (38). Sialoadhesin was 
demonstrated to promote the internalization of PRRSV by interacting with M/GP5 complex (39), 
followed by clathrin-mediated endocytosis (40). However, overexpression of porcine sialoadhesin in 
unsusceptible cells does not support uncoating, genomic RNA release, and efficient infection, which 
suggests additional macrophage-specific entry factors are required for PRRSV infection (37). 
Other critical entry mediators were not reported until 2007 (30). The overexpression of 
transmembrane glycoprotein CD163 makes the non-permissive cells be susceptible to PRRSV. 
Incubation of host cells with CD163-specific antibody at 37 °C, but not at 4 °C, inhibits PRRSV 
infection dramatically, indicating that CD163 is not involved in the attachment of PRRSV on the cell 
surface but later steps (41). The experiment with the presence or absence of sialoadhesin demonstrated 
that sialoadhesin is responsible for the attachment and internalization of PRRSV virions, while CD163 is 
critical for the capsid uncoating and genomic RNA release, both of which are crucial for the productive 







After entering the cells via clathrin-mediated endocytosis, PRRSV releases the viral genomic 
RNA into the cytoplasm following the fusion of viral envelope with the endosomal membrane and 
uncoating of nucleocapsid by endosome acidification. The genomic RNA is directly translated into the  
 
 
Fig. 1.3 Schematic illustration of PRRSV replication cycle. PRRSV enters cells by receptor-mediated 
endocytosis and releases its genomic RNA into the cytoplasm by endosome acidification. After translation and 
cleavage, nsp2, nsp3 and nsp5 induce ER membrane rearrangement to form double-membrane vesicles (DMV) 
for double-stranded (ds) RNA synthesis. The newly synthesized viral genome and structural proteins encoded by 
sub-genomic RNAs assemble into new virions, followed by budding, and maturation, and release via exocytosis 
or cell lysis.  
 
 
replicase polyproteins pp1a and pp1ab, generating individual non-structural proteins by proteolytic 
cleavage. The membrane-associated nsps including nsp2, nsp3, and nsp5 induce the membrane 
rearrangement of endoplasmic reticulum (ER) to form double-membrane vesicles (DMV), which is also 





efficiency of viral replication and evades the cellular pattern recognition receptors and consequent 
antiviral response.  
The RTC allows the synthesis of new genomic RNA and minus-strand RNA, which is used as 
the template for the generation of sub-genomic RNAs (sgRNAs) to express structural proteins. The 
sgRNAs are composed of the identical 5′ leader sequence derived from the 5′ untranslated region (UTR) 
of viral genomic RNA, and a common 3′-poly(A) tail, to form a 5′- and 3′-coterminal nested set of 
transcripts (44). The individual ORFs that encode the viral structural proteins have partially overlapping 
sequences in different frames and located at the 3′ end of the PRRSV genome. It has been demonstrated 
that the nested set sgRNAs are generated by discontinuous transcription during the synthesis of minus-
strand RNAs, mediated by specific RNA signals, transcription-regulatory sequences (TRS) (45). Each 
sgRNA expresses at least the first ORF for a structural protein (Fig. 1.2). The newly synthesized viral 
genome and structural proteins assemble into new virions through encapsidation, budding, and 
maturation before released via exocytosis or cell lysis (46). The replication cycle of PRRSV is illustrated 
in Fig. 1.3. 
PRRSV pathogenesis 
PRRS causes reproductive disease manifested as a high abortion rate, premature or delayed 
farrowing, and the increasing number of mummified, stillborn and weak-born piglets. Inappetence, 
reluctance to drink and agalactia occurring during the farrowing and lactating period, resulting in 
increased mortality of suckling piglets. PRRSV infection also causes postweaning respiratory disease. 
The infected suckling piglets develop severe macroscopic lung lesions. Histopathologic examination and 
microscopic lesions analysis show necrotizing interstitial pneumonia, arteritis, encephalitis, and 
myocarditis (47, 48).  
PRRSV infection is also characterized by prolonged viremia up to one month followed by 





have shown that subclinical PRRSV infection persists in pigs (50). PRRSV uses a variety of strategies to 
antagonize the host immune responses, which results in the prolonged viremia and persistent infection. 
Therefore, persistent infection of PRRSV plays a critical role in PRRSV survival and transmission, and 
becomes a big challenge in PRRS control. Typical features of the immune responses to PRRSV 
infection in pigs include delayed production and low titer of virus neutralizing antibodies and weak cell-
mediated immune response (51, 52). 
PRRSV effect on apoptosis and autophagy 
Programmed cell death (PCD) is considered as one of the first line host defense strategies against 
viral infection. Different from the innate and adaptive immunity effectors, PCD is cellular-based and its 
effectors are generally expressed constitutively, not relying on virus-stimulated signaling (53).  
Apoptosis is a well-known form of PCD mediated by intracellular programs. It is a highly 
regulated and controlled process during growth and development for maintenance of a homeostatic 
condition in tissues. Apoptosis occurs once cells are damaged by pathogens or toxins in order to 
eliminate the unhealthy cells and the invasive pathogens (54). 
During the early phase of apoptosis, cell shrinkage is visible under microscope, followed by 
pyknosis resulting from chromatin condensation which is the most typical feature of apoptosis. The 
shrank cells are divided into apoptotic bodies by the blebbing of the plasma membrane during a process 
named “budding” (54). Phagocytic cells then phagocytose the apoptotic bodies to avoid the unnecessary 
damage of surrounding cells. 
Autophagy is a conserved, regulated, and destructive metabolic process to maintain cellular 
homeostasis by disassembling, degrading, and recycling dysfunctional, damaged, or unnecessary cellular 
components, such as damaged organelles and protein aggregates (55). Autophagy has distinct roles 
under various cellular conditions. In response to nutrient deficiency, autophagy is induced to ensure cell 





tuberculosis. Stimulation of autophagy could defeat the pathogen by inducing the maturation of 
phagolysosome (56). However, excessive autophagy can cause cell death morphologically different 
from apoptosis.  
Since apoptosis can eliminate virus or limit viral infection by destructing viral infected cells, and 
autophagy can devastate the intracellular pathogens, many pathogens especially viruses including 
PRRSV have evolved to evade or even take advantage of these processes for their survival and infection. 
In its initial phase of infection, PRRSV has been reported to induce anti-apoptotic activity. GP2 
protein has been shown to delay the process of apoptosis by modulating transcription factors nuclear 
factor κB (NF-κB) and activation protein 1 (AP-1) (57). On the other hand, PRRSV activates 
phosphatidylinositol-3-kinase (PI3K)/Akt1 signaling for the phosphorylation of BAD, a pro-apoptotic 
protein, in order to delay apoptosis (58). Moreover, inhibition of autophagy by 3-methyladenine (3-MA) 
resulted in a significant increase of apoptosis induced by PRRSV, indicating a potential link between 
autophagy and apoptosis (59).	PRRSV also facilitates the interaction between BAD and Beclin1, an 
autophagy regulator, to postpone apoptosis. In summary, inhibition of apoptotic cell death provides 
PRRSV enough time for replication, assembly and the generation of large quantities of progeny virions. 
Nuclear condensation, DNA fragmentation, and PARP cleavage normally occur in PRRSV-
infected cells between 36 to 48 hours post infection (hpi) in vitro, indicating that PRRSV can induce 
apoptosis at late stage (60). Furthermore, both intrinsic and extrinsic pathways are involved in the 
apoptotic activity induced by PRRSV. The inhibition of reactive oxygen species (ROS) has been shown 
to suppress the cleavage of PRRSV infection-induced PARP, which indicates that ROS could serve as 
an inducer of apoptosis through the intrinsic pathway during PRRSV infection (61). PRRSV infection 
disrupts the membrane of mitochondria by upregulating Bax protein to release cytochrome c, followed 
by caspase-9 activation. In addition, tumor necrosis factor (TNF)-α (62) and GP5 (63) released from 





in vivo. GP5 can enhance caspase 3 activity to induce apoptosis in vitro (64). E protein has been 
demonstrated to induce apoptosis through interacting with mitochondrial proteins ATP5A to suppress 
the production of ATP (65). Moreover, nsp4 and nsp10 are capable of triggering apoptotic process by 
activating the pro-apoptotic proteins Bim and Bid, respectively (66). In addition, nsp5 has been shown to 
induce autophagy by some unknown mechanism (67). 
In conclusion, PRRSV is able to manipulate and take advantage of the host machineries for its 
own replication and survival through inducing anti-apoptotic, autophagic, and pro-apoptotic activities in 
different context. However, the interplay between PRRSV and apoptosis/autophagy is so complicated 
that more studies are needed to examine the mechanisms in whole virus infection in vivo and in vitro.  
PRRSV inhibits the host innate immune response 
The innate immunity is the early line host defense to prevent, control, and eliminate infections by 
pathogens. Innate immune responses are immediate and do not require prior exposure to the pathogens. 
The host innate immune system consists of three major components: (1) physical and chemical barriers 
such as skin and the gastrointestinal and respiratory tracts; (2) phagocytic cells, dendritic cells (DCs), 
natural killer (NK) cells, and other innate lymphoid cells; and (3) cell-free soluble factors, including the 
inflammatory cytokines and the complement system (68). Cytokines are a broad and loose category of 
small secreted proteins with a variety of structures and functions. Cytokines that are produced at the site 
of infection stimulate and coordinate the innate and adaptive immunity against invading pathogens. 
They act through their specific receptors on the surface of target cells, followed by cascades of 
intracellular signaling.  
The innate immunity protects the host against viruses through two major types of responses: 
antiviral defense and inflammation, initiated by host pattern-recognition receptors (PRRs). PRRs are 
expressed in innate immune cells, such as DCs and macrophages, and other types of cells (69). PRRs 





distinct from cellular nucleic acids. Upon interaction with the viral PAMPs, PRRs initiate signal 
transduction pathways to activate the production of interferons and proinflammatory cytokines (70, 71).  
Toll-like receptors 
In mammalian cells, there are several distinct classes of cellular PRRs that differ in their 
structure, specificity for different PAMPs, and functions. Among the PRRs, Toll-like receptors (TLRs) 
are the best characterized. TLRs are type I integral transmembrane glycoproteins and expressed on many 
cell types. TLRs contain leucine-rich repeats (LRR) and cysteine-rich motifs in their extracellular 
portion for ligand binding, and a Toll/interleukin-1 receptor (TIR) homology domain in the cytoplasmic 
regions involved in intracellular signaling cascades (72). More than ten different functional TLRs in 
human and murine cells have been reported and are named as TLR1 through TLR10 (73-77). Different 
TLRs recognize distinct ligands with diverse structures covering all molecules derived from 
microorganisms. For virus recognition, TLRs 3, 7, 8, and 9 play critical roles, which are expressed on 
the membrane of intracellular compartments, such as endosomes, where they detect nucleic acids from 
microbial source. TLR3 interacts with dsRNA (78), whereas, TLR7 and TLR8 recognizes single-
stranded viral RNA (ssRNA) (79). TLR9 detects the unmethylated CpG DNA of bacterial or viral 
genomes (75).  
The recognition of PAMPs leads to the dimerization of TLRs, followed by recruitment of TIR 
domain-containing adaptor proteins including MYD88, TRIF, TIRAP, and TRAM (80). Then the 
complexes further recruit and activate multiple protein kinases to induce the activation of various 
transcription factors such as NF-κB, AP1, interferon regulatory factor 3 (IRF3), and IRF7 (81, 82). The 
activated transcription factors translocate into the nucleus to promote the transcription of genes for 
antiviral and inflammatory response. NF-κB and AP-1 control the expression of inflammatory cytokines, 





CCL2, and CD80 (81). IRF3 and IRF7 are critical factors in producing type I interferons (IFN-α and 
IFN-β), the key mediators in host immune response against viral infection (83). 
RIG-I-like receptors 
Besides TLR3, 7, 8, and 9 who are membrane-associated receptors, RIG-I-like receptors (RLRs) 
also recognize virus nucleic acids but by acting as the cytosolic sensors. RLRs recognize dsRNA and 
ssRNA of RNA viruses. RIG-I (retinoic acid–inducible gene I) and MDA5 (melanoma differentiation-
associated gene 5) are two of the well-studied RLRs (84, 85). Both RIG-I and MDA-5 contain two 
tandem N-terminal caspase-recruiting domains (CARDs), a DExD/H-box helicase domain, and a C-
terminal domain (CTD).	The CARDs are required for interacting and activating downstream signaling 
proteins, and the helicase domain is responsible for recognizing viral nucleic acids (86). RIG-I and 
MDA5 recognize complementary sets of viral ribonucleic acids. RIG-I typically recognizes short 5′-
triphosphorylated or 5′-diphosphorylated blunt ends of viral ssRNA or dsRNA, whereas MDA5 is 
activated by long dsRNA with no end specificity (87). Laboratory of genetics and physiology 2 (LGP2), 
another member of RLR family, also binds with dsRNA but lacks CARD for signaling transduction. 
Therefore, LGP2 is suggested to be a negative regulator by sequestering dsRNA from RLRs (88).  
After recognition of the ligands, RIG-I and MDA5 are ubiquitinated with lysine 63 (K63)-linked 
polyubiquitin chains to the CARDs via the E3 ubiquitin ligases (89). This modification leads to their 
homotetramerization and activating mitochondrial antiviral signaling protein (MAVS) on the 
mitochondrial membrane (90). MAVS is then dimerized and associated with multiple adaptor proteins 
such as TRADD, Tumor Necrosis Factor Receptor-associated Factor (TRAF)-2, TRAF-6, and TRAF-3 
(91), followed by recruiting TRAF family member-associated NF-κB activator (TANK) and NAK-
associated protein 1 (NAP1) (92) to induce the activation of TANK-binding kinase 1 (TBK1), IκB 
kinase epsilon (IKKε), and a DEAD box helicase DDX3 (93). These kinases phosphorylate IRF3 and 





the production of type I IFNs. MAVS also interacts with Fas-associated-death-domain (FADD) and 
receptor interacting protein 1 (RIP1) to activate the NF-κB pathway for expression of pro-inflammatory 
cytokines (94). 
Nod-like receptors 
NOD (nucleotide oligomerization domain-containing protein)-like receptors (NLRs) are a 
specialized group of cytosolic receptors recognizing PAMPs and other danger signals for activation of 
inflammatory signaling pathways (95).  
The NLR family consists of 22 different proteins in human and at least 33 genes in mice. Typical 
NLR proteins are defined by a tripartite structure composed of three different domains with distinct 
functions. The sensor domain is a C-terminal LRR similar with TLR, which is responsible for sensing 
and interacting with the ligands. NOD domain locates in the middle and mediates oligomerization with 
another NLR during activation. There are four different NLR subfamilies named NLRA, NLRB, NLRC, 
and NLRP, based on their different N-terminal effector domains: acidic transactivating domain, 
baculovirus inhibitor repeat (BIR) domain, CARD, and pyrin domain (PYD), respectively (96). NOD9, 
localizing in the mitochondria, is called NLRX1 due to its weak homology to any of the four effector 
domains (97). 
Among NLRs, NLRP3 is the best-characterized sensor for viral nucleic acids including viral 
RNA, dsRNA, and viral DNA (98-100). Once binding with a ligand, multiple identical NLRP3 proteins 
could undergo self-oligomerization, followed by recruitment of an adaptor protein called ASC (adaptor 
protein apoptosis speck protein with caspase recruitment) (101). ASC in turn interacts with an inactive 
precursor form of the enzyme caspase-1 (pro-caspase-1) via the CARD on both proteins. After 
recruitment to the inflammasome complex formed by NLRs, caspase-1 becomes active and further 
cleaves pro-IL-1β and pro-IL-18 into their active and mature forms for stimulating various pro-





Type I IFNs 
IFNs are major components of the antiviral innate immunity and have diverse biological 
functions including antiviral activity, anti-proliferative activity, stimulation of T cell cytotoxic activity, 
and modulation of the immune response. There are three types of interferons. Type I IFNs include IFN-
α, IFN-β, IFN-ε, IFN-κ, and IFN-ω in humans. IFN-δ, IFN-τ and IFN-ζ (or Limitin) have been identified 
as type I IFNs in swine, ruminant and mice, respectively. IFN-γ produced by activated T-cells and 
natural killer cells is the only member of Type II IFN. IFN-γ not only enhances the effects of type I 
IFNs, but also involves in the regulation of the immune and inflammatory responses. The recently 
discovered type III IFNs are composed of four IFN-λ molecules called IFN-λ1, IFN-λ2, IFN-λ3 (103) 
and IFN-λ4 (104). It has been demonstrated that IFN-λ can be induced by viruses (105) and stimulates a 
type I IFN-like response through JAK-STAT pathway (106). 
The induction of type I IFNs is the major approach by which the innate immune system defends 
against viral infection through the signaling of TLRs, RLRs, and DNA sensors. Type I IFNs are the 
largest IFN class, in which IFN-α and IFN-β are the most important factors in antiviral defense. The 
specific binding of IFN-α and IFN-β to IFN-α receptor (IFNAR), consisting of IFNAR1 and IFNAR2 
chains on cell surface, triggers phosphorylation of JAK1 and tyrosine kinase 2 (TYK2), which are pre-
associated with the cytoplasmic tails of the receptors. Activated JAK1 and TYK2 in turn phosphorylate 
the specific intracellular tyrosine residues of the receptors, creating docking sites for STAT1 and STAT2 
for further activation. Phosphorylated STAT1 and STAT2 form a heterodimer, followed by interacting 
with interferon regulatory factor 9 (IRF9) to form a complex known as interferon-stimulated gene factor 
3 (ISGF3) (107). The ISGF3 complex translocate into the nucleus to induce the transcription of genes 
regulated by interferon-stimulated response element (ISRE), followed by the expression of interferon-









Fig. 1.4 Schematic illustration of type I IFN induction and signaling. Once +ssRNA virus enters into the host 
cells, viral-derived dsRNAs are recognized by pattern-recognition receptors, including TLR3 in the endosome, 
and RIG-I/MDA5 in the cytosol, resulting in activation and nuclear translocation of IRF3, IRF7, and NF-κB. 
Then type I IFNs are synthesized and released. They bind to the type I IFN receptor IFNAR-1 and IFNAR-2 on 
the cell membrane and activate the JAK-STAT1/STAT2 pathway. The phosphorylated STAT1 and STAT2 form 
heterodimer, followed by interaction with IRF9 to form interferon-stimulated gene factor 3 (ISGF3). Karyopherin 
α1 (KPNA1), an adaptor protein binding ISGF3, is essential to mediate the nuclear import of ISGF3 via 
interaction with karyopherin β1 (KPNB1). The ISGF3 binds to interferon-stimulated response element (ISRE) in 
DNA to activate transcription of interferon-stimulated genes (ISGs). “P” besides STATs indicates 
phosphorylation. 
 
PRRSV evasion of innate immunity 
PRRSV has developed multiple strategies to evade immunological surveillance, especially by 
disturbing host innate immune response through different viral proteins.  
Nsp1:	an	antagonist	of	type	I	IFN	production	and	signaling	
Located in the amino (N)-terminal of pp1a, nsp1 is the first PRRSV protein synthesized in 





and nsp1β. Both of them contain a papain-like cysteine protease (PCP) domain (PCPα and PCPβ) 
indispensable for their self-cleavage. PCPα by nsp1α is responsible for releasing itself from nsp1β at the 
site of 180M↓A181, while PCPβ allows the cleavage at 383G↓A384 between nsp1β and its neighbor 
nsp2 to generate nsp1β (108). It has been reported that PCPα activity is required for PRRSV sgRNA 
synthesis but not related to genome replication (109).  In contrast, inactivation of PCPβ blocks viral 
RNA synthesis completely. For EAV, controlling the abundance of mRNAs to balance the genome 
replication and sgRNA synthesis involves all domains of nsp1 (110). Moreover, some arterivirus nsp1 
mutations independent from either genome replication or sgRNA transcription inhibit the generation of 
infectious progeny virions (111). In this case, nsp1 plays key roles in multiple steps in the arterivirus life 
cycle including polyprotein cleavage, sgRNA transcription, and virion biogenesis. 
The crystal structure of nsp1α shows that it also contains an N-terminal zinc finger (ZF) domain 
(amino acids (aa) 1-65) and a C-terminal extension (CTE) (aa 167-180), with PCPα domain in the 
middle (aa 66-166) containing a ZF motif (112). The ZF domain is critical for viral replication through 
combining the sgRNA synthesis together with replicase expression during nidovirus replication (113). 
Moreover, the DNA-binding ability of the ZF domain in nsp1α also facilitates the inhibition of IFN-β 
production (114). In addition, the ZF domain might participate in IFN suppression as its mutants cannot 
translocate to the nucleus and disrupt the binding of CREB-binding protein (CBP) with IRF3 through 
inducing the degradation of CBP (115, 116). On the other hand, the PCPα domain and CTE are 
suggested to be essential for IFN-β inhibition and suppression of NF-κB activation (117). Recently, 
nsp1α is reported to inhibit NF-κB signaling by interacting with HOIP, one catalytic subunit of the linear 
ubiquitin chain assembly complex, and reduce the linear ubiquitination of NF-κB essential modulator 
(NEMO)  (118). 
Nsp1β is also a strong IFN antagonist. Nsp1β inhibits the phosphorylation and nuclear 





It also inhibits Sendai virus-mediated porcine IFN-β promoter activation in a porcine monocytic cell 
line. In addition, nsp1β has been shown to block STAT1/STAT2 nuclear translocation via inducing 
karyopherin-α1 (KPNA1) degradation for the inhibition of type I IFN-activated downstream signaling 
(120, 121).  
Nsp2:	the	most	variable	PRRSV	protein	
PRRSV nsp2 is the largest PRRSV protein encoded by 21 to 23% contents of the genome. It 
contains an N-terminal conserved putative cysteine protease domain (PLP2), a hypervariable (HV) 
region of 500-700 amino acids, and a transmembrane domain near the C-terminal tail (122). The PLP2 
domain possesses both papain- and chymotrypsin-like cysteine protease catalytic abilities (123), which 
allows nsp2 releasing itself from pp1a/pp1ab polyprotein by its trans- and cis-cleavage features (124). 
Nsp2 is also proposed to serve as a co-factor for nsp4 protease to cleave nsp4/5 junction when 
processing nsp3-8 fragment (125). The PLP2 domain has been also identified to be a member of 
mammalian ovarian tumor domain (OTU) family of deubiquitinating enzymes (DUBs) (126-128). 
Moreover, studies based on immunoelectron microscopy and Western blot assay reveal that nsp2 is 
present in mature PRRSV particles with multiple forms (129). 
Though PRRSV nsp2 features important enzymatic functions, it has been shown to be highly 
variable and heterogeneous due to the HV region. Spontaneous insertions, deletions, and mutations are 
common in the HV region among different PRRSV strains. The high-level variability in nsp2 indicates 
that it has nonessential sequence for virus replication. Consequently, GFP recombinant virus by 
inserting GFP gene into nsp2 region has been constructed (122). In addition, nsp2 is possibly an 
indicator for PRRSV genetic variation and can be used for differential diagnosis. 
Recently, it was revealed that nsp2 is associated with the modulation of the host immune 
responses. A deletion of one immunodominant B-cell epitope ES3 enhances the cytolytic activity of 





of IL-1β and TNF-α in macrophages and peripheral blood mononuclear cells (PBMCs) compared with 
its parental virus. These results indicate that some regions of nsp2 are dispensable for PRRSV 
replication but might play a role in modulation of the host immune response. In addition, with the DUB 
function, nsp2 suppresses ISG15 production and conjugation (131, 132). The DUB domain also 
interferes with the degradation of IκBα via preventing its polyubiquitination, which consequently 
inhibits NF-κB activation (133). The newly identified proteins nsp2TF and nsp2N that are generated via 
the -2/-1 ribosomal frameshifting in nsp2 region are also shown to interfere with the host immune 
response (15). On the other hand, nsp2 is involved in the formation of DMV via inducing host cell 
membrane rearrangement together with nsp3 and nsp5 (12, 42).  
Nsp4:	the	main	protease		
Following the auto-proteolytic release of three N-terminal proteases: nsp1α, nsp1β and nsp2, the 
main protease nsp4 is released with simultaneous generation of nsp3 through self-cleavage. Nsp4 
subsequently cleaves the remaining pp1a and pp1ab polyproteins and facilitate the release of nsp5 to 12 
(134). Nsp4 belongs to the 3C-like serine protease (3CLSP) group, which combines the substrate 
specificity of the 3C-like cysteine proteases and the catalytic triad of the chymotrypsin-like proteases. 
Crystal structures reveal that nsp4 contains a unique C-terminal domain which is essential for its 
proteolytic activity, and this critical domain is connected to the typical chymotrypsin-like two-β-barrel 
structures (135). 
Nsp4 not only functions as the main protease, but also acts as an antagonist of the host innate 
immune response. For example, PRRSV nsp4 has been shown to suppress NF-κB-mediated IFN-β 
production by cleaving the NEMO at the E349-S350 site (136). Moreover, the nsp4 of highly-
pathogenic (HP)-PRRSV has recently been revealed to undermine type I IFN response by cleaving 
MAVS and releasing MAVS from mitochondrial membrane (137). Also, the localization in the nucleus 






Arterivirus nsp5, a transmembrane protein, is highly hydrophobic and is thought to be involved 
in the induction of membrane rearrangement to form the replication and transcription complex together 
with nsp2 and nsp3 (12, 139). Nsp5 induces autophagic cell death when overexpressed alone (67). 
Moreover, nsp5 has been implicated in the induction of IFN-γ (140). 
Nsp11:	the	endoribonuclease		
PRRSV nsp11 contains a nidovirus uridylate-specific endoribonuclease (NendoU) domain, 
which is conserved in all nidoviruses and indispensable for arterivirus replication (141). NendoU, 
similar to the endoribonuclease XendoU in eukaryotes, has been demonstrated to cleave 5’ uridine 
nucleotides of RNA substrates to generate a 2’-3’-cyclic phosphate end product (142, 143). According to 
the crystal structure analysis (144), nsp11 has three different domains including N-terminal domain, 
linker domain and C-terminal domain. The C-terminal domain is the endoribonuclease domain. Nsp11 
exists as a dimer with the N-terminal domain of one molecule interacting with the C-terminal domain of 
the other molecule.  Recently, nsp11 is reported to have DUB activity, which facilitates the perturbation 
of NF-κB activation (145) and interacts with the cellular deubiquitinase OTULIN (146) when 
overexpressed alone. However, the crystal structure analysis (144) does not support this as there is no 
DUB domain is identified. It is most likely that nsp11 interacts with the cellular deubiquitinase OTULIN 
and exerts the reported function in NF-κB inhibition. Further work using infectious cDNA clone is 
needed to verify the finding.  
 PRRSV nsp11 is also an IFN antagonist by promoting the degradation of MAVS and RIG-I 
mRNA through its endoribonuclease domain (147-149). Additionally, the endoribonuclease activity of 
nsp11 inhibits lipopolysaccharide (LPS)-mediated NLRP3 inflammasome in PAM cells through the 






The N protein is a major structural protein with multiple functions. N protein is the only protein 
component of the viral capsid encapsidating the viral RNA genome via covalent and non-covalent self-
interactions (151). Phosphorylation of N proteins are common for nidoviruses but with unknown 
function and importance (152). Similar to other +ssRNA viruses, PRRSV replicates in the cytoplasm, 
but N protein can localize at the nucleolus (153). Sequence analysis shows that N protein contains two 
classic nuclear localization signals (NLS), NLS-1 and NLS-2, among which NLS-2 is essential and 
sufficient for the localization of N protein in the nucleolus. Currently, there are some hypotheses 
attempting to explain why the nucleocapsid protein of some +ssRNA viruses enters into the nucleolus: 
1. By localizing in the nucleolus, N protein can modulate the function of nucleolus such as rRNA 
synthesis and regulation of cell cycle to optimize virus replication. 2. It is a host cell defensive strategy 
to accumulate N protein in the nucleolus to inhibit viral assembly, whereas virus produces more N and 
incorporates NES in N protein to surmount this strategy (154-156). 
In addition, N protein has been reported to disturb dsRNA-mediated phosphorylation and nuclear 
translocation of IRF3 to inhibit type I IFN induction (157). N protein was also shown to inhibit the 
expression of IFN-activated ISRE reporter expression via blocking the nuclear translocation of STAT1 
(158). On the other hand, N protein stimulates DNA-binding activity of NF-κB to induce the expression 
of NF-κB-responsive genes, indicating that N protein might participate in PRRSV-induced inflammatory 
response (159). 
Other mechanisms PRRSV utilizes to evade host innate immune response 
PRRSV has also been found to inhibit poly(I:C)-mediated phosphorylation of PKR in PAM cells 
during the early stage of infection, leading to lower phosphorylation of eIF2α, a translation initiator, and 
consequently evading the PKR’s antiviral function. Structural components of PRRSV virions appear to 
be required for the inhibition as inactivated virus also shows the inhibition (160). High PRRSV burden 





burden pigs, which has the ability to antagonize JAK-STAT signaling pathway (161). Recently, PRRSV 
was reported to elevate a host microRNA, miR-30c, via activating NF-κB (162). The miR-30c is shown 
to negatively regulate type I IFN signaling by targeting JAK1. In addition, PRRSV induces the 
expression of miR-373 to facilitate viral replication and inhibit the production of IFN-β (163). 
Moreover, nsp7, nsp12, and GP3 have been shown to antagonize IFN-activated signaling (158). The 
interference with type I IFN induction and downstream signaling by PRRSV is illustrated in Fig. 1.5.  
 
 
Fig. 1.5 PRRSV Interference with type I IFN induction and signaling. For IFN induction, PRRSV nsp1α 
inhibits NF-κB signaling and IFN promoter activation. Nsp1β and N protein inhibit the phosphorylation and 
nuclear translocation of IRF3. Nsp2 and nsp11 interfere with the degradation of IκBα via preventing its 
polyubiquitination. Nsp4 suppresses NF-κB and MAVS-mediated IFN-β production by cleaving NEMO and 
MAVS, respectively. Nsp11 also induces RIG-I and MDA-5 RNA degradation. For IFN downstream signaling, 
PRRSV nsp1β inhibits ISGF3 nuclear translocation via inducing degradation of KPNA1. PRRSV N protein also 
inhibits ISGF3 nuclear translocation. PRRSV nsp2 reduces ISG15 production and conjugation via its 
deubiquitination activity. PRRSV induces elevation of miRNA miR-30c to downregulate JAK1 and SOCS1 to 
inhibit JAKs. PRRSV inhibits PKR during its early infection of pulmonary alveolar macrophages.  
 
PRRSV infection also stimulates the translocation and secretion of the high mobility group box 1 





normal cells but induces the inflammatory response via TLR2/4 when released out of the cells (166). 
PRRSV E and ORF5a proteins are responsible for the PKCδ activation. 
PRRSV modulates the host adaptive immune response 
Different from the innate immunity, the adaptive immunity is highly specific and can provide 
long-lasting protection to a particular pathogen. Moreover, immunological memory cells are generated 
after the primary exposure to a foreign antigen and generally mount a recall response of greater 
magnitude with faster kinetics. There are two types of adaptive immune response: humoral immunity 
and cell-mediated immunity. 
Humoral immunity is mediated by B lymphocytes, which produce antibodies that circulate in the 
blood and mucosal secretions. Antibodies recognize specific antigens and induce agglutination, 
opsonization, neutralization, activation of complement, and antibody-dependent cell-mediated 
cytotoxicity (ADCC) to protect the host from the invading pathogens (167). 
Cell-mediated immunity is mediated by T lymphocytes to destroy intracellular pathogens and 
eliminate the infected cells. T cells are composed of functionally distinct populations, such as helper T 
cells, cytotoxic T cells (CTLs), and regulatory T cells. CD4+ helper T cells are the mediators of immune 
response through secreting cytokines to stimulate B cell differentiation, activate macrophages and CTLs, 
and induce inflammation (168). Effector CTLs deliver the granules containing granzymes and perforins 
into the target cells, leading to their apoptotic death (169). Regulatory T cells modulate immune 
responses via suppressing other lymphocytes (170). 
Passive transfer of PRRSV neutralizing antibodies (NAbs) protects the pigs against the challenge 
of homologous virulent PRRSV strain, indicating that NAbs play important roles in protective immune 
response against PRRSV (171, 172). However, PRRSV-infected pigs display the weak and delayed 





and CD8+ T cells are stable during PRRSV infection (52), which suggests that PRRSV has certain 
strategies to evade the host adaptive immune system. 
Similar to other viruses, PRRSV uses post-translational modifications in envelope proteins to 
dampen the induction of NAbs (175-177). The ectodomain of GP5 from both PRRSV-1 and PRRSV-2 
contains a major epitope stimulating NAbs (178-181). Moreover, the mutant PRRSV lacking of N-
glycosylation sites surrounding the neutralization epitope in GP5 and GP3 could elicit higher level NAbs 
than wild-type virus, indicating that PRRSV glycan shielding can evade the NAb responses. Another 
possible strategy that PRRSV escapes the humoral immunity is by preventing the exposure of viral 
antigens on the surface of viral-infected cells, to avoid the clearance by antibody-mediated phagocytosis 
or cell lysis (182). 
In addition, PRRSV has been found to downregulate the level of the swine leukocyte antigen 
class I (SLA-I) molecules, the swine major histocompatibility complex (MHC), on the surface of 
macrophages and dendritic cells through nsp1α-, nsp2TF-, and GP3-induced degradation, resulting in 
weak induction of CTL responses (183-186). PRRSV nsp4 can downregulate the transcription and 
expression of β2-microglobulin that is required for SLA-I antigen presentation. This observation reveals 
another mechanism that PRRSV might modulate SLA-I antigen presentation and cell-mediated immune 
response (187). 
PRRS control and treatment 
Since the discovery of PRRS, there have been considerable efforts to establish rapid diagnosis, 
heighten control strategies and develop effective vaccines.  
Diagnosis of PRRS 
First, the clinical signs of PRRS are variable due to infection by various PRRSV strains, different 





PRRSV-infected sows manifest high rate in abortions, stillborn, and mummified piglets. PRRSV also 
causes severe respiratory diseases, fever, and loss of appetite in adults and weaned pigs. 
Secondly, laboratory tests allow the accurate identification and confirmation of PRRSV 
infection, even as strain-specific. After obtaining serum, lung, lymph node, or tonsil samples, virus 
isolation in cultured cells and immunofluorescence assay can be done to detect live virus; RNA 
isolation, reverse transcription polymerase chain reaction (RT-PCR) can be used to determine the 
presence of PRRSV genome and generate template for sequencing to determine the sequence of the 
PRRSV strain; real-time PCR can also be done for speed and specificity; and serological tests can be 
used to detect PRRSV antibodies. 
Control and prevention 
PRRSV is stable when it is held under low temperature or frozen, however, the stability becomes 
lower with increasing temperature: only survive for 6 days at 20°C, and 20 minutes at 50°C (188). 
Moreover, PRRSV is very sensitive to chemical disinfection, such as chloroform, formaldehyde, 
phenols, etc. Acidic and basic environments are also detrimental to PRRSV (189). 
In addition to control PRRSV transmission, vaccination is often used to control PRRSV infection 
of virulent strains (190). Modified-live virus (MLV) and killed virus (KV) vaccines have been licensed 
for commercial application in many countries worldwide. The MLV vaccine confers delayed but 
effective humoral and cell-mediated protective immune responses against homologous PRRSV and 
partial protection against heterologous virus strain. However, this vaccine has a major disadvantage for 
its potential reversion to virulence and causing disease. On the other hand, the KV vaccine is safe but 
elicits limited protection against PRRSV infection. 
Although substantial efforts have been made, no vaccination regimen or control strategy has 
been demonstrated to be adequate for long-term PRRS control. The failure to completely control 





of protective immune response. Therefore, further studies about the interplay between PRRSV and the 
host immunity as well as the mechanism of PRRSV evasion are necessary and may pave the way for 






Chapter 2: JAK-STAT signaling pathway and PRRSV perturbation 
Introduction 
Cytokines are a broad and loose group of small cell-signaling proteins that play important roles 
in cell growth, proliferation, differentiation, apoptosis, angiogenesis, immunity and inflammatory 
response. They include IFNs, interleukins, chemokines, lymphokines, and TNFs. They are produced by 
a variety of cells, including macrophages, B and T lymphocytes, mast cells, endothelial cells, epithelial 
cells, fibroblasts, and various stromal cells. Cytokines that are produced at the site of infection stimulate 
and coordinate innate and adaptive immune responses against invading pathogens (191-193). They act 
through their matching receptors on the surface of target cells, followed by cascades of intracellular 
signaling. One such frequently activated intracellular signaling is the JAK-STAT pathway, which is 
indispensable and pivotal in many biological processes including immunity and inflammatory response 
(194, 195). Dysregulation of the JAK-STAT signaling results in immunodeficiency and immune-
mediated disorders (195, 196). Mutations in components of the JAK-STAT pathway cause 
immunodeficient and autoimmune disorders (197, 198). 
JAKs and STATs 
In mammals, there are four JAKs: JAK1, JAK2, JAK3, and Tyk2, ranging in size from 120 to 
140 kDa (199). JAK1, JAK2, and Tyk2 are ubiquitously expressed, whereas JAK3 expression is 
restricted to cells of the hematopoietic system. The JAK protein is pre-associated with cytokine 
receptors in the cytoplasmic side, which is an important determinant of their levels and signaling 
potential (199). Upon cytokine binding, the receptor chains are brought into close proximity, leading to 
the juxtaposition of two JAK kinase domains and consequent trans-phosphorylation. Once activated, 





responding to different cytokines, JAKs selected by different receptors activate specific STAT members 
for defined functions (199). 
There are seven mammalian STAT proteins: STAT1, STAT2, STAT3, STAT4, STAT5A, 
STAT5B, and STAT6, which range from 750 to 950 amino acids in polypeptide length and feature 
several conserved domains (194, 201). STATs are latent transcription factors located in the cytoplasm 
until activated. Each STAT member responds to a defined set of cytokines (195, 196, 202). The seven 
STATs go through similar activation processes and exhibit global conservation in function (194). In 
brief, ligand-mediated receptor multimerization leads to trans-phosphorylation of JAKs, which then 
create docking sites in the receptor for STATs and phosphorylate the latter. Phosphorylated STATs form 
the homodimer or heterodimer complexes, followed by translocation into the nucleus by importins and 
binding to the response element in DNA to activate or repress transcription of a defined set of genes 
(194).  
STAT signaling and functions 
Among the seven STATs, STAT1 and STAT2 mainly mediate the IFN-activated signaling (196). 
STAT1 is involved in signaling by type I, type II, and type III IFNs. In response to type I IFNs (IFN-α, 
IFN-β, and so on), STAT1 and STAT2 are phosphorylated, followed by heterodimer formation and then 
interacting with IRF9 to form a heterotrimer known as ISGF3 (107) (Fig. 1.4). The ISGF3 is 
translocated into the nucleus and binds to ISRE in DNA to activate the expression of ISGs. IFN-γ is the 
only type II IFN. Upon IFN-γ stimulation, STAT1 is activated to form homodimers, followed by nuclear 
translocation and activation of gene expression via binding to interferon-gamma-activated-sequence 
(GAS) in DNA (196). Type III IFNs (IFN-λ1, IFN-λ2, IFN-λ3, and IFN-λ4) also activate STAT1 and 






In addition to the canonical signaling pathway described above, IFNα signaling occurs through 
alternative complexes containing STAT2 and IRF9 but without STAT1 (204, 205) (Fig. 2.1). Moreover, 
STAT2 can form a heterodimer with other STATs, like STAT3 and STAT6, followed by binding to 
diverse sequences, like GAS. Further studies demonstrate the existence of a STAT1-independent IFN 
signaling pathway, in which STAT2/IRF9 directs a prolonged antiviral activity (206, 207).  
 
Fig. 2.1 STAT1-independent IFN signaling. Type I IFNs activate alternative JAK-STAT2 signaling without 
STAT1. The ISGF3-like complex binds to ISRE and interferon-gamma-activated sequence (GAS) to activate 
alternative sets of ISGs.  
 
STAT3 is activated by many cytokines and had multiple functions including differentiation of T 
helper 17 (Th17) and generation of CD8+ T cell memory response (195, 208, 209). Numerous cytokines 
including IL-5, IL-6, IL-9, IL-10, IL-11, IL-12, IL-21, IL-22, IL-27, oncostatin M (OSM), IFN-γ, TNF-α 
and leukemia inhibitory factor (LIF), trigger STAT3 activation (202, 210). The IL-6 family of cytokines 
including IL-6, OSM, and LIF bind to the receptor complex containing the common glycoprotein 130 
(gp130) and activate STAT3, known as the gp130/JAK-STAT3 signaling (Fig. 2.2). STAT3 is needed 





dendritic cells (DCs) (212). Mutations in STAT3 cause autosomal dominant hyper-IgE syndrome, a rare 
multisystem primary immunodeficiency characterized by recurrent bacterial infections in skin and lung 
and with abnormally high levels of IgE (213, 214). STAT3 is indispensable for promoting host defense 
against viral infections. For instance, during Herpes simplex virus-1 (HSV-1) infection, STAT3 
promotes the activation of CD8+ T cells response (215). It has been shown that the gp130-STAT3 
signaling is critical for the innate immune response against coxsackievirus B3 virus (CVB3) infection 
(216). In addition, STAT3 plays a protective role in regulating virus-induced proinflammatory response, 
as shown in STAT3 knockout studies (217-219). Highly pathogenic avian influenza (HPAI) H5N1 virus 
induces strong proinflammatory response in chickens via inhibition of STAT3 phosphorylation (220).  
 
Fig. 2.2 JAK-STAT3 signaling activated by IL-6 family cytokines. IL-6 binds to its receptor IL-6R and gp130, 
leading to JAK phosphorylation of STAT3, followed by STAT3 homodimer formation. KPNA6 is the adaptor 
protein to bind to STAT3 and interact with KPNB1 for the nuclear translocation. The STAT3 homodimer binds to 
STAT3 response element (RE) in DNA to activate transcription of target genes. 
 
STAT4 is activated by IL-12 and is essential for Th1 cell differentiation (221). Even though its 
distribution is restricted in myeloid cells, testis and thymus, STAT4 is critical for the host immunity. It is 





Moreover, STAT4 is crucial for the biological effects of macrophage, natural killer cell, mast cell, and 
dendritic cell as well as IFN-γ production (222). 
STAT5 is activated by IL-2, IL-3, IL-5 and granulocyte macrophage colony-stimulating factor 
(GM-CSF) and is essential for regulatory T cell (Treg) differentiation (196). STAT5 can also be 
activated by IL-7 and IL-15, contributing to the generation of CD8+ memory cells and B lymphopoiesis 
(195, 196). STAT5A and STAT5B are two highly related proteins and have indispensable roles, 
especially to the Treg response, for which STAT5B is dominant (223). Treg takes charge of maintaining 
homeostasis and controlling the immune response by restraining immunocompetent effector cells (224).  
 
 
Fig. 2.3 Canonical JAK-STAT6 signaling. IL-4 and IL-13 bind to receptors, leading to JAK phosphorylation of 






STAT6 is activated by IL-4 and IL-13 and is pivotal for Th2 and Th9 lymphocyte differentiation 
(195, 225) (Fig. 2.3). STAT6 has been demonstrated to regulate lung inflammatory responses in animal 
models (225). Moreover, STAT6 contributes to alternative activation of macrophages and lung antiviral 
responses in a JAK-independent manner (226) (Fig. 2.4). Viral or cytoplasmic nucleic acids trigger 
STING (stimulator of interferon genes) or MAVS to recruit STAT6 to the endoplasmic reticulum, 
followed by TBK1 phosphorylation of STAT6 and nuclear translocation. Expression of chemokines, 
including CCL2, CCL20, and CCL26, are then activated to recruit immune cells to combat viral 
infection (226). 
 
Fig. 2.4 JAK-independent STAT6 signaling. Viral nucleic acids (dsRNA or dsDNA) activate MAVS and 
STING on mitochondria and ER, respectively, leading to TBK1 phosphorylation of STAT6, followed by 







Viral interference with JAK-STAT signaling 
To evade the host antiviral response, viruses have evolved numerous strategies including 
dysregulating the JAK-STAT pathway. For example, Epstein-Barr virus (EBV) suppresses IFN 
signaling by inhibiting the expression of the IFN-γ receptor (227). Paramyxovirus V protein induces 
STAT protein degradation to evade IFN response (228). Dengue virus (DENV) NS5 protein interacts 
with UBR4 to induce STAT2 degradation (229). Yellow fever virus NS5 binds to STAT2 after IFN 
stimulation to prevent ISGF3 binding to ISRE (230). Ebola virus VP24 blocks pSTAT1 nuclear 
translocation by binding KPNA1 (231, 232). Measles virus V protein not only binds to STAT2 to disrupt 
type I IFN signaling for viral evasion (233), but also inhibits the IL-6 mediated STAT3 signaling (234). 
The ORF6 product of severe acute respiratory syndrome coronavirus disrupts nuclear import of pSTAT1 
by tethering KPNA2 to the endoplasmic reticulum/Golgi membrane (235). HPAI H5N1 influenza virus 
induces a strong proinflammatory response in chickens by inhibiting STAT3 phosphorylation (220). 
Zika virus NS5 promotes STAT2 degradation through the ubiquitin-proteasome system in a different 
mechanism from DENV as UBR4 does not involve (236). Vaccinia virus C6 protein prevents IFN 
signaling by binding to the TAD domain of STAT2 (237). V protein of mumps virus prevents responses 
to IL-6 and v-Src by inducing the STAT3 ubiquitination and degradation (238). Rabies virus interferon 
antagonist P protein inhibits gp130 receptor signaling by interacting with activated STAT3 (239). 
PRRSV interference with JAK-STAT signaling  
PRRSV inhibits IFN-activated JAK-STAT signaling 
PRRSV inhibits the IFN-activated JAK-STAT signal transduction and ISG expression in both 
MARC-l45 and PAM cells (120, 121, 158). PRRSV proliferation in MARC-145 cells suppresses the 





STAT2 in PRRSV-infected cells were much lower than mock-infected cells upon IFN stimulation. 
PRRSV blocks the nuclear translocation of the IFN-induced ISGF3 complex via nsp1β (120, 240). 
Avirulent Ingelvac® PRRS MLV has no effect on the IFN-activated JAK-STAT signaling in PAMs 
(120).  
Further studies demonstrate that nsp1β inhibits the JAK-STAT signaling via inducing the 
degradation of KPNA1, which is a critical adaptor protein to mediate the nuclear import of ISGF3 (121). 
Infection of MARC-145 cells by moderate virulent PRRSV strains VR-2332 and VR-2385 also result in 
KPNA1 reduction, whereas the Ingelvac® PRRS MLV does not. Nsp1β of VR-2385 induces elevation 
of KPNA1 ubiquitination and shortening of its half-life. Analysis of nsp1β deletion constructs identifies 
its N-terminal domain to be involved in the ubiquitin-proteasomal degradation of KPNA1 (121). 
Sequence analysis of nsp1β from VR-2332 and MLV indicates there are only two different nucleotides, 
leading to two different amino acids at residue 19 and 151. Substitution of the N-terminal nucleotide 
resulting in alteration of residue 19 from valine to isoleucine abolishes the ability of VR-2385 nsp1β to 
induce KPNA1 degradation and to inhibit IFN-mediated signaling. In contrast, MLV nsp1β has no effect 
on KPNA1, however, a mutant MLV nsp1β with residue 19 alternation from isoleucine to valine gains 
the ability to induce KPNA1 degradation (121). These data demonstrate that nsp1β blocks ISGF3 
nuclear translocation to inhibit the JAK-STAT signaling via inducing KPNA1 degradation and that the 
residue valine-19 in nsp1β correlates with the inhibition. 
Besides nsp1β, other PRRSV proteins including nsp7, nsp12, GP3 and N also inhibit the IFN-
induced downstream signaling, albeit at a smaller scale (158). The N protein inhibits the IFN-activated 
signaling by blocking STAT1 nuclear translocation (158). Among PRRSV strains, there are variable 
effects on the IFN-activated JAK-STAT signaling. In MARC-145 cells, PRRSV strains VR-2385, VR-
2332, NVSL97-7895, and Lelystad, but not MN184, block the activity of exogenous IFN-α (158). In 





activity of IFN-α. For NVSL97-7895 and MN184, the same virus infection in MARC-145 and PAM 
cells has variable effects on the IFN-activated signaling. This is not totally unexpected as the NVSL 
strain differs from other PRRSV strains in its failure to induce IL-10 expression in vivo (241). These two 
strains might have alternative interacting mechanisms with the JAK-STAT signaling in the two types of 
cells. 
A recent study shows that PRRSV upregulates a host microRNA, miR-30c, which is a negative 
regulator by targeting JAK1 (162). PRRSV reduces JAK1 expression in infected cells and is expected to 
affect the phosphorylation of both STAT1 and STAT2. However, in our studies, IFN-induced 
phosphorylation of both STAT1 and STAT2 in PRRSV-infected MARC-145 cells is not affected (120). 
It may play a role in vivo as PRRSV infection in pigs leads to elevation of miR-30c in lungs and PAMs 
and its level corresponds to the viral load (162). This indicates that PRRSV has multiple strategies to 
block host IFN-signaling, which is illustrated in Fig. 1.5.  
PRRSV effect on other STAT signaling  
PRRSV uses multiple strategies to evade the host innate and adaptive immunity. By interfering 
with the JAK-STAT signaling, PRRSV may perturb the function of cytokines in the regulation of the 
host immune response. Minimizing the PRRSV’s effect on the JAK-STAT signaling is assumed to 
improve the PRRSV-elicited protective immune response, which should be a desirable feature for an 
improved vaccine against PRRSV.   
As aforementioned, other STATs also have important roles in the host immune response. Besides 
inhibiting the JAK-STAT1/STAT2, PRRSV might interfere with other STATs.  
STAT2 is involved in STAT1-independent signaling by interacting with IRF9 to drive the 
expression of ISRE-containing genes (205, 206). We assume PRRSV inhibits the STAT1-independent 





STAT3 has pleiotropic activity and plays important roles in many biological processes. STAT3 
is a central regulator of lymphocyte differentiation and function (197). STAT3 is needed for activation 
and maturation of dendritic cells (DCs) and plasmacytoid DCs are considered to be the major source of 
IFN-α production during viral infection. STAT3 deficiency affects the generation of memory CD8+ T 
cells (242, 243) and memory B cells (244, 245). PRRSV infection induces a weak cell-mediated immune 
response, in which PRRSV-specific T cells transiently appears two weeks after infection without a 
change in frequencies of CD4+ and CD8+ T-cells (52). PRRSV might antagonize STAT3 for 
interference with the host development of the protective immune response.  
PRRSV’s effect on the signaling of STAT4, STAT5 and STAT6 has not been determined yet. 
STAT4 distribution is restricted to myeloid cells, testis and thymus (221). STAT5 and STAT6 
distribution are more ubiquitous. The main target cells for PRRSV infection are certain lineages of 
monocytes/macrophages in vivo. The PRRSV effect on the JAK-STAT signaling in T cells would be 
indirect, such as by exosomes from infected cells (246, 247). However, its interference of the JAK-
STAT signaling in infected macrophages would have significant consequence as the response of PAMs 
against viral or bacterial pathogens is critical in determining the outcome of infection in the host. 
Cytokines like IFN-γ and GM-CSF activate the JAK-STAT signaling to regulate macrophage phenotype 
and activation (248). Activated macrophages secrete immune regulatory cytokines including IL-1β, IL-
6, IL-12, TNF-α and so on (22). STAT6 has been demonstrated to have JAK-independent antiviral 
signaling (226). PRRSV might inhibit this alternative STAT6 signaling, which may contribute to the 
PRRSV evasion.  
Conclusion 
In conclusion, PRRSV perturbs the JAK-STAT signaling pathways by disturbing STATs protein 
level and their nuclear translocation. PRRSV has been found to inhibit the IFN-activated JAK-STAT 





STAT signaling to interfere with the host protective immune response. PRRSV interaction with the 
JAK-STAT signaling pathways is complex and consequences would be possibly depending on the 
context of the milieu during infection.  
Despite substantial efforts to study and control PRRS, no production or vaccination regimen has 
demonstrated sustained success (249, 250). This is likely in part due to the PRRSV poor induction of the 
protective immune response, allowing for PRRSV replication, spread, and persistence in the infected 
populations. Elucidation of the mechanisms of PRRSV evasion of the JAK-STAT signaling would yield 
insightful information that may facilitate the development of improved vaccines or therapeutics against 





Chapter 3: Nuclear importins and viral manipulation 
Introduction 
For JAK-STAT signaling, the nuclear translocation of STAT complexes is an essential step to 
activate the expression of ISGs. Importins are the transport factors to assist the nuclear translocation of 
the STAT complexes. For example, the importin α5 is responsible for STAT1 nuclear translocation and 
the importin α7 is responsible for STAT3 nuclear translocation. Karyopherins mediate the nuclear 
import and export of numerous proteins. So they are also known as importins and exportins. In this 
chapter, the nuclear importins, their functions and virus manipulation of importins are to be discussed.  
Nuclear transport 
The nuclear pore complex 
The nucleus is tightly controlled to protect the cellular genetic material from other cellular 
components, maintain the integrity of genetic information and control gene expression. The double 
membrane nuclear envelope encloses and isolates the entire nucleus from the cytoplasm. Despite the 
protective isolation is important for the nucleus to organize and control genetic information, its 
communication with the cytoplasm is also indispensable for the nuclear and cytoplasmic activities, such 
as exchange proteins, RNAs, ions, and other molecules. To accomplish this, nuclear pore complexes 
(NPCs) provide aqueous channels for these molecules travelling between the nucleus and the cytoplasm.  
NPC is the largest macromolecular structure of approximately 125 megadaltons (MDa) in 
mammalian cells, composed of more than 30 proteins, named nucleoporins (Nups) (251). NPC has an 
eightfold symmetrical cylindrical structure with a 65 nm-central pore decorated with eight filaments 
attached to the cytoplasmic and nuclear rings on the cytoplasmic and nuclear side, respectively. The 





The transport cycle 
Due to the gap in the center of the pore is only 9 nm wide, NPCs only allow the passive shuttling 
of small hydrophilic molecules. Therefore, transport of macromolecules, including large proteins (>40 
kDa) and nucleic acids, requires highly coordinated active process, relying on importins to enter the 
nucleus and exportins to exit. In canonical nuclear transport system, cargo proteins bearing nuclear 
localization signals (NLS) are recognized and translocated into the nucleus by the importins, while those 
proteins containing nuclear export signals (NES) are recognized and transported from the nucleus to the 
cytoplasm by the exportins (253). The transport receptors act as chaperones to assist the cargos to pass 
through the central pores of NPCs via the interaction with Nups. A typical feature of Nups is rich in 
hydrophobic motifs, such as the FG-repeat regions, which is critical for the interactions with the 
importins and exportins (252, 254). Additionally, the assembly and disassembly of transport receptors 
and cargo complexes are tightly regulated by Ras-related GTPase Ran through its interconversion 
between RanGTP and RanGDP states due to different locations. Once the complex composed of 
importin and cargo encounters RanGTP in the nucleus, the complex is disassembled, leaving the protein 
cargo in the nucleus and the importin recycled back to the cytoplasm. On the other hand, exportin 
binding to its cargo protein requires the interaction with RanGTP in the nucleus, resulting in a ternary 
complex consist of RanGTP, exportin and cargo. After the ternary complex translocates throughout the 
NPC, hydrolysis of GTP to GDP leads to dissociation of the complex to release the cargo in the 
cytoplasm and recycle exportin back to the nucleus (253, 255). 
Karyopherin α 
Karyopherins are the largest group of nuclear transport receptors in eukaryotic cells, including 
importins and exportins. Karyopherins α (KPNAs) are also known as importins α and karyopherins β 





and form a heterotrimeric KPNB1/KPNA/cNLS-cargo complex (Fig. 3.1). KPNB1 has high affinity to 
associate with Nups and RanGTP to facilitate the import of the cNLS-cargo into the nucleus. Different 
KPNA proteins show differences in their abilities to interact with specific cargos, indicating that each 
KPNA subtype has distinctive roles involving specific subsets of target proteins (256).  
The structural features of KPNAs 
Human cells encode 7 subtypes of KPNAs, from KPNA1 to KPNA7, featuring a highly 
conserved architecture consisting of three functionally distinct domains. The N-terminal domain is 
importin β-binding (IBB) domain, which functions to recruit KPNB1 for nuclear transport (257). A 
series of 10 tandem armadillo (Arm) repeats are located next to the IBB and functions to bind the cNLS-
containing cargos. There are two major groups of cNLSs: monopartite NLS, such as SV40-NLS, and 
bipartite NLS, exemplified by nucleoplasmin (NPM)-NLS. The Arm repeats form major and minor 
helical surface grooves for binding monopartite and bipartite NLS, respectively (256). The IBB domain 
contains a short basic region containing an NLS and functions an autoinhibitory effect to regulate 
KPNA’s NLS-cargo binding (258). In the absence of KPNB1, the flexible IBB domain occupies the 
cNLS-binding groove formed by Arm motifs, to inhibit cNLS-cargo binding to the groove. The 
autoinhibitory function precludes KPNA from binding cargo proteins until KPNB1 interacts with the 
IBB domain. The C-terminal region containing a short hydrophilic acidic cluster, together with Arm 





susceptibility) protein, leading to KPNA recycling back to the cytoplasm for reuse (259). The 
nucleocytoplasmic shuttling cycle of importin α is illustrated in Fig. 3.1. 
 
Fig. 3.1 The nucleocytoplasmic shuttling cycle of importin α. Importin α acts as adaptor to bind the cargos 
containing NLS signals, and form complexes with importin β which has the ability to interact with the nuclear 
pore complex. After transporting into the nucleus, the trimer dissociates once binding to Ran-GTP to release the 
cargo protein into the nucleus. The importin α shuttles to the cytoplasm via interacting with its exportin CAS.  
 
The distinctive functions of KPNAs		
In spite of the same architecture, KPNAs are classified into three subfamilies based on their 
sequence homology: clade α1 is composed of KPNA1, KPNA5 and KPNA6; clade α2 contains KPNA2 
and KPNA7; clade α3 is made up of KPNA3 and KPNA4 (256). Different KPNAs exhibit different 
specificity for their cargos, resulting in diverse roles due to particular target proteins.  
The three members of clade α1 have a high sequence identity at approximately 80% identical 
amino acids. When KPNA1 was first discovered, it was named NPI-1 (nucleoprotein interact 1) due to 
its interaction with influenza virus nucleoprotein (260). Afterwards, KPNA1 was shown to interact with 
tyrosine-phosphorylated STAT1 relying on its C-terminal region to mediate specific NLS-dependent 





discovered according to their high homology to known importins (263, 264). Unlike most importins, 
which express ubiquitously in human tissues, KPNA5 has restricted expression only in the testis (263). 
KPNA6 and KPNA1 have been shown to be responsible for the nuclear transport of the activated 
STAT3 upon cytokine stimulation (265). KPNA6 has also been shown to mediate the nuclear import of 
keap1 (Kelch-like ECH-associated protein 1), the repressor of Nrf2 (nuclear factor erythroid 2-related 
factor 2)-mediated adaptive response to oxidative stress (266).  
KPNA2 and KPNA7 belonging to clade α2 share only 53% identical amino acids, which is the 
least conserved among the three subfamilies. KPNA2 was discovered to be the human homologue of 
yeast SRP1 (serine-rich protein 1) which is a suppressor of RNA polymerase I mutations (267, 268). 
KPNA2 was also named Rch1 (Rag cohort 1), derived from its interaction with RAG-1, the 
recombination activating proteins regulating V(D)J recombination (269, 270). KPNA2 has been 
identified to have the affinity to both monopartite and bipartite NLS sequences (268). KPNA7, another 
member in clade α2, was identified recently (271). Even though KPNA7 and KPNA2 are closely related, 
KPNA7 has some divergent properties. In contrast to KPNA2 distributing in the cytoplasm, KPNA7 
predominantly localizes in the nucleus. KPNA7 prefers to recognize retinoblastoma (RB) NLS motif 
rather than SV40-NLS and NPM-NLS. In addition, the IBB domain of KPNA7 is distinct from other 
KPNAs, with much stronger affinity to KPNB1. On the other hand, KPNA7 was recently reported to 
mainly express in mouse oocytes and early embryo to facilitate the fertility of mouse (272). KPNA7 has 
also been found to be highly expressed and promote the malignancy in pancreatic cancer cells (273). 
These results indicate that KPNA7 mediates the nuclear translocation of specific NLS-cargos and might 
be involved in the developmental biological process. 
The identity between KPNA3 and KPNA4 in clade α3 is extremely high, up to 86% identical 
amino acids, resulting in their similar functions. They have been demonstrated to mediate the nuclear 





directly bind the NLS signals of p50 and p63 and mediate p50 homodimer translocation into the nucleus 
without stimulation (274). RCC (regulator of chromosome condensation)-1, the chromatin-bound 
RanGDP/GTP exchange factor, could only be imported by KPNA4, not by other importin members 
(264).  
The manipulation of nuclear transport in viral replication 
Viruses must take advantage of host cells for their infection and replication. Many viruses have 
to transport their genomes into the nucleus, in order to replicate in the nucleus, or integrate their 
genomic information into the host chromosomes. For those RNA viruses not replicating in the nucleus, 
certain viral proteins traffic into the nucleus to antagonize host activities and facilitate viral replication.  
DNA virus 
A DNA virus contains DNA as its genetic material and generally replicates in the nucleus of host 
cells. There are various strategies for nuclear import of the incoming viral DNA genomes. For instance, 
Parvovirus is a small non-enveloped virus containing a single-stranded DNA genome associated with 
capsid protein VP1/VP2. After internalization by endocytosis, parvovirus releases the nucleocapsid 
allowing VP1 to interact with NPC to deliver the genomic DNA into the nucleus. It has been 
demonstrated that the N-terminal basic clusters of VP1 are required for the genome import and efficient 
infection (275, 276).  
A large DNA virus, herpes simplex virus type 1 (HSV1), belonging to the Herpesviridae family, 
is enveloped and contains a nucleocapsid of 120 nm. After fusion of the viral envelope with the cellular 
membrane, the nucleocapsid is released to the cytoplasm, followed by transportation to the NPCs. The 
interaction between the capsid and NPCs must have specific spatial orientation, with the portal DNA 
channel of the capsid adjacent to the NPC entrance. Subsequently, the docked nucleocapsid is capable to 





VP1/2, VP13/14, and VP22 to NPCs have been reported to rely on importin β (252, 277, 278). Recently, 
KPNA2 was found to be required for the nuclear import of several HSV-1 proteins for capsid assembly 
to assist HSV-1 replication in neurons and fibroblasts (279). 	
Retrovirus 
Unlike other single-stranded positive-sense RNA viruses, retrovirus depends on a DNA 
intermediate for its replication. Once entered into the host cytoplasm, retrovirus utilizes its reverse 
transcriptase (RT) to synthesize double-stranded DNA (proviral DNA) from its genomic RNA, 
generating preintegration complex (PIC). The PIC is composed of proviral DNA, RT, integrase (IN), 
matrix (MA), the small accessory protein Vpr, and several cellular proteins (280). After transported into 
the nucleus, PIC integrates the proviral DNA into the host chromosomes for persistent infection. Vpr has 
been documented to play critical roles in the nuclear import of PIC through its association with NPC 
protein hCG1 (281). Also, importin 7, which is able to interact with Ran and NPC directly, is crucial for 
the transportation through binding to the C-terminal region of IN (282).  
Negative-sense RNA virus 
Influenza virus, belonging to Orthomyxovirus, contains eight segmented negative-sense RNA 
genomes. Each segmented RNA genome is encapsidated by the viral nucleoprotein (NP) into a 
ribonucleoprotein (RNP) complex, composed of RNA, NP, and the heterotrimeric RNA-dependent RNA 
polymerase (RdRp) containing PB1, PB2, and PA (252). Unlike the most RNA viruses, for which the 
replication is restricted to the cytoplasm of the host cells, influenza viruses transport their RNPs into the 
nucleus for transcription and replication. After the import of influenza virions to the host cells through 
clathrin-mediated endocytosis or macropinocytosis, the increasing acidity in late endosomes induces the 





conformational changes of hemagglutinin (HA) to mediate fusion of the viral envelope with the 
endosomal membrane, followed by the release of RNPs to the cytoplasm (283).  
The complex of RNPs recruit cellular transport factors to enter into the nucleus. This process 
requires NP and PB2, the critical virulence factors involved in viral pathogenicity and host adaptation, to 
interact with importin α (284). NP has been shown to be recognized by KPNA1 (NPI-1) and KPNA2 
(NPI-3) in digitonin-permeabilized cells through its non-classical NLS signal (285, 286). On the other 
hand, it has been demonstrated that the import of NP and PB2 into the nucleus depends on KPNA4 
(importin-α3) for avian influenza viruses, while for mammalian influenza viruses, the specificity 
switched to KPNA2 (importin-α1) and KPNA6 (importin-α7) which is required for the replication of 
H1N1 influenza virus in the alveolar epithelium and enhanced virulence in mice (287-289). Moreover, 
the structural analysis indicated that the bipartite NLS sequence in PB2 could bind with KPNA1 
(importin-α5) to allow influenza viruses adapting from avian to mammalian cells (290).   
Positive-sense RNA virus 
Positive-sense single-stranded RNA (+ssRNA) viruses contain RNA genomes, which function as 
the messenger RNA to translate into proteins directly by cellular machinery in the host cells. Thus, 
+ssRNA viruses generally replicate in the cytoplasm rather than in the nucleus of infected cells. 
However, some viral proteins localize to the nucleus for specific functions, such as interference with 
host gene expression, hindering host antiviral immune response or other essential activities. 
Nucleocapsid proteins are the typical ones that enter into the nucleus or nucleolus of the host cells. The 
nucleocapsid proteins of arteriviruses contain NLS motif and nucleolar retention/localization signal 
(NoRS/-LS) allowing its interaction with importin α/β to transport into the nucleus and accumulate in 
the nucleoli (291). It has been reported that the nuclear localization of PRRSV N protein is crucial in 






On the other hand, hepatitis C virus (HCV) was shown to induce a significant relocation of the 
nuclear transport factors from the nuclear membrane to ER membrane-derived membranous vesicles 
(293). In the vesicles, the viral RNA and RdRp of HCV are concentrated and protected from the host 
defenses and nucleases in the cytoplasm, supporting viral replication with a high efficiency (294). The 
redistributed host transport factors are supposed to form an NPC-like structures to promote specific 
cargos to the membranous vesicles in order to promote viral RNA replication (295).   
The modulation of karyopherins in viral pathogenesis 
Due to their importance in host activities, especially immune response, importins are often 
targeted by viruses to disturb the host antiviral response. For instance, Ebola virus has been shown to 
block the interaction between KPNA1 and phosphorylated STAT1 (pSTAT1) through VP24 
competitively binding with KPNA1, followed by inhibition of the nuclear translocation of pSTAT1 in 
order to prevent IFN-activated antiviral signaling pathway (231, 296). Hepatitis B virus was found to 
block the nuclear transportation of STAT1/2 complex via the polymerase competitively interacting with 
KPNA1 by its RNase H domain (297). PRRSV was shown to interfere with the IFN signaling by nsp1β 
inducing the degradation of KPNA1 to inhibit the nuclear translocation of STAT1/2 complex (121). 
Moreover, HCV could trigger the cleavage of KPNB1 by NS3/4A complex to restrain the nuclear import 
of IRF3 and NF-κB p65, resulting in the inhibition of antiviral response (298).  
Despite substantial efforts have been made to research the interplay between viruses and host 
nucleocytoplasmic trafficking system, there are still many unknowns. For instance, the cellular proteins 
and viral factors required for viral genome uncoating and the translocation of the nucleoprotein 
complexes for many viruses remain unknown. In addition, the subsequent events after the nuclear 
translocation of the complexes are not well understood. On the other hand, it is not clear that certain 





and addressing these questions will yield informational data to assist our understanding of the virus-host 






Chapter 4: Porcine reproductive and respiratory syndrome virus inhibits 
STAT2 signaling via nsp11-mediated downregulation 
Abstract 
IFNs play a crucial role in host antiviral response via activating JAK-STAT signaling pathway to 
induce expression of myriad genes. PRRSV antagonizes the antiviral response by inhibiting IFN 
synthesis and JAK-STAT signaling. STAT2 is a key player in the IFN-activated JAK-STAT signaling. 
The objective of this study was to investigate the PRRSV effect on STAT2 signaling. Here, we 
discovered that PRRSV downregulated STAT2 to inhibit the IFN-activated signaling. PRRSV strains of 
both PRRSV-1 and PRRSV-2 species decreased STAT2 protein level, whereas its transcript had minimal 
change. PRRSV reduced STAT2 level in a dose-dependent manner and shortened STAT2 half-life 
significantly from approximately 30 to 10 hours. PRRSV-induced STAT2 degradation could be restored 
by treatment with the proteasome inhibitor MG132. In addition, PRRSV nsp11 was identified to reduce 
STAT2. The N-terminal domain (NTD) of nsp11 was responsible for STAT2 degradation and interacted 
with STAT2 NTD and coil-coil domain (CCD). Mutagenesis analysis showed that three amino acids 
(57-59, IHK) located in the nsp11 NTD were critical for the interaction of nsp11 with STAT2, resulting 
in the reduction of STAT2 protein level. Together, these results demonstrate that PRRSV antagonizes 
STAT2 signaling via nsp11-mediated downregulation. This study provides further insight of PRRSV 
interference with IFN signaling and the consequent host immune response.  
Introduction 
IFN is an indispensable component in the innate immunity. Three types of IFNs have been 





cascade through JAK and STAT, and induce antiviral state by activating expression of a myriad of ISGs, 
such as ISG15, ISG56, PKR, 2’,5’-oligoadenylate synthetase, and Mx GTPases (301, 302).  
Both type I and type III IFNs can activate the same canonical JAK-STAT pathway, in which 
JAKs phosphorylate STAT1 and STAT2, followed by interaction with IRF9 to form a heterotrimer 
termed ISGF3 (221, 301). The ISGF3 complex translocates into the nucleus to activate the expression of 
ISGs. On the other hand, there is a STAT1-independent pathway, named non-canonical JAK-STAT 
signaling. This pathway induces expression of certain ISGs, including APOBEC3G (A3G) having a 
broad antiviral activity (207). In this non-canonical JAK-STAT pathway, STAT2 and IRF9 form a 
complex that has ISGF3-like functions to induce prolonged expression of ISGs as well as STAT2/IRF9-
specific ISGs, such as A3G, retinoic acid-induced gene G (RIG-G), CCL8 and CX3CL1, in the absence 
of STAT1 (207). Therefore, STAT2 is indispensable in both canonical and non-canonical IFN-activated 
signaling pathways.  
Due to its essential role in the JAK-STAT pathway, many viruses target STAT2 to antagonize 
IFN signaling. For example, measles virus V protein binds to STAT2 (233). Yellow fever virus NS5 
binds to STAT2 upon IFN stimulation (230). Dengue virus (DENV) NS5 protein recruits the E3 ligase 
UBR4 to induce STAT2 degradation (229). Similar to DENV, Zika virus (ZIKV) NS5 also promotes 
STAT2 degradation (236). 
Since the first emergence in the late 1980s, PRRS has remained a top challenge to the swine 
industry (46). PRRSV, the causative agent, is a member of the genus Porartevirus, the family 
Arteriviridae, the order Nidovirales (1, 50, 303). The conventional two genotypes, Type 1 (European) 
and Type 2 (North American) PRRSV, have been classified as two species, PRRSV-1 and PRRSV-2, 
respectively (7). PRRSV is a small enveloped virus containing a positive-sense, single-stranded RNA 





associated polyproteins pp1a and pp1ab are encoded by the ORF1a and ORF1b regions, which comprise 
4/5 of the viral genome. The polyproteins are processed into more than 14 nonstructural proteins (nsp1-
nsp12) by the host and viral proteases. The ORF2, 2a, 3, 4, 5a, 5, 6, and 7 encode structural proteins 
including minor membrane-associated proteins GP2, E, GP3, GP4, ORF5a, a major envelope 
glycoprotein (GP5), a membrane protein (M), and a nucleocapsid protein (N), respectively (46, 304). 
PRRSV has a very restricted tropism for cells of monocyte/macrophage lineage, and pig is the only 
natural host. In vivo, PRRSV preferentially targets porcine PAMs (305). In vitro, PRRSV is generally 
propagated in MARC-145 cell, an epithelial cell-derived cell line from African green monkey kidney 
(28). 
PRRSV infection of pigs induces poor innate (306) and adaptive immune responses (51). It has 
been shown that PRRSV has several evasion strategies to interfere with the host innate immune response 
(139, 307). PRRSV appears to suppress the induction of type I IFNs by interfering with the RIG-I 
signaling pathway (308). PRRSV nsp1α, nsp1β and nsp11 modulate induction of type I IFNs (115, 119, 
240). Moreover, PRRSV interferes with the IFN downstream signaling by blocking STAT1/STAT2 
nuclear translocation via nsp1β-mediated degradation of KPNA1, which is responsible for ISGF3 
nuclear translocation (120, 121, 139). N protein could also inhibit ISGF3 nuclear translocation (158). 
PRRSV also antagonizes STAT3 signaling via nsp5 (309). PRRSV elevates miR-30c to downregulate 
JAK1 to inhibit IFN signaling (162). However, the effect of PRRSV infection on STAT2 signaling is 
unknown.  
In this study, we demonstrated that PRRSV downregulated STAT2 to inhibit the IFN-activated 
signaling. PRRSV strains from both PRRSV-1 and PRRSV-2 species reduced STAT2 protein level, 
whereas its transcript had minimal change. PRRSV infection shortened STAT2 half-life significantly. 





interacts with STAT2 NTD and CCD domains. Three amino acids (57-59) in nsp11 are crucial for the 
interaction with and reduction of STAT2. In conclusion, this study demonstrates that PRRSV 
antagonizes STAT2 signaling via nsp11-mediated degradation. The data improves our understanding on 
the mechanism of PRRSV interference with the IFN-activated JAK-STAT signaling.  
Materials and methods 
Cells, viruses, and chemicals  
MARC-145 (28), HEK293 (ATCC CRL-1573) and HeLa (ATCC CCL-2) cells were cultured in 
Dulbecco modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Primary 
porcine PAM cells were revived from cryopreserved stock and cultured in RPMI 1640 medium with 
10% FBS as previously described (120, 310). 
PRRSV strains VR-2385 (29), Ingelvac PRRS MLV (311), Lelystad (312) and A2MC2 (313) 
were used to inoculate MARC-145 cells at an MOI of 1 or amount indicated in figure legends or results. 
The median tissue culture infectious dose (TCID50) of PRRSV was determined in MARC-145 cells 
(314). 
For virus inactivation, virus inoculum was treated in a UV cross-linker for two 10-min pulses 
separated by a 1-min interval. Virus inactivation was confirmed by lack of PRRSV-positive cells in 
inoculated MARC-145 cells at 72 hpi (120). 
Cycloheximide (Sigma-Aldrich, St. Louis, MO), a protein translation inhibitor, was added to 
PRRSV-infected and mock-infected cells at a final concentration of 50 µg/ml to determine the half-life 
of STAT2. MG132 (Sigma), a proteasome inhibitor, was used to treat cells at a final concentration of 10 
µM for 6 h prior to harvesting. Human IFN-α (Genscript) was used to activate the JAK-STAT signaling 






The nsp11 of PRRSV VR-2385 was cloned into a pCAGEN-HA vector and pCDNA3-VenusC1 
vector (309) with the primers 32nsp11F1 and 85nsp11R1 (Table 1). The nsp11 deletion mutants were 
cloned into pCAGEN-HA vector using the following primers: 32nsp11F1 and 85nsp11-NTD-R for 
nsp11-NTD, 32nsp11F1 and 85nsp11-NL-R for nsp11-NTDL, 85nsp11-LC-F and 85nsp11R1 for 
nsp11-LCTD, and 85nsp11-CTD-F and 85nsp11R1 for nsp11-CTD (Table 1). Nsp11-NTD was also 
cloned into pCDNA3-VenusC1 vector with the same primers. The nsp11-NTD truncate fragments were 
cloned into pCDNA3-VenusC1 using the following primers: 32nsp11F1 and 85nsp11-NTD-1R for 
nsp11-NTD-D1, 85nsp11-NTD-2F and 85nsp11-NTD-R for nsp11-NTD-D2, 85nsp11-NTD-3F and 
85nsp11-NTD-3R for nsp11-NTD-D3. STAT2 was cloned into a pCAGEN-Myc vector and pCDNA3-
VenusC1 vector with the primers STAT2F1 and STAT2R1. The STAT2 deletion mutants were cloned 
into pCAGEN-Myc vector using the following primers: STAT2F1 and STAT2R2 for STAT2-D1, 
STAT2F1 and STAT2R3 for STAT2-D2, STAT2F2 and STAT2R1 for STAT2-D3. The mutants of 
nsp11-NTD-D2 were cloned into pCDNA3-VenusC1 vector using the following primers: 85nsp11N-D2-
m1-F1 and 85nsp11-NTD-R for D2M1, VenusC1F-HindIII, 85nsp11N-D2-m2-F1, 85nsp11N-D2-m2-
R1, and 85nsp11-NTD-R for D2M2. The resulting recombinant plasmids were confirmed by restriction 
enzyme digestion and DNA sequencing.  
The construction of the other PRRSV nsp plasmids were described previously (158). The 
pCDNA3-STAT2 was a gift from Curt M. Horvath (228). The pGL-ISRE used for the IFN-STAT1/2 
reporter assay was described previously (158).  
RNA isolation and real-time PCR 
Total RNA was isolated from MARC-145 cells with TRIzol reagent (ThermoFisher Scientific, 





PCR (RT-qPCR) (ThermoFisher Scientific) were conducted as described previously (310). Transcripts 
of ribosomal protein L32 (RPL32), the reference gene, were also detected. The relative transcript levels 
were shown as fold compared to the control cells after RPL32 normalization. The real-time PCR primers 
used for STAT2 were R-STAT2-F1 and R-STAT2-R1 (Table 1). The primers used for PRRSV, ISG15, 
ISG56, and RPL32 were described previously (120). All experiments were repeated at least three times, 
with each conducted in triplicate.  
Western blot (WB) analysis 
Cell lysates in Laemmli sample buffer were subjected to SDS-PAGE and WB as described 
previously (315). The primary antibodies used in this study were against STAT2 (Santa Cruz 
Biotechnology, Inc., Dallas, TX), STAT1 (Santa Cruz), PRRSV nsp2 protein (14, 316), β-tubulin 
(Sigma), ubiquitin (Santa Cruz), hemagglutinin (HA) tag (ThermoFisher Scientific), cMyc tag 
(ThermoFisher Scientific) and GFP (Rockland Immunochemicals, Inc., Gilbertsville, PA). The 
secondary antibodies used in this study was goat anti-mouse IgG conjugated with horseradish 
peroxidase (Rockland). The chemiluminescence signal acquisition was conducted by the Quantity One 
program (v4.6) and a Chemi-Doc XRS imaging system (Bio-Rad Laboratories, Hercules, CA). All 
experiments were repeated at least three times to warrant the reliability of the results.  
Immunoprecipitation (IP) 
IP was conducted as previously described (309, 317). The clarified cell lysates were incubated 
with specific antibodies indicated in Results or Figure Legends, followed by incubation with protein 
A/G-magnetic beads (Bimake.com, Houston, TX). The IP products were subjected to WB for detection 
of target proteins. To determine ubiquitinated STAT2, ubiquitin aldehyde (Boston Biochem, Inc., 
Cambridge, MA), a specific inhibitor of ubiquitin C-terminal hydrolases, was added into the lysis buffer 





ISRE Reporter assay  
HEK293 cells were transfected with the ISRE reporter plasmid pGL3-ISRE and nsp11 plasmids. 
The Renilla luciferase vector pRL-TK (Promega, Madison, WI), expressing Renilla luciferase under the 
control of a constitutively active promoter, was also transfected for normalization. At 24 hours post 
transfection (hpt), the cells were treated with 300 U/ml IFN-α and, 24 h later, harvested for luciferase 
activity assay of firefly and Renilla luciferases according to the manufacturer’s instructions (Promega). 
The relative levels of firefly luciferase activity are shown as fold values compared to that of empty 
vector control after normalization with the Renilla activity, as described previously (158, 309).  
Immunofluorescence assay (IFA)  
IFA was conducted as reported previously (317, 318) with antibodies against HA tag 
(ThermoFisher Scientific) and cMyc tag (ThermoFisher Scientific). The specific reactions were detected 
by the conjugated secondary antibodies: goat anti-mouse IgG (H&L) DylightTM 549 and goat anti-rabbit 
IgG (H&L) DylightTM 488 (Rockland Immunologicals). The cover glasses were mounted onto slides 
using SlowFade Gold antifade reagent containing 4’6’-diamidino-2-phenylindole 
(DAPI) (ThermoFisher) and observed using Zeiss LSM 510 Meta Confocal Microscope.  
Statistical analysis 
Differences in indicators between the treatment group and control were assessed by using the 
Student t test. A two-tailed P value of 0.05 was considered significant.  
Results 
PRRSV infection reduces STAT2 protein level  
When we studied the effect of PRRSV infection on JAK-STAT signaling, we discovered that 





effect of PRRSV infection on STAT2, we inoculated MARC-145 cells with PRRSV strain VR-2385 and 
harvested the cells at 36 hours post infection (hpi). Compared to mock-infected cells, PRRSV-infected 
cells had lower level of STAT2 at 16% but similar level of STAT1 (Fig. 4.1A). PRRSV nsp2 was 
determined to verify PRRSV infection. As PRRSV targets PAMs during pig infection, we infected 
primary porcine PAM cells with VR-2385 to confirm the effect of PRRSV infection on STAT2. Due to 
the enhanced replication of PRRSV in PAM cells, these cells were harvested at 16 hpi (309). Like in 
MARC-145 cells, PRRSV infection reduced STAT2 level in PAM cells to 16% in comparison with 
mock-infected control, whereas STAT1 had a minimal change (Fig. 4.1B).  
STAT2 plays a critical role in IFN-activated JAK-STAT signaling pathway. We conducted an 
IFN treatment to confirm that PRRSV infection interfered with type I IFN signaling (120, 121). MARC-
145 cells were inoculated with VR-2385 and, at 24 hpi, treated with IFN-α for 24 h. The reverse 
transcription and quantitative PCR (RT-qPCR) results showed that the transcript levels of ISG15 and 
ISG56 in IFN-treated cells increased by 55- and 32-fold, respectively, in comparison with mock-treated 
cells (Fig. 4.1C). As expected, the transcript level of ISG15 and ISG56 in PRRSV-infected cells with 
IFN treatment were at 9% and 11%, respectively, compared to the mock-infected cells (Fig. 4.1C), 
which is consistent with the previous observation (120). 
We speculated that VR-2385-induced reduction of STAT2 could be relevant to other PRRSV 
strains. Therefore, other strains from both PRRSV-1 and PRRSV-2 species were used to infect MARC-
145 cells to verify that the STAT2 reduction is a common effect among different strains. The strains 
used were Lelystad virus, the prototype of PRRSV-1, Ingelvac® PRRS MLV, and IFN-inducing vaccine 
candidate strain A2MC2 (313, 319), strain of PRRSV-2. As expected, A2MC2 elevated protein level of 
STAT2. In contrast, VR-2385, MLV and Lelystad reduced STAT2 to 12%, 10%, and 33%, respectively, 
compared to mock infected control. STAT1 level in the infected cells remained unchanged (Fig. 4.1D). 





lowest RNA level, which is in consistent with the least effect on STAT2 level in the cells infected by 
this strain.  
 To interrogate if PRRSV replication was indispensable for STAT2 reduction, we inactivated 
VR-2385 by UV light and inoculated MARC-145 cells with the UV-inactivated VR-2385 at the 
multiplicities of infection (MOIs) of 5 and 10. Western blotting (WB) result showed that only live 
PRRSV virions led to the STAT2 reduction, while the UV-inactivated PRRSV had minimal effect (Fig. 
Fig. 4.1 PRRSV infection reduces STAT2 in MARC-145 and PAM cells.  A. PRRSV reduces STAT2 
protein level but has minimal effect on STAT1. MARC-145 cells were infected with VR-2385 at an MOI of 
1 and harvested 36 hours post-infection (hpi) for Western blotting (WB) with antibodies against STAT2, 
STAT1, PRRSV nsp2, and tubulin. Relative levels of STAT2 are shown below the images after 
normalization with tubulin in densitometry analysis. B. PRRSV reduces STAT2 in PAM cells but has 
minimal effect on STAT1. The cells were infected with VR-2385 at an MOI of 1 and harvested for WB at 16 
hpi. C. PRRSV inhibits IFNα-activated expression of ISG15 and ISG56 detected by RT-qPCR. MARC-145 
cells were infected with VR-2385 at an MOI of 1 and, 24 hpi, treated with IFN-α at a final concentration of 
300 U/ml for another 24 hours. VR: VR-2385. D. Reduction of STAT2 by different PRRSV strains with the 
exception of A2 (A2MC2) in MARC-145 cells. The cells were infected with VR-2385, MLV (Ingelvac 
PRRS@ MLV), LV (Lelystad virus), and A2 at the MOI of 1. The relative levels of STAT2 are shown below 
the images after normalization with tubulin. E. PRRSV RNA levels of the PRRSV strains detected by RT-
qPCR. Viral-infected MARC-145 cells were harvested for RNA isolation and RT-qPCR at 24 hpi. Error bars 
represent the standard errors of the results of three repeated experiments. F. UV-inactivated PRRSV has 
minimal effect on STAT2 level. The cells were inoculated with PRRSV VR-2385 at an MOI of 1 or UV-






4.1F), suggesting that PRRSV replication is needed to induce STAT2 reduction and that PRRSV 
structural proteins in the inactivated virions had negligible effect.  
PRRS reduces STAT2 protein level in a dose and time-dependent manner  
 To further study PRRSV-mediated reduction of STAT2, we infected MARC-145 cells with VR-
2385 at the MOIs of 0.1, 1, and 10. Along with the increased amount of VR-2385 inoculum, the STAT2 
protein level decreased in a dose-dependent manner. Compared to the mock-infected cells, the cells 
inoculated at the MOIs of 0.1, 1, and 10 had STAT2 levels at 29%, 13%, and 5%, respectively (Fig. 
4.2A). PRRSV RNA levels in the infected cells significantly increased, which was consistent with the 
incremental inoculum (Fig. 4.2B).  
Fig. 4.2 PRRSV reduces STAT2 in a dose and time-dependent manner. A. Dose-dependent 
reduction of STAT2 by PRRSV. MARC-145 cells were inoculated with incremental MOI of VR-
2385 and harvested for WB at 36 hpi. Relative levels of STAT2 are shown below the images after 
normalization with tubulin. B. PRRSV RNA levels detected by RT-qPCR. Error bars represent the 
standard errors of the means of three repeated experiments. Significant differences in RNA level 
from an MOI of 0.1 are denoted by asterisks (**, P  < 0.01; ***, P < 0.001). C. Temporal kinetics of 
STAT2 levels in PRRSV-infected cells. MARC-145 cells were infected with VR-2385 at an MOI of 
1. At different time points, the cells were harvested for WB. Mock-infected cells at corresponding 
time points were included as controls. Relative levels of STAT2 are shown below the images after 
normalization with tubulin at corresponding time point. D. PRRSV infection has minimal effect on 
STAT2 mRNA level. The cells were harvested at 24 hpi for RNA isolation and RT-qPCR. The 
relative STAT2 mRNA levels are shown in comparison with the mock-infected cells. Error bars 





Temporal kinetics of STAT2 protein level in the infected cells was analyzed to determine if the 
change of STAT2 level occurred during a specific period post infection. MARC-145 cells were infected 
with PRRSV VR-2385 at an MOI of 1 and harvested at 24, 36 and 48 hpi. Compared to the mock-
infected cells, the STAT2 levels in the virus-infected cells at 24, 36, and 48 hpi decreased to 60%, 20%, 
and 20%, respectively, while STAT1 levels remained stable (Fig. 4.2C). This result demonstrated that 
PRRSV infection reduced STAT2 protein level in a time-dependent manner. 
 In mammalian cells, the protein reduction could be due to a decrease in transcription and/or 
translation or accelerated protein degradation. To investigate the reason for PRRSV-induced STAT2 
reduction, we performed RT-qPCR to determine the transcript level of STAT2 in PRRSV-infected cells. 
In comparison with mock-infected cells, PRRSV-infected cells had similar mRNA level of endogenous 
Fig. 4.3 PRRSV infection shortens STAT2 half-life and mediates STAT2 reduction via ubiquitin-
proteasome degradation pathway. A. PRRSV extends STAT2 half-life. MARC-145 cells were 
infected with VR-2385 at an MOI of 1. The cells were treated with cycloheximide at 24 hpi and 
harvested at the indicated time (h) for WB. The relative levels of STAT2 are shown below the images. 
B. MG132 treatment restores STAT2 level in PRRSV-infected cells. MARC-145 cells were infected 
with VR-2385 at an MOI of 1. At 24 hpi, the cells were treated with MG132 for 6 h and then harvested 
for WB. Non-treated and mock-infected cells were included as controls. C. PRRSV induces elevation of 
STAT2 polyubiquitination. MARC-145 cells were infected with PRRSV VR-2385 at an MOI of 1 and 
harvested for IP with STAT2 antibody at 36 hpi, followed by WB with the ubiquitin (Ub) antibody. WB 
of whole cell lysate (WCL) was conducted. The relative levels of Ub after normalization with STAT2 





STAT2 (Fig. 4.2D). The result demonstrated that PRRSV-induced STAT2 reduction was not due to the 
decreased level of mRNA transcription.  
PRRSV infection shortens STAT2 half-life 
Since PRRSV infection did not affect the transcript level of STAT2, we speculated that PRRSV 
might accelerate the rate of STAT2 degradation. We then wondered whether the half-life of STAT2 
would be shortened by PRRSV. PRRSV infected MARC-145 cells for 24 hours were treated with 
cycloheximide, a translation inhibitor, followed by harvesting and immunoblotting at indicated time 
points. In the presence of PRRSV, the STAT2 half-life was shortened to 10 hours, compared to that of 
30 hours in mock-infected cells (Fig. 4.3A). The results suggest that the shortened STAT2 half-life may 
account for its lower level in PRRSV-infected cells. 
PRRSV mediates STAT2 reduction via the ubiquitin-proteasome degradation pathway 
Since PRRSV shortened STAT2 half-life, we further identified the protein degradation pathway 
for PRRSV infection in reducing STAT2 level. The ubiquitin-proteasome system accounts for the 
turnover of most short-lived cellular proteins. We used MG132, a proteasome inhibitor to treat MARC-
145 cells at 30 hpi. After MG132 treatment for 6 hours, the cells were harvested for immunoblotting. 
The MG132-treated PRRSV-infected cells displayed a similar level of STAT2 to mock-infected cells 
(Fig. 4.3B). As described previously, the short treatment with MG132 did not cause detectable 
cytotoxicity or inhibition of PRRSV replication (317). This result indicates that PRRSV induces STAT2 
reduction through the ubiquitin-proteasome degradation pathway.  
Since MG132 treatment could restore STAT2 protein level in PRRSV-infected cells, we 
speculated increased level of STAT2 poly-ubiquitination level in the cells. MARC-145 cells infected 





antibodies against ubiquitin and STAT2 showed the poly-ubiquitination level of STAT2 in PRRSV-
infected cells was 12-fold higher than that of mock-infected cells after normalization with STAT2 
protein level (Fig. 4.3C). In contrast, WB analysis of whole-cell lysates (WCL) showed similar levels of 
the total ubiquitination with or without PRRSV infection.  
 PRRSV nsp11 reduces STAT2 protein level 
As Fig. 1F indicated that PRRSV replication was critical for STAT2 reduction, we speculated 
that certain non-structural proteins (nsps) were responsible for PRRSV-induced STAT2 reduction. 
Fig. 4.4 PRRSV nsp11 induces reduction of STAT2. A. Nsp11 reduces STAT2 in HEK293 cells, 
whereas other PRRSV nsps have minimal effect. The cells were transfected with individual HA-nsp 
plasmids and STAT2 plasmid. An empty vector (EV) was included as a control. The relative levels of 
STAT2 protein are shown below the images. Molecular mass markers are added on left side of the nsp 
images. B. Nsp11 reduces STAT2 in HeLa cells in a dose-dependent manner. HeLa cells were 
transfected with nsp11 plasmid in incremental amounts. C. Nsp11 inhibits IFN-α activated expression 
of ISRE reporter in HEK293 cells. The cells were co-transfected with ISRE luciferase reporter, Renilla 
luciferase plasmid, and HA-nsp11. The relative levels of firefly luciferase activity are shown as fold 
compared to the EV control after normalization with the Renilla activity. A significant difference in 





HEK293 cells were transfected with plasmids encoding PRRSV VR-2385 nsps to assess their effects on 
STAT2 degradation. WB results showed that nsp11 resulted in a lower level of STAT2 protein 
compared to that of empty vector (EV), whereas other PRRSV plasmids did not affect STAT2 
degradation (Fig. 4.4A). Therefore, we further analyzed the role of nsp11 in STAT3 degradation.  
HeLa cells were transfected with nsp11 plasmid to confirm its effect on STAT2. Densitometry 
analysis showed that the STAT2 levels in HeLa cells transfected with 0.25, 0.5, and 1.0 g of nsp11 
plasmid were reduced to 30%, 20%, and 10%, respectively, compared to that of the empty vector control 
(Fig. 4.4B). The nsp11 protein level increased along with the incremental DNA in the transfection. This 
indicated that nsp11 reduced STAT2 protein level in a dose-dependent manner. IFN-stimulated response 
element (ISRE) promoter luciferase assay confirmed that nsp11 significantly inhibited type I IFN 
signaling (Fig. 4.4C).  
The N-terminal domain of nsp11 is responsible for the reduction of STAT2 via interacting with STAT2 
PRRSV nsp11 contains a nidovirus uridylate-specific endoribonuclease (NendoU) domain, 
which is indispensable for arterivirus replication (141, 144). NendoU has been demonstrated to cleave 5’ 
uridine nucleotides of RNA substrates to generate a 2’-3’-cyclic phosphate end product, similar with 
XendoU, an endoribonuclease in eukaryotes (142, 143). STAT2 mRNA level in PRRSV-infected cells 
remained the same level as mock-infected cells (Fig. 4.2D), indicating that the NendoU did not 
contribute to the nsp11-mediated STAT2 reduction. 
The crystal structure analysis of nsp11 shows that nsp11 has three different domains, N-terminal 
domain (NTD), linker domain, and C-terminal domain (CTD) (144). To map the nsp11 domain 
corresponding to the STAT2 degradation, we constructed four truncation plasmids of VR-2385 nsp11: 
NTD from amino acid (aa) 1 to 90, NTD with linker domain (NTDL) from aa 1 to 106, linker domain 





cells were transfected with the nsp11 truncation plasmids. WB results and densitometry analysis showed 
that the cells transfected with nsp11-NTD and nsp11-NTDL had lower STAT2 protein levels at 40% and 
30%, respectively, compared to that of the cells transfected with the empty vector (Fig. 4.5B). The 
expression levels of the nsp11 truncation constructs in HEK293 cells were confirmed with HA antibody. 
The results indicate that the NTD of nsp11 is responsible for the PRRSV-induced degradation of 
STAT2. 
 Furthermore, we evaluated whether nsp11-NTD had interaction with STAT2. HEK293 cells 
were transfected with myc-STAT2 and YFP-nsp11-NTD plasmids. Indeed, IP of STAT2 co-precipitated 
nsp11-NTD (Fig. 4.5C). The expression of YFP, YFP-nsp11-NTD, and myc-STAT2 was confirmed in 
whole cell lysate.   
Fig. 4.5 The N-terminal domain of PRRSV nsp11 is required for STAT2 reduction. A. Schematic 
illustration of truncation plasmids of nsp11: NTD, NTDL, LCTD, and CTD. The numbers above the 
lines indicate amino acid positions in nsp11. NTD: N-terminal domain; CTD: C-terminal domain; L: 
linker domain. B. The NTD and NTDL lead to STAT2 reduction, whereas LCTD and CTD have 
minimal effect. HEK293 cells were co-transfected with the HA-tagged nsp11  truncation plasmids and 
STAT2 plasmid. EV was included as a control. C. IP of STAT2 co-precipitates nsp11-NTD. IP with 
cMyc antibody followed by WB with YFP and cMyc antibodies were done. Samples of whole-cell 





The N-terminal domain of STAT2 interacts with nsp11-NTD 
 As a transcription factor, STAT2 has a conserved structure containing several domains, such as 
coil-coil, DNA binding, Src homology 2 (SH2) and transactivation domains (320). To identify 
interacting domains with nsp11-NTD, we constructed three truncates of STAT2: D1 (aa 1-315), D2 (aa 
1-480) and D3 (aa 481-851) using Myc-tagged recombinant plasmids (Fig. 4.6A). HEK293 cells were 
transfected with YFP-nsp11-NTD and one of the Myc-tagged STAT2 truncates, followed by IP with 
YFP antibody and WB with antibodies against cMyc and YFP. The IP of nsp11-NTD co-precipitated 
Fig. 4.6 Nsp11 NTD interacts with N-terminal domain of STAT2. A. Schematic illustration of 
truncation plasmids STAT2: D1, D2 and D3. The numbers above the lines indicate amino acid positions 
in STAT2. N: N-terminal domain; C-C: coil-coil domain; DBD: DNA binding domain; L: linker domain; 
SH2: Src homology 2 domain; TAD: transactivation domain. B. IP of nsp11-NTD co-precipitates 
STAT2, STAT2-D1 and STAT2-D2, but not STAT2-D3. HEK293 cells were transfected with YFP-
nsp11-NTD and Myc-STAT2 or STAT2 truncate plasmids. IP with YFP antibody followed by WB with 
cMyc and YFP antibodies was done. Empty vector (EV) was included as control. WB of whole cell 
lysate (WCL) were done. C. Nsp11-NTD has co-localization with STAT2, STAT2-D1, and STAT2-D2, 
but not STAT2-D3 in HeLa cells. The cells were transfected with plasmids of HA-nsp11-NTD and Myc-
STAT2 or STAT2 truncate plasmids. IFA with antibodies against HA and cMyc was conducted, followed 
by confocal microscopy. The red fluorescence indicates STAT2 or STAT2 truncates, while the green 
fluorescence indicates nsp11-NTD. DPAI staining of DNA is also shown. The bars in lower right corners 





STAT2, STAT2-D1 and STAT2-D2, whereas it failed to pulldown STAT2-D3 (Fig. 4.6B). The 
expression of these plasmids was confirmed in HEK293 cell lysates.  
The IP results suggest that nsp11-NTD might have co-localization with STAT2, STAT2-D1 and 
STAT2-D2, but not STAT2-D3. Therefore, we further transfected HeLa cells with HA-nsp11-NTD and 
Myc-STAT2 or STAT2 truncate plasmids, followed by IFA with antibodies against HA and cMyc. 
Confocal microscopy analyses showed that nsp11-NTD had co-localization with STAT2, STAT2-D1, 
and STAT2-D2, but not STAT2-D3 (Fig. 4.6C). STAT2-D3 had homogenous distribution throughout 
the cytoplasm, different from the puncate pattern of nsp11-NTD. 
Both co-IP and confocal microscopy results indicate that nsp11-NTD interacts with STAT2-D1 
and STAT2-D2. These two STAT2 truncates have the same first 315 aa in the N-terminal and coil-coil 
domains of STAT2, thus identifying this first 315 aa of STAT2 as the nsp11 interaction site.  
Three amino acids of nsp11 are crucial for the interaction with STAT2 
Structural analysis of the nsp11 showed several stretches of amino acids in nsp11-NTD with 
potential surface orientation, indicating that these surface-oriented amino acids might correlate with 
STAT2 degradation. Therefore, we constructed three truncates of nsp11-NTD: D1 (aa 1-51), D2 (aa 52-
90), and D3 (aa 35-65) into pCDNA3-VenusC1 vector (Fig. 4.7A). HEK293 cells were transfected with 
nsp11, nsp11-NTD, and the three nsp11-NTD truncates to determine their effects on STAT2 protein 
level. WB analyses showed that except for the empty vector and nsp11-NTD-D1, all the others induced 
STAT2 degradation (Fig. 4.7B). The nsp11-NTD-D2 induced the STAT2 reduction to 17% and nsp11-
NTD-D3 to 46%. This indicates that aa 52-65 of nsp11 contain the key site for the induction of STAT2 





 The fragment of aa 52-65 contains one stretch of amino acids, aa 57-62, with potential surface 
orientation, which are also highly conserved across different PRRSV strains. We then conducted 
Fig. 4.7 Mapping motifs in Nsp11-NTD that are required for STAT2 reduction. A. Schematic illustration of 
truncation plasmids nsp11-NTD: D1, D2 and D3. The numbers above the lines indicate amino acid positions in 
nsp11. B. The NTD-D2 and NTD-D3 lead to STAT2 reduction, whereas NTD-D1 has minimal effect. HEK293 cells 
were co-transfected with the YFP-tagged nsp11-NTD truncation plasmids and STAT2 plasmid. EV was included as a 
control. The cells were harvested at 36 hpt for immunoblotting with antibodies against STAT2, YFP, and tubulin. 
Relative levels of STAT2 are shown below the images after normalization with tubulin. C. A possible model of nsp11 
protein constructed by SWISS-MODEL (https://swissmodel.expasy.org/). The loop of aa 57-62 is shown on upper 
and right side of the nsp11 dimer. D. Schematic illustration of mutant plasmids of nsp11-NTD-D2: D2M1 (I57A, 
H58A, and K59A) and D2M2 (Y60A, S61A, and R62A). E. The NTD-D2M1 fails to reduce STAT2, whereas NTD-
D2M2 induces STAT2 decrease similarly to wild type NTD-D2. F. IP of STAT2 co-precipitates nsp11 NTD-D2 and 
NTD-D2M2 but much less NTD-D2M1. IP of YFP-tagged nsp11 NTD-D2 and NTD-D2M2 co-precipitates STAT2, 





SWISS-MODEL analysis (https://swissmodel.expasy.org/) to determine if the aa 57-62 (IHKYSR) are 
located on surface of nsp11 protein. Indeed, aa 57-62 are located on one of the outside loops in the 
nsp11 NTD (Fig. 4.7C). PRRSV nsp11 is known to form a homodimer with by interaction between 
NTD and CTD of each monomer (144, 321). Accordingly, two loops of aa 57-62 are shown.   
We speculated that aa 57-62 might correlate with STAT2 interaction or degradation. We 
constructed two mutants of nsp11-NTD-D2: D2M1 (I57A, H58A, and K59A) and  D2M2 (Y60A, S61A, 
and R62A) with each having three amino acids changed to alanine (Fig. 4.7D). HEK293 cells were 
transfected with these mutants to test their effect on STAT2 protein level. WB results showed that nsp11 
NTD-D2M1 could not induce STAT2 reduction, while NTD-D2M2 had the similar effect to wild type 
NTD-D2 (Fig. 4.7E). These results indicate that the mutations in NTD-D2M1 led to the loss of the 
capability to induce STAT2 reduction and that aa 57-59 (IHK) were crucial for the nsp11 induction of 
STAT2 degradation.  
We further conducted co-immunoprecipitation to determine whether the mutation in NTD-D2M1 
led to the loss of interaction with STAT2. IP of STAT2 co-precipitated nsp11 NTD-D2 and NTD-D2M2 
in similar levels but NTD-D2M1 at a reduced level. In contrast, cells transfected with EV and NTD-
D2M1 had higher level of STAT2 than those of NTD-D2 and NTD-D2M2, as shown in WB of whole 
cell lysate (Fig. 4.7F). Conversely, YFP IP of NTD-D2 and NTD-D2M2 co-precipitated STAT2, 
whereas much less STAT2 could be co-precipitated by IP of NTD-D2M1 and no STAT2 in IP of YFP 
empty vector. These results demonstrated that the mutations of aa 57-59 in NTD-D2M1 affected nsp11 
function in the STAT2 degradation via weakening its interaction with STAT2.  
Discussion  
Canonical JAK-STAT pathway is activated by many cytokines, including IFNs, interleukins, and 





STAT members: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6. Among these 
seven STATs, STAT2 is unique (320). STAT2 is only activated by type I and type III IFNs, while 
STAT1 can respond to all three types of IFNs, IL-4, and IL-6 (322). Except for STAT2, all other STAT 
proteins have at least two isoforms with specific functions. Moreover, STAT2 is the largest STAT with 
the molecular mass of 113 kDa.  
In addition to be a key component in the canonical IFN-activated JAK-STAT signaling, STAT2 
involves in STAT1-independent IFN signaling (207). In the non-canonical IFN signaling pathway, 
STAT2/IRF9 complex functions an ISGF3-like response and provides an alternative antiviral activity in 
the deficiency of STAT1 (207). It was reported that STAT2 binds to the ISRE of ISG15, ISG56, IFI27, 
MX1, OAS2, and IFIT3 genes in the absence of STAT1. Moreover, the study of STAT2/IRF9 identified 
a set of ISGF3-independent ISGs, including CCL8 and CX3CL1. In addition, during lymphocytic 
choriomeningitis virus (LCMV) infection, STAT2/IRF9 directed pro-inflammatory immune response in 
the absence of STAT1, suggesting that the ISGF3-like complex has a novel role in inflammation (323). 
Therefore, STAT2 is indispensable in IFN-activated signaling. 
In this study, we demonstrated that PRRSV antagonizes STAT2 signaling via nsp11-mediated 
degradation. The observation was confirmed from multiple aspects. First, PRRSV induced STAT2 
degradation in both MARC-145 and PAM cells but had no effect on STAT1 protein level. Several 
strains from both PRRSV species reduced STAT2, without affecting STAT1, which indicates that the 
PRRSV-induced STAT2 reduction was specific and might be an inherent property of PRRSV infection. 
Secondly, the PRRSV-induced STAT2 reduction was dose and time-dependent. Thirdly, MG132 
treatment restored STAT2 level in PRRSV-infected cells, which indicates that PRRSV-mediated STAT2 





shortened by PRRSV from 30 to 10 hours. PRRSV infection had minimal effect on STAT2 transcript 
level, but induced significantly higher STAT2 poly-ubiquitination level than mock-infected cells.  
UV-inactivated PRRSV had no effect on STAT2 protein level, which indicates that the structural 
proteins of PRRSV had a negligible role in PRRSV-mediated STAT2 reduction. PRRSV nsp11 was 
identified to be responsible for STAT2 reduction. Consequently, nsp11 was able to inhibit IFN-α 
activated expression of ISRE reporter. Nsp11 was found to suppress MAVS and RIG-I expression 
through its endoribonuclease domain to antagonize type I IFN induction (147, 148). It was reported that 
nsp11 has DUB activity, which perturbs NF-κB activation (145). Recently, it was reported that nsp11 
recruits cellular deubiquitinase OTULIN to inhibit the production of type I IFNs (324).  
Since we demonstrated that PRRSV had no effect on STAT2 mRNA level and that nsp11 NTD 
was responsible for STAT2 reduction, the endoribonuclease activity in the C-terminal domain of nsp11 
should have no role in the STAT2 downregulation. Wang et al. (145) reported that nsp11 has pan-DUB 
activity and that amino acids C112, H144, D173, K180, and Y219 are crucial for the DUB activity. 
However, we found that STAT2 poly-ubiquitination level in PRRSV-infected cells was higher than 
mock-infected cells. Overexpression of nsp11 NTD (aa 1-90) also led to higher STAT2 poly-
ubiquitination level (data not shown). The discrepancy is possibly because that different PRRSV strains 
and cells are used in different labs and that nsp11 might exert the DUB activity indirectly. The second 
speculation is more plausible. Our results is consistent with another report that nsp11 lacks conserved 
catalytic residues for DUB and cannot pulldown the ubiquitin (321). It was proposed that nsp11 is not 
directly involved in deubiquitinating activity.  
We further determined the mechanism of nsp11-mediated STAT2 reduction. The nsp11 NTD is 
formed by six β-strands and two α-helices and is connected to the catalytic CTD through a linker domain 





NTD induced STAT2 degradation. Interestingly, IP of nsp11-NTD co-precipitated STAT2, which 
suggests that nsp11-NTD induces STAT2 degradation through interacting with STAT2.  
We also analyzed the interaction domain in STAT2. Like other STATs, STAT2 has six 
conserved domains. NTD is required for the tyrosine phosphorylation (325) and the interaction with IFN 
receptor (326). CCD of STAT2 is the specific domain that IRF9 binds (327). Direct binding of ISGF3 to 
DNA is mediated by STAT1 and IRF9, not STAT2, so STAT2 DNA-binding domain (DBD) seems to 
bind the promoter of ISGF3-independent ISGs (328). Moreover, STAT2 DBD contains a cluster of basic 
amino acids to function as a bipartite NLS when binding with the conserved corresponding region of 
STAT1 (329). The function of linker domain (LD) remains unknown. The SH2 domain is responsible 
for STAT2 to bind to phosphorylated IFN receptor and interact with phosphorylated STAT1 to form a 
heterodimer (330). Transactivation domain (TAD) is indispensable for transcription factors to recruit 
other co-activators or transcriptional regulators (331). One nuclear export signal (NES) lies in STAT2 
TAD to mediate STAT2 exportation from the nucleus back to the cytoplasm (332).  
Our IP and confocal microscopy analyses showed that the NTD and CCD of STAT2 interacted 
with nsp11-NTD. Interestingly, the STAT2 truncates had different distribution pattern from the full-
length STAT2 (Fig. 6C). STAT2-D1 and STAT2-D2 showed more punctates in the cytoplasm than the 
full-length STAT2, whereas STAT2-D3 displayed homogenous cytoplasmic distribution. When co-
transfected with nsp11, there were more punctates of STAT2, STAT2-D1 and STAT2-D2 in distribution 
than they were expressed alone. These results indicate that the interaction of nsp11 and STAT2 results in 
more punctate distribution pattern.  
In addition, we identified the critical amino acids in nsp11 that correlate with the STAT2 
reduction. Our results showed that the nsp11 NTD-D2 and NTD-D3 led to STAT2 reduction, whereas 





computational structure analyses, and generated two mutants. Mutation at aa 57-59 (IHK) in NTD-
D2M1 led to the loss of the nsp11 capability in inducing STAT2 degradation. This suggests that aa 57-
59 residues are crucial to the nsp11-induced STAT2 reduction. Co-IP results showed that NTD-D2M1 
had much weaker interaction with STAT2 than NTD-D2M2 and wild type NTD-D2. The NTD-D2M2 
could co-precipitate similar level of STAT2 to NTD-D2. These results indicate that aa 57-59 are 
indispensable for nsp11 to interact with and downregulate STAT2.  
As the first line of defense against viral infections, IFN is indispensable in the host innate 
immunity. To antagonize IFNs, PRRSV suppresses the production of type I IFNs by inhibiting IRF3 
phosphorylation (119), cleaving MAVS (333), and suppressing RIG-I and MAVS expression (147), and 
blocks IFN-activated downstream signaling by degrading KPNA1 to block STAT1/STAT2 nuclear 
translocation (121) and inducing STAT3 degradation (309). In this study, we further demonstrated that 
PRRSV also targets STAT2 to antagonize IFN signaling.  
In conclusion, our results demonstrated that PRRSV infection induced STAT2 degradation via 
the ubiquitin-proteasome pathway. Specifically, PRRSV induces STAT2 degradation by interaction 
between nsp11-NTD and STAT2 NTD and CCD, and aa 57-59 residues in nsp11 are critical for the 
interaction with and downregulation of STAT2. This provides further insights of PRRSV interference 
with IFN signaling, in addition to inhibiting STAT1/2 translocation from the cytoplasm into the nucleus. 
This study not only identifies additional function of nsp11 having endoribonuclease and DUB activities, 
but also provides further insight into PRRSV interference with IFN signaling and consequent host 
immune response. 
 
Table 4.1 List of primers used in Chapter 4 






a.  F: forward primer, R: reverse primer. The “32” and “85” before a primer name indicate 
the primer is based on sequences of PRRSV VR-2332 (GenBank accession# U87392) and VR-2385 
(GenBank accession# JX044140), respectively. The “R” before a primer name indicates the primer was 
designed for real-time PCR.  
b.  The italicized alphabets indicate restriction enzyme cleavage sites for cloning.    
 










85nsp11-LC-F CGGAATTCGTTAAGGGCGAGGCTCAA Nsp11-LCTD 




85nsp11-NTD-2F CGGAATTCACCAGCCTTCGCCCTATC Nsp11-NTD-D2 
















STAT2F2 GCGAATTCAACCAGCAGTTCTTCTCC STAT2D3 
R-STAT2-F1 AACCGTACACGAAGGAGGTG STAT2 

























Chapter 5: Porcine reproductive and respiratory syndrome virus antagonizes 
JAK-STAT3 signaling via nsp5 by inducing STAT3 degradation 
Abstract 
 STAT3 is a pleiotropic signaling mediator of many cytokines including IL-6 and IL-10. STAT3 
is known to play critical roles in cell growth, proliferation, differentiation, immunity and inflammatory 
responses. The objective of this study was to determine the effect of PRRSV infection on the STAT3 
signaling since PRRSV induces a weak protective immune response in host animals. Here we report that 
PRRSV infection of MARC-145 cells and primary porcine pulmonary alveolar macrophages led to 
significant reduction of STAT3 protein level. Several strains of both PRRSV type 1 and type 2 led to a 
similar reduction of STAT3 protein level but had minimum effect on its transcripts. The PRRSV-
mediated STAT3 reduction was in a dose-dependent manner as STAT3 level decreased along with 
incremental amount of PRRSV inocula. Further study showed that nsp5 of PRRSV induced the STAT3 
degradation by increasing its polyubiquitination level and shortening its half-life from 24 h to 
approximately 3.5 h. The C-terminal domain of nsp5 was shown to be required for the STAT3 
degradation. Moreover, the STAT3 signaling in the cells transfected with nsp5 plasmid was significantly 
inhibited. These results indicate that PRRSV antagonizes the STAT3 signaling by accelerating STAT3 
degradation via the ubiquitin-proteasomal pathway. This study provides insight into the PRRSV 
interference with the JAK-STAT signaling, leading to perturbation of the host innate and adaptive 
immune responses.  
Introduction 
PRRS has been an economically important viral disease in the swine industry since it was first 





causative agent of the devastating disease is PRRSV, a small enveloped RNA virus belonging to the 
genus Arterivirus, family Arteriviridae, order Nidovirales (7, 335). There are two PRRSV species in the 
newly proposed taxonomy, PRRSV-1 and PRRSV-2, corresponding to the currently known genotype 
Type 1 (European)  and Type 2 (North American) PRRSV, respectively (7).  PRRSV virions contain a 
single-stranded, positive-sense RNA genome in a size of approximately 15 kb. The PRRSV genome 
encodes over ten ORFs (46, 312, 335). PRRSV mainly targets PAMs and some lineages of monocytes in 
pigs (336). PRRSV propagation in vitro is generally conducted on MARC-145 cells, which are derived 
from epithelial cells of a monkey kidney (337).  
A typical feature of the immune response to PRRSV infection in pigs is delayed onset and low 
titer of virus neutralizing antibodies, and weak cell-mediated immune response (52, 338). PRRSV 
infection is also characterized by prolonged viremia followed by persistent viral replication in regional 
lymph nodes for as long as 250 days (49).  One of the possible reasons for the weak protective immune 
response is that PRRSV interferes with the innate immunity, such as inhibition of the synthesis and 
downstream signaling of type I IFNs (120, 121, 306, 339). Cytokines including type I IFNs that are 
produced at the site of infection, stimulate and coordinate the innate and adaptive immune responses 
against the invading pathogen (191-193). Many of the cytokines initiate function by binding to specific 
receptors on cells to activate the JAK-STAT signal pathway (194, 195). STATs are a family of 
transcription factors that regulate cell growth, differentiation, proliferation, apoptosis, immunity, 
inflammatory responses, and angiogenesis. There are seven STAT proteins (STAT1, 2, 3, 4, 5A, 5B, and 
6) in mammalians. Each STAT member responds to a defined set of cytokines, though some of the 
cytokines can induce signaling via several STAT proteins (195, 196, 202). STAT proteins are activated 
by JAK phosphorylation of specific tyrosine residues, followed by homodimer or heterodimer formation 





Among all the STAT proteins, STAT3 is known as highly pleiotropic in mediating the 
expression of a variety of genes in response to both cytokines and growth factors, and thus plays a 
pivotal role in numerous cellular processes including cell survival, proliferation, embryogenesis, and the 
immune response (195, 208, 209). Numerous cytokines, including IL-5, IL-6, IL-9, IL-10, IL-11, IL-12, 
IL-21, IL-22, IL-27, OSM, IFN-γ, TNF-α and LIF, trigger STAT3 activation (202, 210). The IL-6 
family cytokines including IL-6, OSM, and LIF bind to the gp130 receptor and activate STAT3, known 
as the gp130/JAK-STAT3 signaling. IL-6, a pleiotropic cytokine, plays important roles in triggering 
acute phase response of the body to injury or inflammation. OSM, a multifunctional cytokine produced 
by activated T lymphocytes, monocytes, and dendritic cells, enhances the antiviral effects of IFN-α and 
plays a role in the induction of the adaptive immune response to pathogens (340, 341). STAT3 is found 
to be a central regulator of lymphocyte differentiation and function (197).  Mutations in STAT3 cause 
autosomal dominant hyper-IgE syndrome, a rare multisystem primary immunodeficiency characterized 
by recurrent bacterial infections in skin and lung and with abnormally high levels of IgE (213, 214).  
PRRSV blocks the nuclear translocation of STAT1 and STAT2 to inhibit the IFN signaling 
pathway via the nsp1β (120, 121).  However, PRRSV effect on the gp130/JAK-STAT3 signaling 
remains unknown. In this study, the objective was to determine PRRSV effect on the STAT3 signaling. 
We discovered that PRRSV inhibits the STAT3 signaling via inducing STAT3 degradation via nsp5. 
Infection of MARC-145 cells by several PRRSV type 1 and type 2 strains resulted in a reduction of 
STAT3 protein without affecting its transcript level. The addition of the proteasome inhibitor MG132 to 
the PRRSV-infected cells restored the STAT3 protein levels. Transient expression of nsp5 led to a 
reduction of STAT3 protein via degradation through the ubiquitin-proteasome pathway. The C-terminal 
portion of nsp5 is responsible for the induction of STAT3 degradation.  In consequence, nsp5 inhibited 
the OSM-activated gp130/JAK-STAT3 signaling pathway. This finding provides further insight into 





Materials and methods 
Cells, viruses, and chemicals 
MARC-145 (337), HEK293 (ATCC® CRL-1573™) and HeLa (ATCC® CCL-2™) cells were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS). Primary PAM cells were prepared and cultured in RPMI1640 medium as previously 
described (310). The cryopreserved PAM cells were revived and pre-cultured for 24 hours before used 
for virus inoculation.  
PRRSV strains VR-2385 (342), VR-2332 (343), Ingelvac PRRS® MLV (311), and Lelystad 
(312) were used to inoculate MARC-145 cells at a multiplicity of infection (MOI) of 1. The median 
tissue culture infectious dose (TCID50) of PRRSV was determined in MARC-145 cells (344).  
MG132 (Sigma-Aldrich, St. Loius, MO), a proteasome inhibitor, was used to treat cells at a final 
concentration of 10 mM for 6 h prior to harvesting for further analysis. In order to determine the half-
life of STAT3, cycloheximide (Sigma) was added to cultured cells at a final concentration of 100 µg/ml 
to block protein translation. OSM (R&D Systems, Inc., Minneapolis, MN) was used to activate the 
gp130/JAK-STAT3 signaling pathway at a final concentration of 10 ng/ml. The cells were harvested at 
the time points indicated in Results or the figure legends for Western blotting. The half-life of STAT3 
was determined using nonlinear regression in GraphPad Prism (GraphPad Software, Inc., La Jolla, CA) 
in the analysis of the densitometry data of the immunoblotting results.  3-Methyladenine (3-MA) 
(Thermo Fisher Scientific, Waltham, MA), an inhibitor of autophagy by blocking autophagosome 
formation (345), was used at 5 mM in treatment of cells for 12- 24 h. 
Cell viability assay was done with CellTiter-Glo® Luminescent Cell Viability Assay according 
to the manufacturer’s instructions (Promega, Mandison, WI). The cells to be tested were placed into 96-






The nsp5 of PRRSV VR-2385 was cloned into a pCAGEN-HA and pCDNA3-VenusC1 vectors 
(121) with the primers 32nsp5F1 and 85nsp5R2 (Table 1). The nsp5 deletion mutants were cloned into 
pCDNA3-VenusC1 vector with the primers: 32nsp5F1 and 85nsp5R7 for nsp5D1, 85nsp5F3 and 
85nsp5R2 for nsp5D2, 32nsp5F1 and 85nsp1R5 for nsp5D3, 85nsp5F6 and 85nsp5R2 for nsp5D4 
(Table 1). The resulting recombinant plasmids were confirmed by restriction enzyme digestion and 
DNA sequencing. The construction of pCDNA3-Ubiquitin-Myc plasmid and other PRRSV nsp plasmids 
was described previously (158, 346).  
The pEGFP-C1-STAT1 was a gift from Alan Perantoni (Addgene plasmid # 12301) (347). The 
pCDNA3-STAT3 was a gift from Jim Darnell (Addgene plasmid # 8706) (348). The pRc/CMV-FLAG-
STAT3 was a gift from Jim Darnell (Addgene plasmid # 8707) (349). The 4xM67 pTATA TK-Luc was 
a gift from Jim Darnell (Addgene plasmid # 8688) (350) and used for STAT3 reporter assay.  
Western blot analysis 
Protein samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and analyzed by Western blotting as described (313, 315). The primary antibodies used in 
this study were against STAT3 (Santa Cruz Biotechnology, Inc., Dallas, TX), phospho-STAT3 (Tyr705, 
clone EP2147Y) (Thermo Fisher Scientific), ubiquitin (Santa Cruz), hemagglutinin (HA) (Thermo 
Fisher Scientific), FLAG (Sigma), green fluorescence protein (GFP) (Rockland Immunochemicals, Inc., 
Gilbertsville, PA), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Santa Cruz) and β-tubulin 
(Sigma). The secondary antibodies used in this study were goat anti-rabbit or goat anti-mouse IgG 
conjugated with horseradish peroxidase (Rockland Immunochemicals). The chemiluminescence signal 
acquisition and densitometry analysis were conducted using the Quantity One program, version 4.6 in a 





Immunoprecipitation (IP)  
IP was conducted as previously described (121). The clarified cell lysate was incubated with the 
STAT3 antibody (Santa Cruz), followed by incubation with protein G-agarose (KPL, Inc., Gaithersburg, 
MD). The IP samples were subjected to Western blotting with antibodies against ubiquitin, STAT3, and 
HA. To determine ubiquitinated STAT3, ubiquitin aldehyde (Boston Biochem, Inc., Cambridge, MA), a 
specific inhibitor of ubiquitin C-terminal hydrolases, was included in the lysis buffer at a final 
concentration of 2.53 µM.  
RNA isolation and real-time PCR 
Total RNA was isolated from HEK293 and MARC-145 cells with TRIzol reagent (Thermo 
Fisher Scientific) in accordance with the manufacturer’s instructions. Reverse transcription and real-time 
quantitative PCR (RT-qPCR) were conducted as described (310, 351). The real-time PCR primers used 
for STAT3 were R-STAT3-F1 and R-STAT3-R1 (Table 1). Transcripts of ribosomal protein L32 
(RPL32) were also amplified and used to normalize the total input RNA. Primers for PRRSV and 
RPL32 were described (121). The relative transcript levels were shown as folds in comparison with the 
mock-treated control after RPL32 normalization.  
Reporter assay 
HEK293 cells were transfected with the STAT3 reporter plasmid 4xM67 pTATA TK-Luc (350) 
and nsp5 plasmids. The Renilla luciferase vector pRL-TK (Promega, Madison, WI), which expresses 
Renilla luciferase under the control of a constitutively active promoter, was also transfected for 
normalization. At 24h after transfection, OSM was added into the cells at a final concentration of 10 
ng/ml. After incubation for another 24 hours, the cells were lysed for luciferase activity assay of firefly 





without OSM treatment was included as a control for assessment of the STAT3 activation level. The 
relative firefly luciferase activity is shown after normalization with the Renilla level as described (158).  
Statistical analysis 
Differences in indicators between treatment group and control were assessed using the Student t 
test. A two-tailed P value of less than 0.05 was considered significant.  
Results 
OSM inhibits PRRSV replication and PRRSV infection reduces STAT3 without affecting its transcript 
level  
OSM, a member of the IL-6 family, was found to synergistically inhibit the replication of 
hepatitis C virus in combination with IFN-α (340, 341). We wondered if OSM alone had any antiviral 
role against PRRSV. MARC-145 cells were pre-treated with OSM for 24 h before inoculated with 
PRRSV strain VR-2385. Real-time PCR result showed that the OSM treatment significantly reduced 
PRRSV RNA replication in comparison with mock-treated control, whereas OSM had minimum effect 
on cell viability (Fig. 5.1A). Based on our early study of the IFN-activated JAK-STAT signaling (120), 
we reasoned that PRRSV would antagonize the OSM-activated gp130/JAK-STAT3 signaling. We first 
determined the OSM-activated STAT3 phosphorylation in PRRSV-infected cells. The result showed that 
the STAT3 phosphorylation level in the PRRSV-infected cells was 15% of the mock-infected cells after 
OSM stimulation (Fig. 5.1B). The STAT3 protein level in the infected cells was significantly reduced to 





To exclude the possibility that PRRSV reduced STAT3 non-specifically, we examined STAT1 
protein level. Compared to mock-infected cells, STAT3 level in the infected cells was reduced to 0.36-
fold, whereas STAT1 level was unchanged (Fig. 5.1C). As MARC-145 cells are monkey-derived though 
they are PRRSV-permissible, we wondered if PRRSV had the same effect on STAT3 in primary PAM 
cells, which are main target cells in pigs during acute PRRSV infection. PAM cells were infected with 
VR-2385 and harvested 16 hpi for immunoblotting. Similarly, STAT3 level in the PRRSV-infected 
PAM cells was reduced to 0.37-fold in comparison to mock-infected control, whereas STAT1 remained 
steady (Fig. 5.1D). The harvesting of infected PAMs was done at 16 hpi as VR-2385 infection in the 
 Fig. 5.1 PRRSV infection reduces STAT3 in MARC-145 and PAM cells.  A. OSM treatment of MARC-145 
cells inhibits PRRSV replication and has minimum effect on cell viability. The cells were pre-treated with 
OSM for 24 h before inoculated with PRRSV VR-2385 at an MOI of 1. The cells were harvested 24 h post 
infection (hpi). Relative percentage of PRRSV RNA levels determined by real-time PCR is shown. Significant 
difference from the untreated cells is denoted by “**” for P < 0.01. B. PRRSV reduces STAT3 phosphorylation 
in MARC-145 cells upon OSM stimulation. The cells were infected with VR-2385 at an MOI of 1, incubated 
for 48 h, and treated with OSM for 30 min before harvested for Western blotting (WB) with antibody against 
STAT3, phosphorylated STAT3 (pSTAT3), and tubulin. Relative levels of pSTAT3 and STAT3 are shown 
below the images after normalization with tubulin in densitometry analysis. C. PRRSV reduces STAT3 protein 
level in MARC-145 cells but has minimum effect on STAT1. Relative levels of STAT3 are shown below the 
images after normalization with GAPDH. D. PRRSV reduces STAT3 level in PAM cells but has minimum 






cells progresses faster than in the MARC-145 cells.  
To exclude the possibility that the STAT3 reduction is the consequence from infection of 
PRRSV strain VR-2385 only, we included strains from both PRRSV type 1 and type 2 in the test. 
MARC-145 cells were infected with PRRSV type 2 strains VR-2385, Ingelvac PRRS® MLV, and VR-
2332 or PRRSV type 1 strain Lelystad. Compared to mock-infected cells, STAT3 protein levels in the 
cells infected with VR-2385, MLV, VR-2332 and Lelystad were reduced to 0.37, 0.33 0.24, and 0.33-
fold, respectively, whereas STAT1 remained steady (Fig. 5.2A and 5.2B). We reasoned that STAT3 
reduction could be due to a decrease of transcription and/or translation, or accelerated protein 
degradation. To determine the mRNA level of STAT3 in the cells with PRRSV infection, we conducted 
RT-qPCR. The results showed that there was no significant difference in the mRNA levels of 
endogenous STAT3 between the PRRSV-infected and mock-infected cells (Fig. 5.2C). These results 
Fig. 2. Infection of MARC-145 cells  
 
Fig. 5.2 Infection of MARC-145 cells with both PRRSV-1 and PRRSV-2 strains reduces STAT3 
protein level, but has minimum effect on STAT3 transcripts. A. Reduction of STAT3 protein level but 
no effect on STAT1 level in MARC-145 cells infected with PRRSV-1 strains. The cells were infected with 
PRRSV-1 strains VR-2385 (VR), Ingelvac PRRS
®
 MLV, and VR-2332 (VR1). At 48 hpi, the cells were 
harvested for WB with antibody against STAT3, STAT1 and tubulin. Relative levels of STAT3 are shown 
below the images after normalization with tubulin. B. Reduction of STAT3 protein level by PRRSV-2 strain 
Lelystad.  C. STAT3 mRNA levels in PRRSV-infected cells. Relative STAT3 mRNA levels are shown in 






indicated that the PRRSV-induced reduction of STAT3 protein level was not due to perturbation of its 
transcripts. 
PRRSV reduces STAT3 protein level in a dose and time-dependent manner  
To further study the PRRSV-mediated reduction of STAT3, we inoculated MARC-145 cells with 
a different amount of VR-2385. Along with the incremental amount of VR-2385 inoculation, the STAT3 
protein level was reduced in a dose-dependent manner, whereas STAT1 level remained relatively stable 
(Fig. 5.3A). Densitometry analysis showed that the STAT3 level in MARC-145 cells inoculated with an 
MOI of 0.01, 0.1, 1 and 10 was reduced to 0.43, 0.38, 0.27, and 0.22-fold, respectively, compared with 
mock-infected control. VR-2385 RNA levels in the infected cells significantly increased along with the 
incremental inocula (Fig. 5.3B), as expected.  
Fig. 3. PRRSV reduces STAT3 protein  Fig. 5.3 PRRSV reduces STAT3 protein level in a dose and time-dependent manner. A. Dose-
dependent reduction of STAT3 by PRRSV strain VR-2385. MARC-145 cells were inoculated with 
incremental MOI of VR-2385 and harvested for WB with antibodies against STAT3, STAT1, and tubulin 
at 48 hpi. Relative levels of STAT3 are shown below the images after normalization with tubulin. B. 
PRRSV RNA levels in the infected cells. The cells were harvested for RNA isolation and RT-qPCR at 24 
hpi. Error bars represent standard errors of the results of repeated experiments. Significant differences in 
RNA level from an MOI of 0.01 are denoted by “**” for P < 0.01 and “***” for P< 0.001. C. Temporal 
kinetics of STAT3 levels in PRRSV-infected cells. MARC-145 cells were infected with VR-2385 at an 
MOI of 1. At different time points, the cells were harvested for WB. Relative levels of STAT3 are shown 





To examine the PRRSV effect on the temporal kinetics of STAT3, we infected MARC-145 cells  
with VR-2385 and harvested the cells 24, 36, and 48 hpi. Compared to the mock-infected cells at each 
time point, the STAT3 levels in the virus-infected cells at 24, 36 and 48 hpi were reduced to 0.63, 0.33, 
and 0.24-fold, respectively (Fig. 5.3C). This result demonstrated that PRRSV infection reduces STAT3 
protein level in a time-dependent manner.  
Fig. 5.4 PRRSV mediates STAT3 reduction via ubiquitin-proteasomal degradation pathway. A. MG132 
treatment restores STAT3 level in PRRSV-infected cells. MARC-145 cells were infected with VR-2385 at an 
MOI of 1. At 30 hpi, the cells were treated with MG132 for 6 h and then harvested for Western blotting with 
antibodies against STAT3 and GAPDH. Non-treated and mock-infected cells were included as controls. 
Relative levels of STAT3 are shown as folds below the images after normalization with GAPDH. B. PRRSV 
replication is not affected by the MG132 treatment. Relative PRRSV RNA levels determined by real time 





PRRSV mediates STAT3 reduction via the ubiquitin-proteasomal degradation pathway  
The results above showed that PRRSV infection reduced the level of STAT3 protein, but had 
minimum effect on its transcript level. We reasoned that the STAT3 reduction could be possibly due to 
accelerated degradation by the ubiquitin-proteasomal pathway. To test this, MG132, a proteasome 
inhibitor, was added to the cells at 30 h after VR-2385 infection. The cells were harvested 6 h later for 
STAT3 examination. The MG132 treatment of the infected cells resulted in the restoration of STAT3 to 
a level similar to the mock-infected cells (Fig. 5.4A). PRRSV RNA levels in the cells with or without 
MG132 treatment are similar (Fig. 5.4B). This result indicates that PRRSV mediates the STAT3 
reduction via ubiquitin-proteasomal degradation pathway. 
 
Fig. 5. Screening of PRRSV nsps to  
 
Fig. 5.5 Screening of PRRSV nsps to identify the viral protein that is responsible for reduction of 
STAT3 level. A. Nsp5 reduces STAT3 in HeLa cells, whereas other PRRSV nsps have minimum effect. 
The cells were transfected with individual HA-nsp plasmids.  A GFP plasmid was included as a control. At 
36 hours post transfection (hpt), WB against STAT3, HA and tubulin were done to detect endogenous 
STAT3 protein level in cells with transient expression of the nsps. Relative levels of STAT3 are shown 
below the images. B. The nsp2, nsp9, and nsp10 have minimum effect on STAT3 level in HeLa cells. The 
cells were transfected with FLAG-nsp2, FLAG-nsp9, HA-nsp10 or GFP plasmid.  C. The nsp3 has 





PRRSV nsp5 reduces STAT3 protein level  
Having demonstrated that PRRSV infection reduces the STAT3 protein level, we wondered 
which protein of PRRSV was responsible for the reduction. HeLa cells were transfected with plasmids 
encoding PRRSV VR-2385 nsps or structural proteins for assessment of their effect on STAT3 levels. 
Western blotting results showed that cells transfected with nsp5 plasmid had 0.4-fold STAT3 protein 
level compared with cells transfected with GFP, whereas cells transfected with the other PRRSV 
plasmids had no significant reduction (Fig. 5.5A, 5.5B, & 5.5C). The nsp2, nsp3, nsp9, nsp10 are much 
larger than the other nsps and were analyzed separately in the immunoblotting. The structural proteins 
had minimum effect on STAT3 and were not pursued further in this study (data not shown). Therefore, 
nsp5 was selected for further analysis.  
Fig. 5.6 PRRSV nsp5 reduces STAT3 protein level.  A. Nsp5 reduces STAT3 protein level in a 
dose-dependent manner. HEK293 cells were transfected with nsp5 plasmid in incremental amounts. 
WB with antibodies against STAT3, HA and tubulin was conducted at 48 hpt. Relative levels of 
STAT3 are shown below the images after normalization with tubulin. B. 3-MA treatment is unable to 
rescue STAT3 protein level in HEK293 cells co-transfected with 0.5 µg HA-nsp5 and 0.5 µg STAT3 
plasmid. Mock-treated cells were included as controls. The cells were treated with 3-MA for 24 h 
before harvested for WB. Relative levels of STAT3 are shown below the images. C. Nsp5 has no 
effect on STAT1 expression. HEK293 cells were transfected with 0.5 µg pCAGEN-HA-nsp5 plasmid 
and 0.5 µg pEGFP-C1-STAT1 plasmid. WB against STAT1 antibody was done at 36 hpt. Relative 





Nsp5 plasmid was used to transfect HEK293 cells to confirm the effect on STAT3. Compared with 
the cells transfected with empty vector, the cells transfected with nsp5 plasmid reduced STAT3 protein level 
in a dose-dependent manner (Fig. 5.6A). Densitometry analysis showed that the STAT3 levels in HEK293 
cells transfected with 0.25, 0.5, 1.0 and 2.0 µg of nsp5 plasmid were reduced to 0.64, 0.40, 0.33 and 0.05-
fold, respectively, compared with the empty vector control. Nsp5 protein level increased along with the 
incremental amount of the plasmid DNA in the transfection.  
 Nsp5 is known to induce autophagy (352, 353). To exclude the possibility that nsp5 reduces STAT3 
via autophagy pathway, we treated the cells with autophagy inhibitor 3-MA (345). Compared with cells 
transfected with the empty vector, the cells with nsp5 had similar lower STAT3 level in the presence or 
absence of 3-MA (Fig. 5.6B). Like the whole virus infection, nsp5 alone had no effect on the STAT1 level 
(Fig. 5.6C).  
PRRSV nsp5 leads to elevation of STAT3 ubiquitination and shortening of its half-life  
Since MG132 treatment restored STAT3 levels in cells with PRRSV infection, we reasoned that 
the STAT3 ubiquitination levels in the cells with nsp5 expression would increase. HEK293 cells were 
co-transfected with STAT3 and nsp5 plasmids. The cells were lysed for IP with an antibody against 
STAT3. Western blotting with ubiquitin antibody showed that ubiquitinated STAT3 in the cells with 
nsp5 expression was 12.6-fold greater than that in the cells transfected with the empty vector (Fig. 
5.7A), which indicates that there was more polyubiquitination of STAT3 in the cells with nsp5 
expression. Blotting with HA antibody failed to determine any nsp5 band in the IP complex lane, which 
suggests that STAT3 did not interact with nsp5 under our testing conditions. In addition, the input of 
whole-cell lysate was included in the blotting and results showed that the total ubiquitination level in the 
cells with nsp5 expression was similar to the cells transfected with empty vector (Fig. 5.7A). These 





We next tested whether the half-life of STAT3 would be shortened. HEK293 cells were co-
transfected with STAT3 and nsp5 plasmids and treated with cycloheximide, a translation inhibitor, 
followed by harvesting and immunoblotting at different time points. In the presence of nsp5, the STAT3 
level decreased at a higher rate than that in the cells transfected with the empty vector (Fig. 5.7B). At 5, 
10, 24, and 28 h after the cycloheximide treatment, the STAT3 levels in the cells with nsp5 expression  
were reduced by 59%, 85%, 93%, and 94%, respectively, whereas STAT3 in the cells transfected with 
the empty vector were reduced by 25%, 20%, 50%, and 71%, separately (Fig. 5.7B). The densitometry 
analysis was normalized with β-tubulin, which has a long half-life of 50 h (354). The expression of nsp5 
induced a shortening of the STAT3 half-life from 24 h to approximately 3.5 h. This result is consistent 
with the elevation of STAT3 polyubiquitination in the cells with nsp5 expression.  
Fig. 7. PRRSV nsp5 leads to STAT3  
 
Fig. 5.7 PRRSV nsp5 leads to STAT3 degradation by ubiquitin-proteasomal pathway.  A. Presence 
of nsp5 leads to elevation of STAT3 polyubiquitination level. IP with STAT3 antibody and then WB with 
antibodies against ubiquitin (Ub), STAT3 and HA were done. Samples of whole cell lysate (WCL) were 
included as controls. Relative levels of ubiquitinated STAT3 are shown below the images after 
normalization with STAT3 level. B. Nsp5 shortens STAT3 half-life from around 24 to 3.5 hours. 
HEK293 cells were transiently co-transfected with 0.5 µg STAT3 and nsp5 plasmids. The cells were 
treated with cycloheximide (CHX) at 100 µg/ml at 24 hpt and harvested at indicated hours post treatment, 
followed by WB with antibodies against STAT3 and tubulin. Relative levels of STAT3 are shown below 





The C-terminal domain of nsp5 appears to be responsible for the induced degradation of STAT3  
To map the domain of nsp5 involved in inducing the degradation of STAT3, deletion constructs 
of VR-2385 nsp5 were prepared. Based on analysis of nsp5 polypeptide sequence using Lasergene, four 
fragments of nsp5 were cloned into the pCDNA3-VenusC1 vector (Fig. 5.8A). Overexpression of the 
nsp5 truncation constructs in HEK293 cells was confirmed by immunoblotting with GFP antibody (Fig. 
5.8B).  
Immunoblotting results showed that the cells transfected with YFP-nsp5D2 (aa 59 to 170), YFP-
nsp5D3 (aa 1 to 122), and YFP-nsp5D4 (aa 86 to 170) had considerably lower STAT3 protein levels 
than the cells transfected with the empty vector (Fig. 5.8B). Densitometry analysis showed that the cells 
with YFP-nsp5D1, YFP-nsp5D2, YFP-nsp5D3, and YFP-nsp5D4 had STAT3 levels reduced by 8%, 
76%, 58%, and 67%, respectively, compared to the cells transfected with the empty vector. The results 
indicate that the nsp5D1 (aa 1 to 85) corresponding to the N-terminal domain has minimum effect on 
STAT3 level, whereas the C-terminal domain (aa 86-170) of nsp5 is responsible for the induced 
degradation of STAT3.   
Sequence analysis suggests that nsp5 polypeptides are highly hydrophobic and may be 
membrane associated. Analysis with TMHMM, a membrane protein topology prediction method (355), 
showed that nsp5 has five transmembrane domains spanning residues aa 13-35, 45-67, 79-101, 121-143, 
and 150-169 (Fig. 5.8C). There are two outside-oriented loops spanning residues aa 36-44 and aa 102-
120, and three inside-oriented loops spanning residues aa 1-12, 68-78, and 144-149 in nsp5. The 
outside-oriented loop spanning aa 102-120 is longer than other loops and located in the C-terminal 
domain.  
Sequence alignment of nsp5 showed that VR-2385 nsp5 has 96.5%, 85.3%, and 69.4% identical 
amino acid residues with VR-2332, MN184, and Lelystad, respectively. Among the 52 aa variations 





are in the C-terminal half. There is a highly conserved stretch of residues, aa 110-118, in the outside-
oriented loop spanning aa 102-120 (Fig. 5.8D). Among the nine residues in aa 110-118 of nsp5 from the 
Fig. 8. The C-terminal domain of nsp5  
 
Fig. 5.8 The C-terminal domain of nsp5 is required for STAT3 degradation. A. Schematic illustration 
of truncation plasmids nsp5D1, nsp5D2, nsp5D3, and nsp5D4. The numbers above the lines indicate amino 
acid residues of nsp5. B. The nsp5D2, nsp5D3, and nsp5D4 lead to STAT3 degradation, whereas nsp5D1 
has minimum effect. HEK293 cells were transfected with 0.5 µg YFP-tagged plasmids and harvested at 36 
hpt for immunoblotting with antibodies against STAT3, YFP and tubulin. Relative levels of STAT3 are 
shown below the images after normalization with tubulin. Molecular weight markers are added on the left 
of image YFP-nsp5. EV: empty vector. FL: full length. C. Predicted membrane protein topology of nsp5 
with TMHMM. The numbers on X-axis denote nsp5 residues. The bars in different colors indicate 
topology. The loops inside or outside of membrane are indicated by different colors. D. Alignment of 
amino acid sequence of nsp5 of PRRSV VR-2385, VR-2332, MN184 and Lelystad. The rectangle 
highlights the highly conserved residues. The numbers below the consensus sequence and on left indicate 





four PRRSV strains, eight are identical, which needs further study to determine whether they correlate 
with the nsp5 induction of STAT3 reduction.  
Nsp5 inhibits gp130/JAK-STAT3 signaling  
As a transcription activator, STAT3 mediates multiple important signaling pathways related to 
immune responses, cell growth, and cell survival. So we speculated nsp5 would inhibit the STAT3 
signaling as it reduced STAT3 protein level. First, we tested whether it inhibits the OSM-mediated 
STAT3 activation. As expected, the STAT3 phosphorylation in HEK293 cells transfected with nsp5 
plasmid was much lower than the cells with empty vector (Fig. 5.9A). The relative phosphorylated 
STAT3 levels in the cells with 0.25 and 1 µg nsp5 were reduced by 60% and 74%, respectively, in 
comparison with the control cells with empty vector. The relative STAT3 levels in the cells with 0.25 
and 1 µg nsp5 were reduced by 50% and 72%, respectively, in comparison with the control cells. The 
results indicate that the nsp5 inhibition of STAT3 phosphorylation was due to the reduction of STAT3 
protein level.  
Fig. 9. PRRSV nsp5 inhibits STAT3  
Fig. 5.9 PRRSV nsp5 inhibits STAT3 signaling. A. HEK293 cells transfected with nsp5 has much lower 
OSM-mediated STAT3 phosphorylation than the control cells with empty vector (EV). The cells were 
treated with OSM for 30 minutes before harvested for WB. Relative levels of phosphorylated STAT3 
(pSTAT3) and total STAT3 are shown below the images.  B. Nsp5 inhibits OSM-stimulated STAT3 
reporter expression.  HEK293 cells were co-transfected with 0.5 µg nsp5 plasmid, 0.5 µg STAT3 reporter 
and 0.05 µg Renilla plasmids. At 24 h post transfection, the cells were treated with OSM and harvested for 
luciferase activity assay 24 h later. Relative levels of firefly luciferase activity are shown as folds in 
comparison with EV control after normalization with Renilla activity. Significant difference in firefly 





We next tested whether nsp5 inhibits STAT3 reporter expression. HEK293 cells were co-
transfected with the incremental amount of nsp5 plasmid DNA along with STAT3 reporter plasmid 
4xM67 pTATA TK-Luc and pRL-TK. The cells were then treated with OSM for 24 h before harvested 
for luciferase assay. OSM induced obvious transactivation of 4xM67 pTATA TK-Luc in the cells 
transfected with the empty vector (Fig. 5.9B), whereas the luciferase activity values in the cells 
transfected with nsp5 plasmid from 0.125 to 1.0 µg were significantly (P < 0.001) lower. This result 
demonstrated that nsp5 led to the inhibition of the OSM-mediated gp130/JAK-STAT3 signaling via 
inducing degradation of the STAT3 protein.  
Discussion 
Our results in this study demonstrated that PRRSV inhibits the STAT3 signaling pathway by 
inducing degradation of STAT3. The JAK-STAT pathway is critical in relaying signals from cytokines 
and growth factors to regulate gene expression in biological processes including apoptosis, angiogenesis, 
differentiation, cell proliferation, inflammatory response, and immunity (194, 195). In particular, 
STAT3 is a central regulator of lymphocyte differentiation and function (197). It can regulate CD4+ T 
cell differentiation and control Th17 cells differentiation by IL-6 and IL-23. STAT3 deficiency affects 
the generation of memory CD8+ T cells (242, 243) and memory B cells (244, 245). Therefore, STAT3 is 
indispensable in the host immune system. PRRSV infection induces a weak cell-mediated immune 
response, in which PRRSV-specific T cells transiently appear two weeks after infection without a 
change in frequency of CD4+ and CD8+ T-cells (52). The STAT3 antagonizing may be one of the 
reasons for PRRSV interference with the development of protective immune response.  
We discovered that PRRSV inhibits the STAT3 signaling by inducing degradation of STAT3. 
The PRRSV-mediated degradation of STAT3 is specific as PRRSV has no effect on STAT1 protein 
level in MARC-145 and PAM cells.  The PRRSV-induced reduction of STAT3 also occurs in primary 





PRRSV as several strains from both PRRSV type 1 and type 2 including a vaccine strain are able to do 
so in MARC-145 cells. The STAT3 decrease was found due to degradation via the ubiquitin-mediated 
proteasome pathway because blocking this degradation pathway with MG132 resulted in the restoration 
of STAT3 levels in the cells infected with PRRSV.  
Macrophages are important immune effector cells and can respond to endogenous stimuli 
generated by injury or infection (356). PRRSV infection of PAMs leads to inhibition of IFN induction 
(339), suppression of the JAK-STAT signaling (120), and may result in the poor generation of stimuli to 
other cells, consequently ineffectual immune response. PRRSV infection in pigs leads to elevation of IL-
10 (357, 358) and induces lung lesions with inflammatory cell infiltration (359). IL-10 signaling via 
mediator STAT3 results in the generation of regulatory macrophages, which have an anti-inflammatory 
activity to dampen immunopathology.  PRRSV antagonizing the STAT3 signaling could interfere with 
the IL-10 regulatory function and leads to inflammation.  
PRRSV nsp5 was found to be responsible for the STAT3 reduction. Nsp5 induces elevation of 
the STAT3 polyubiquitination and shortens its half-life from 24 h to approximately 3.5 h. Our data 
suggests that nsp5 enhances STAT3 degradation via the ubiquitin-proteasomal pathway. There seems no 
direct interaction between nsp5 and STAT3 because IP with an antibody against STAT3 did not 
pulldown nsp5. Likewise, immunofluorescence assay and confocal microscopy did not determine co-
localization of nsp5 and STAT3 in cells co-transfected with both plasmids (data not shown). These 
results suggest that STAT3 and nsp5 have no direct interaction or, if any, transient. We presume that 
nsp5 activates an ubiquitin E3 ligase of STAT3 and accelerates proteasome degradation of the 
transcription activator. The E3 ligase for STAT3 proteasome degradation remains unknown though 
TMF/ARA 160, a Golgi-resident protein, was found to mediate the degradation of STAT3 (360). 
However, nsp5 was found to co-localize with the endoplasmic reticulum, not Golgi (data not shown). 





MA to block autophagy in this study did not rescue the STAT3 level, indicating autophagy was not the 
reason for the STAT3 reduction.  
Nsp5 is a hydrophobic transmembrane protein and can possibly form a membranous structure in 
the cytoplasm that could be the site for PRRSV replication (46). The C-terminal domain (aa 86 to 170) 
of nsp5 might be responsible for the STAT3 degradation as the deletion constructs nsp5D2, nsp5D3, and 
nsp5D4 containing the full or partial C-terminal domain led to the reduction, while nsp5D1 (aa 1 to 85) 
failed to do so. This C-terminal domain contains a mixture of hydrophobic and hydrophilic residues with 
a potential surface location motif, as shown by TMHMM analysis. In the outside-oriented loop in the C-
terminal domain, there is a stretch of residues that are highly conserved across the two PRRSV species.  
This suggests that these conserved residues might play a role in the nsp5-induced STAT3 reduction. 
Further work is needed to address the speculation.  
The nsp5-mediated degradation of STAT3 led to blocking the STAT3 signaling. In the OSM-
dependent transactivation of the reporter plasmid of the STAT3 binding promoter, the presence of nsp5 
resulted in significant reduction of the reporter expression. This result substantiates that PRRSV nsp5 
mediates the inhibition of the gp130-dependent signaling via its inducing STAT3 degradation.  
Due to its importance in the host innate and adaptive immune responses, STAT3 has been found 
to be the target of some viral pathogens. Measles virus V protein inhibits the IL-6 mediated STAT3 
signaling (234). V protein of mumps virus prevents responses to IL-6 and v-Src by inducing STAT3 
ubiquitination and degradation (238). Rabies virus interferon antagonist P protein inhibits the gp130 
receptor signaling by interacting with activated STAT3 (239). Inhibition of the STAT3 signaling by 
these viruses and PRRSV can lead to inhibition of a broad spectrum of cytokines and growth factors to 
thwart host antiviral responses and allow virus replication and spread in vivo. PRRSV was shown to 
inhibit the IFN-activated JAK-STAT signaling via blocking STAT1 nuclear translocation (120). The 





α5) (121). Here we found PRRSV interferes with the gp130/JAK-STAT3 signaling via nsp5. This sheds 
further light on PRRSV antagonizing the JAK-STAT signaling to have a conducive environment for its 
own replication and spread.  
In conclusion, our results demonstrated that PRRSV infection induces STAT3 degradation via 
the ubiquitin-proteasomal pathway. PRRSV nsp5 was found to be responsible for the STAT3 reduction 
and blocking its signaling. This finding provides insights for PRRSV pathogenesis and its interference 
with the host immune response.  
 
Table 5.1 List of primers used in Chapter 5 
Primera Sequences (5’ to 3’)b Target gene  
32nsp5F1 CGGAATTCGGAGGCCTCTCCACCGTCC Nsp5 
85nsp5R2 CCGCTCGAGTTACTCGGCAAAGTACCGCAGG Nsp5 
85nsp5R7 GCTCGAGTTAGCTGAAAAAGGCAAGTGAC Nsp5D1 
85nsp5F3 GGAATTCCCATGGTCTGCGCAAGTTC Nsp5D2 
85nsp5R5 GCTCGAGTTACACAACCATCATCCGAGGCAG Nsp5D3 
85nsp5F6 CGGAATTCAGCCTTGGTGCGGTGACCGG Nsp5D4 
R-STAT3-F1 GTGATGCTTCCCTGATTGTG STAT3 
R-STAT3-R1 GCAAGGAGTGGGTCTCTAGG STAT3 
a. F: forward primer, R: reverse primer. The “32” and “85” before a primer name indicates the primer 
is based on sequences of PRRSV VR-2332 (GenBank accession# U87392) and VR-2385 
(GenBank accession# JX044140), respectively. The “R” before a primer name indicates the primer 
was designed for real-time PCR.  





Chapter 6: Karyopherin alpha6 is required for the replication of porcine 
reproductive and respiratory syndrome virus and zika virus 
Abstract 
Movement of macromolecules between the cytoplasm and the nucleus occurs through the nuclear 
pore complex (NPC). Karyopherins comprise a family of soluble transport factors facilitating 
nucleocytoplasmic translocation of proteins through the NPC. In this study, we discovered that 
karyopherin alpha6 (KPNA6, also known as importin alpha7) was required for the optimal replication of 
PRRSV and Zika virus (ZIKV), which are positive-sense, single-stranded RNA viruses replicating in the 
cytoplasm. The KPNA6 protein level in virus-infected cells was much higher than that of mock-infected 
controls, whereas KPNA6 transcript remains stable. Viral infection blocked the ubiquitin-proteasomal 
degradation of KPNA6, which led to an extension of KPNA6 half-life and the elevation of KPNA6 level 
in comparison with mock-infected cells. PRRSV nsp12 protein induced the KPNA6 stabilization. 
KPNA6 silencing was detrimental to the replication of PRRSV, and KPNA6 knockout impaired ZIKV 
replication. Moreover, KPNA6 knockout blocked the nuclear translocation of PRRSV nsp1β but had a 
minimal effect on two other PRRSV proteins with nuclear localization. Exogenous restitution of KPNA6 
expression in the KPNA6 knockout cells results in restoration of the nuclear translocation of PRRSV 
nsp1β and the replication of ZIKV. These results indicate that KPNA6 is an important cellular factor for 
the replication of PRRSV and ZIKV.  
Introduction 
Transport of macromolecules in to and out of the nucleus must go through the nuclear pore 
complexes (NPCs), macromolecular structures (>60 MDa) consisting of approximately 30 proteins, on 





Transport of macromolecules across the NPCs requires a regulated energy-dependent process, which 
needs either direct interaction with the NPCs or association with different types of transport receptors. 
The largest group of transport receptors is designated as karyopherins (259, 363-365), which mediate the 
nuclear import of many cytoplasmic proteins. In the classical nuclear import pathway, cytoplasmic 
cargoes bearing a nuclear location sequence (NLS) are first recognized by karyopherin α, followed by 
association with karyopherin β1 (KPNB1) (259). The ternary importing complex karyopherin β/α/NLS-
cargo translocates through the NPCs to the nucleus. 
There are seven isoforms of karyopherin α (KPNA1-7) (259, 271, 366).  Due to their importance 
in nucleocytoplasmic trafficking, KPNAs play indispensable roles in signal transduction, especially 
immune response. For instance, KPNA1 is responsible for the nuclear translocation of STAT1 in 
interferon-stimulated gene expression (367, 368); KPNA1 and KPNA6 transport STAT3 (265) to 
activate interleukin-6  signaling pathway. Therefore, KPNAs are often targeted by viruses to interfere 
with the immune response. For example, Ebola virus VP24 interacts with KPNA1 in the region 
overlapping with phosphorylated STAT1 (pSTAT1), which blocks pSTAT1 nuclear translocation (231, 
232). HCV induces the cleavage of KPNB1 by NS3/4A to disrupt the IRF3 and NF-κB translocation to 
inhibit the IFN-β production (298). Hepatitis B virus (HBV) polymerase interferes with the IFN-α-
stimulated signaling by inhibiting the nuclear transportation of STAT1/2 via binding to KPNA1 
competitively (297). PRRSV inhibits the interferon-activated JAK-STAT signaling by blocking the 
nuclear translocation of the STAT1/STAT2 complex via inducing KPNA1 degradation (121). 
On the other hand, many viruses, especially those with DNA genome, have been found to exploit 
the karyopherins for their own benefit. DNA viruses generally deliver their genetic elements into the 
nucleus for propagation or integration into the host genome for latent infections. Karyopherins play an 
essential role in this process and thus are pivotal host dependency factors. For example, parvovirus 





papillomavirus is inhibited by antibodies against KPNA2 and KPNB1 (369). Moreover, herpesvirus and 
adenovirus are shown to rely on karyopherins for their nuclear entry (252). In addition, among RNA 
viruses, human immunodeficiency virus (HIV) (282) and influenza A virus (289) exploit karyopherins to 
translocate their proteins or genetic elements into the nucleus. KPNA1 and KPNA6 were found to be 
positive cellular factors for efficient replication of influenza A virus (287, 289, 370, 371).  
However, most RNA viruses, especially +ssRNA viruses, replicate in the cytoplasm rather than 
in the nucleus. Therefore, the nucleocytoplasmic trafficking machinery has not been linked to +ssRNA 
viruses. Particularly, it remains unknown whether KPNAs contribute to the replication of +ssRNA 
viruses. 
The +ssRNA viruses including the flavivirus, coronavirus, picornavirus, and arterivirus cause 
severe human or animal diseases. PRRSV is a small enveloped RNA virus belonging to the genus 
Rodartevirus, the family Arteriviridae (7, 372). This virus causes a contagious disease that is 
characterized by reproductive failure in sows and respiratory disease of variable severity in pigs of all 
ages (46). PRRS causes substantial economic losses to the swine industry and remains one of the top 
challenges since it was first reported in 1987. Zika virus (ZIKV) is a mosquito-borne flavivirus that 
caused recent outbreaks accompanied by severe manifestations including fetal microcephaly and the 
Guillain-Barre syndrome (GBS) (373-375). ZIKV belongs to the same Flavivirus genus of the 
Flaviviridae family as several other global human pathogens including dengue virus, yellow fever virus 
and West Nile virus (376).  
In a previous study, we discovered that PRRSV mediated KPNA1 degradation to antagonize 
interferon-activated signaling (121). Unexpectedly, we noticed that KPNA6 protein level was higher in 
PRRSV-infected cells than mock-infected control. The objective of this study is to examine KPNA6 
level in the infected cells, the mechanism of KPNA6 elevation, and its functions in the viral replication. 





infections induce KPNA6 elevation via extending its half-life and abrogating its ubiquitin-proteasomal 
degradation.  KPNA6 knockdown in MARC-145 cells via RNAi silencing inhibits the replication of 
PRRSV.  In addition, KPNA6 knockout in Vero cells via CRISPR/Cas9 system suppresses ZIKV 
replication. The nuclear translocation of PRRSV nsp1β is blocked in KPNA6 knockout cells. Exogenous 
restitution of KPNA6 expression in the KPNA6 knockout cells leads to the restoration of ZIKV 
replication and the nuclear translocation of PRRSV nsp1β. These results demonstrate that PRRSV and 
ZIKV harness KPNA6 for their own proliferation. 
Materials and methods 
Cells, viruses, and chemicals  
HEK293 (ATCC CRL-1573), MARC-145 (ATCC CRL12231) (337), HeLa (ATCC CCL-2), and 
Vero (ATCC CCL81) cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) at 37°C. Aedes albopictus clone C6/36 (ATCC CRL-
1660) were cultured in Minimum Essential Media (MEM) with 10% FBS at 28°C. 
Primary PAMs were revived from frozen stock that was previously collected from broncho-
alveolar lavage fluid of 4 to 5 weeks old, PRRSV-negative piglets (120), and maintained in RPMI1640 
medium supplemented with 10% FBS at 37°C as previously described (120).  
PRRSV VR-2385 (377) and VR-2332 (378) strains used in this study were propagated in 
MARC-145 cells. ZIKV PRVABC59 strain (379) was reproduced in C6/36 cells. Virus titers were 
determined in cultured cells by 10-fold serial dilutions and shown as the median tissue culture infectious 
dose (TCID50) (314).  
FuGeneHD (Promega, Madison, WI) was used to transfect plasmid DNA into the cells according 





Cycloheximide (CHX) (Sigma-Aldrich, St. Louis, MO), an inhibitor of protein synthesis, was 
used to treat cells at a final concentration of 50 µM to test the half-life of KPNA6 (121, 380). MG132 
(Sigma-Aldrich), a proteasome inhibitor, was used at a final concentration of 10 µM to treat cells for 6 h 
prior to harvesting cells (121, 380).  
MARC-145 cells stably expressing KPNA6 shRNA were established by the transfection of cells 
with pSIREN-RetroQ-ZsGreen-KPNA6-shRNA and pTK-Hyg plasmids. Then the cells were cultured 
under antibiotic hygromycin at a concentration of 50 µg/ml. The surviving cells were subjected to single 
cell cloning by the limited dilution. KPNA6 knockout Vero and HeLa cells by the CRISPR/Cas9 system 
(381, 382) were established by flow cytometry sorting of GFP-positive cells, that were transfected with 
the CRISPR plasmid PX461-sgKPNA6 containing a guide RNA (gRNA) and a CRISPR-associated 
endonuclease (Cas9). The empty vector containing Cas9 but no target gRNA was also used to establish 
stable Vero cells as controls. Restitution of KPNA6 expression in KPNA6 knockout Vero cells was 
established by the transfection of KPNA6-/- Vero cells with pCAGEN-KPNA6 and pTK-Hyg plasmids, 
followed by selection under the pressure of hygromycin.  
Plasmids  
KPNA6 (GenBank accession number NM_012316) was cloned into pCAGEN (Addgene plasmid 
11160) (383) with a Myc-tag at the N-terminus as previously reported (121). Plasmids of PRRSV nsps 
from strain VR-2385 (GenBank accession number JX044140) were described (121, 380). KPNA6 
shRNA were designed and cloned into plasmid pSIREN-RetroQ-ZsGreen according to the instructions 
of the manufacturer (Takara Bio USA, Inc., Mountain View, CA). Plasmid pTK-Hyg (GenBank 
accession number U40398) was purchased from Takara Bio USA. To establish KPNA6-knockout Vero 
cells by CRISPR/Cas9 system, a gRNA was designed and cloned into the vector pSpCas9n(BB)-2A-





plasmid construction are listed (Table 1). All plasmids constructed in-house were subjected to DNA 
sequencing to verify the inserts.  
Western blot analysis   
Whole cell lysate in Laemmli sample buffer was subjected to SDS-PAGE and Western blotting 
as previously described (315, 384). Antibodies against KPNA6 (Santa Cruz Biotechnology, Inc., Dalla, 
TX), KPNA1 (Santa Cruz), KPNA2 (Prosci Inc, Poway, CA), PRRSV nsp2 protein (14, 316), 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Santa Cruz), flavivirus E protein (385), 
hemagglutinin (HA) tag (ThermoFisher Scientific, Waltham, MA), cMyc tag (ThermoFisher Scientific), 
ubiquitin (Santa Cruz), β-tubulin (Sigma-Aldrich), and FLAG tag (Sigma-Aldrich) were used in the 
blotting. Pig anti-PRRSV serum (386) was used to detect nsp2 of PRRSV strain VR-2332 as the 
monoclonal antibody against nsp2 (14, 316) did not work with this strain. The secondary antibodies used 
in this study were horseradish peroxidase-conjugated rabbit anti-goat IgG (Rockland Immunochemicals, 
Inc., Gilbertsville, PA), goat anti-mouse IgG (Rockland), and goat anti-swine IgG (SeraCare Life 
Sciences, Gaithersburg, MD). The specific reactions were detected with chemiluminescence substrate, 
and the signal was recorded digitally using a ChemiDoc XRS imaging system using the Quantity One 
Program, Version 4.6 (Bio-Rad Laboratories, Hercules, CA). All experiments were repeated at least 
three times to ensure reproducibility.  
Reverse transcription and real-time PCR (RT-qPCR)  
Total RNA was isolated from cells with the TRIzol reagent (ThermoFisher Scientific) in 
accordance with the manufacturer’s instructions. Reverse transcription and real-time PCR with SYBR 
Green detection (ThermoFisher Scientific) were performed as described (310, 380). Transcript of RPL32 





PCR primers for KPNA6 and PRRSV are listed (Table 1). Primers for ZIKV are described previously 
(387). All experiments were repeated at least three times, with each experiment performed in triplicate. 
Immunofluorescence assay (IFA)  
IFA was carried out as reported (318) with antibodies against HA tag (ThermoFisher Scientific), 
cMyc tag (ThermoFisher Scientific), KPNA6 (Santa Cruz Biotechnology, PRRSV nsp2 protein (14, 
316), and flavivirus E protein (385). The specific reactions were detected by the conjugated secondary 
antibodies: goat anti-mouse IgG (H&L) Dylight™ 549, goat anti-mouse IgG (H&L) Dylight™ 488 and 
goat anti-rabbit IgG (H&L) Dylight™ 488 (Rockland Immunologicals). The cover glasses were 
mounted onto slides using SlowFade Gold antifade reagent containing 4’6’-diamidino-2-phenylindole 
(DAPI) (ThermoFisher) and observed using fluorescence microscopy. 
Cell viability assay  
To test the cytotoxicity of MG132, MARC-145 cells infected with PRRSV for 24 h were treated 
with MG132. DMSO-treated and non-infected cells were included as controls. After 6 h, cell viability 
was detected with CellTiter-Glo (Promega, Madison, WI) according to the manufacturer’s instruction. 
To compare the cell viability of KPNA6 knockdown and knockout cells with control cells, the same 
number of cells were plated in different wells. After 24 h, cell viability was determined with CellTiter-
Glo. All experiments were repeated at least three times, with each experiment performed in triplicate. 
Immunoprecipitation (IP)  
IP was conducted as described (380). The cell lysate was clarified and incubated with the 
specific antibody indicated in Results, followed by incubation with protein G-agarose (SeraCare Life 
Sciences). The IP complexes were subjected to Western blotting. To determine polyubiquitination of 





ubiquitin hydrolases, to the lysis buffer at a final concentration of 2.53 µM. The IP complexes were 
subjected to immunoblot analysis with the antibodies against ubiquitin and KPNA6. 
Statistical analysis  
Differences in indicators between treatment samples, such as KPNA6 mRNA level between the 
group in the presence of PRRSV infection and the mock-infected control, were assessed by Student t-
test. A two-tailed P-value of less than 0.05 was considered significant. 
Results 
PRRSV induces the increase of KPNA6 protein level  
In our study of the PRRSV virus-host interaction, we discovered that PRRSV infection of 
MARC-145 cells led to a higher expression level of KPNA6, while the KPNA2 level remained 
unchanged (Fig. 6.1A). To confirm the KPNA6 elevation, we infected MARC-145 cells with two 
PRRSV strains: VR-2385 and VR-2332, at an MOI of 1 and harvested the cells at 24 h post infection 
(hpi). We showed that the virus-infected cells exhibited a 2-fold increase in KPNA6 protein level 
compared to mock-infected cells (Fig. 6.1B). MARC-145 cells are derived from the kidney of an 
African Green monkey, which is not the natural host of PRRSV (28). Pigs are the only host animals for 
PRRSV infection, and the main target cells for PRRSV infection are pulmonary alveolar macrophages 
(PAMs) (46). Thus, we examined KPNA6 level in PAMs after PRRSV infection. The result showed that 
PRRSV VR-2385 infection also induced KPNA6 elevation (Fig. 6.1C).  
To determine if the virus-induced KPNA6 elevation is a dose-dependent response, we infected 
MARC-145 cells with PRRSV VR-2385 at the MOI of 0.1, 1, and 10 and assessed KPNA6 level with 
Western blotting. The result showed that KPNA6 protein levels increased in the PRRSV-infected cells 
in a dose-dependent manner (Fig. 6.1D). Compared with the mock-infected cells, PRRSV infection 





1, and 10, respectively, at 24 hours post infection (hpi). IFA results showed that almost all of the cells 
inoculated at the MOI of 1 and 10 were infected, while majority of the cells inoculated at the MOI of 0.1 
Fig. 1. PRRSV infection induces  
 
Fig. 6.1 PRRSV infection induce  Fig. 6.1 PRRSV infection induces elevation of KPNA6 protein level but has minimal effect on KPNA6 
transcript level. A. KPNA6 protein in PRRSV-infected MARC-145 cells is higher than mock-infected control, 
whereas there is minimal change in KPNA2 level. The cells were infected with PRRSV strain VR-2385 at a 
multiplicity of infection (MOI) of 1 and were harvested at 24 hours post infection (hpi). Western blotting (WB) with 
antibodies against KPNA6, KPNA2, PRRSV nsp2, and GAPDH was done. Relative levels of KPNA6 after 
normalization with GAPDH are shown below the images. B. Elevation of KPNA6 level in MARC-145 cells infected 
with different PRRSV strains. The cells were infected with VR-2385 and VR-2332 at an MOI of 1, incubated for 24 h 
before harvested for WB with antibodies against KPNA6, GAPDH and pig anti-PRRSV serum. C. KPNA6 level 
increased in primary PAM cells infected with PRRSV strain VR-2385 at an MOI of 1. D. The dose-dependent 
increase of KPNA6 protein level by PRRSV. MARC-145 cells were infected with the incremental MOI of PRRSV 
VR-2385 and harvested at 24 hpi. Relative levels of KPNA6 are shown below the images. E. IFA of PRRSV-infected 
cells. The panel of overlay IFA images shows PRRSV-nsp2 in green and nuclear DNA staining with DAPI in blue. 
The bars in the low right of the images denote 10 µm. F. The relative PRRSV RNA level in the MARC-145 cells 
infected with the incremental MOI. The cells were harvested at 24 hpi for RNA isolation and RT-qPCR. Error bars 
represent the standard errors of three repeated experiments. G. The transcript level of KPNA6 remains stable in 





were positive (Fig. 6.1E). The increase of PRRSV RNA level in the infected cells was positively 
correlated to the amount increase of the virus inoculum (Fig. 6.1F).   
Multiple factors, such as enhanced mRNA transcription or translation, or less protein 
degradation, can contribute to elevated KPNA6 expression in virus-infected cells. First, we detected 
KPNA6 transcript level in PRRSV-infected cells. The RT-qPCR analysis suggested KPNA6 mRNA 
levels were similar between PRRSV-infected and control cells (Fig. 6.1G). This result indicates that the 
elevation of KPNA6 protein level was not due to alteration at the transcriptional level. 
The KPNA6 half-life is extended, while its poly-ubiquitination level is reduced in the PRRSV-infected 
cells  
Since the KPNA6 increase in the PRRSV-infected cells was not due to the change of its 
transcriptional level and PRRSV infection stabilized KPNA6, we wondered if the virus infection might 
extend the KPNA6 half-life. To address this question, we infected MARC-145 cells with PRRSV and 
treated the cells with cycloheximide, a protein translation inhibitor, at 24 hpi. The KPNA6 half-life in 
the PRRSV-infected cells was 32 hours, compared to 12 hours in the mock-infected cells (Fig. 6.2A). 
The results suggest that extended KPNA6 half-life may account for its higher levels in viral infections.   
Since KPNA6 half-life was extended by viral infections, we speculated there might be a delay in 
the degradation of KPNA6. As the ubiquitin-proteasome system is involved in the turnover of most 
cellular proteins, we hypothesized that treatment of cells with proteasome inhibitors, like MG132, would 
block KPNA6 degradation. As expected, MG132-treated MARC-145 cells exhibited a higher level of 
KPNA6 than mock-treated cells (Fig. 6.2B). PRRSV infection did not result in an additive effect to 
MG132 treatment in the elevation of KPNA6, or vice versa. Due to its short treatment time (6 hours), 
MG132 did not cause apparent cytotoxicity (Fig. 6.2C) and had a minimal effect on PRRSV replication 
(Fig. 6.2D). These results indicated that the proteasome blocking stabilized KPNA6 to a level similar to 





Based on these results, KPNA6 appeared to be degraded via the ubiquitin-proteasomal pathway. 
KPNA6 poly-ubiquitination level was expected to be down-regulated in PRRSV-infected cells. To 
confirm this, we conducted an immunoprecipitation (IP) assay of KPNA6 from MARC-145 cells in the 
presence or absence of PRRSV infection, followed by immunoblotting with a ubiquitin antibody. The 
Fig. 2. PRRSV extends KPNA6 half-life  
Fig. 6.2 PRRSV extends KPNA6 half-life and reduces KPNA6 poly-ubiquitination. A. PRRSV 
infection extends KPNA6 half-life. MARC-145 cells were infected with VR-2385 at an MOI of 1. The 
cells were treated with cycloheximide at 24 hpi and harvested at the indicated time (h) for WB. Mock-
infected cells at corresponding time points were included as controls. The relative levels of KPNA6 are 
shown below the images. B. MG132 treatment blocks KPNA6 turnover in MARC-145 cells. The cells 
were infected with VR-2385 at an MOI of 1. At 18 hpi, the cells were treated with MG132 and, 6 h later, 
harvested for WB with antibodies against KPNA6 and tubulin. The MG132-negative wells were treated 
with the solvent, DMSO. Mock-infected cells were included as controls. The relative levels of KPNA6 are 
shown below the images after normalization with tubulin. C. The cell viability assay of MARC-145 cells 
treated with MG132 or DMSO and/or infected with PRRSV. D. PRRSV viral RNA level in the cells 
treated with MG132 or DMSO. E. PRRSV infection reduces KPNA6 poly-ubiquitination. MARC-145 cells 
were infected with PRRSV VR-2385 at an MOI of 1 and harvested for IP with KPNA6 antibody at 24 hpi, 
followed by WB with the ubiquitin (Ub) antibody. WB of whole cell lysate (WCL) with the antibodies 
against ubiquitin, KPNA6, PRRSV nsp2, and tubulin was conducted. The relative level of Ub after 





result showed that the KPNA6 ubiquitination level in the PRRSV-infected cells was ten-fold lower than 
that of mock-infected control, whereas there was minimal difference in the total ubiquitination level of 
whole cell lysates from both infected and control cells (Fig. 6.2E). Collectively, the extension of 
KPNA6 half-life through reduction of its ubiquitination may lead to the virus-mediated KPNA6 
upregulation.  
PRRSV nsp12 protein upregulates KPNA6 protein level in cells  
We speculated that some PRRSV proteins were responsible for the KPNA6 elevation in the 
virus-infected cells. To determine the viral proteins, we transfected HEK293 cells with plasmids 
encoding the PRRSV non-structural proteins (nsps) and assessed their effects on the KPNA6 level. WB 
results showed that PRRSV nsp1β, nsp7α, nsp7β, and nsp12 led to a higher KPNA6 level, compared 
with the empty vector, whereas the other PRRSV proteins had less effect (Fig. 6.3A). As nsp12 induced 
the highest elevation of KPNA6, we selected it to further confirm its effect by using a stable HEK293 
cell line expressing nsp12 that was established earlier in the laboratory. WB result showed there was a 
2.1-fold increase in KPNA6 protein level in the nsp12-stable cells compared with the control HEK293 
cells (Fig. 6.3B). In addition, IP assay showed that PRRSV nsp12 also reduced KPNA6 ubiquitination 
(Fig. 6.3C). This suggested that the nsp12 might interfere with the KPNA6 turnover in cells. Yet, no 
physical interaction between KPNA6 and nsp12 was detected in the IP (Fig. 6.3C), implicating that 
mechanisms other than direct protein binding might mediate the effect.  
KPNA6 silencing impairs PRRSV replication  
To determine whether KPNA6, stabilized in the virus-infected cells, could play a positive role in 
viral replication, we generated a KPNA6 shRNA construct for knockdown of KPNA6 expression in 
MARC-145 cells via RNAi silencing. A random shRNA was included as a negative control. Cells were 





the antibiotics G418. WB results showed KPNA6 was reduced to 0.3-fold in the cells with stable 
expression of KPNA6 shRNA, while KPNA1 level had minimal change (Fig. 6.4A). The KPNA6 
knockdown had no detectable effect on the cell viability (Fig. 6.4B). To investigate the effect of the 
KPNA6 knockdown on PRRSV replication, we infected the KPNA6-silenced cells with VR-2385. Viral 
titration assay showed that the KPNA6-silenced cells produced significantly lower virus yield (750-fold 
decrease) compared with control cells (Fig. 6.4C).  
Fig. 3. PRRSV nsp12 induces KPNA6  
 
Fig. 6.3 PRRSV nsp12 induces KPNA6 elevation.  A. Screening of PRRSV nsps to identify the viral 
protein that is responsible for the elevation of KPNA6. Empty vector (EV) was included as a control. After 
36 hours post transfection (hpt), HEK293 cells were harvested for WB. The lower panel of images show the 
bands of PRRSV nsps. The relative levels of KPNA6 protein are shown below the images. Molecular mass 
markers are denoted on left of the images. B. Higher KPNA6 level in the nsp12-stable HEK293 cells than 
the control. The relative level of KPNA6 is shown below the images. C. Lower KPNA6 poly-ubiquitination 
in the HEK293 cells transfected with the nsp12 plasmid. The MG132 treatment was done before the cell 
harvesting. The KPNA6 IP followed by WB with an antibody against ubiquitin (Ub) was done. The relative 
level of Ub is shown below the images. WB of WCL with the antibodies against Ub, KPNA6, PRRSV 





PRRSV nsp1β relies on KPNA6 to translocate into the nucleus  
Although PRRSV replicates in the cytoplasm, some viral proteins including nsp1α, nsp1β, and 
nucleocapsid protein (N) translocate into the nucleus during infection. Nsp1β has been identified to 
restrain host mRNA in the nucleus to inhibit host protein synthesis (388). Nsp1α may inhibit IFN 
promoter activation in the nucleus (114). N protein localizes in the nucleus to affect host nuclear 
processes (156).  
 
To determine if KPNA6 is responsible for the translocation of these viral proteins with nuclear 
localization, we established KPNA6-/- and control HeLa cells and confirmed the deletion of KPNA6 in 
the KPNA6-/- cells (Fig. 6.5A). The KPNA6 knockout had no detectable effect on the cell viability (Fig. 
6.5B). We then transfected the KPNA6-/- and control HeLa cells with plasmids expressing PRRSV 
nsp1α, nsp1β, and N for IFA to determine their subcellular locations. Confocal microscopy results 
showed that KPNA6 knockout blocked the nuclear translocation of PRRSV nsp1β, while there was 
Fig. 4. KPNA6 silencing leads to a lower  
Fig. 6.4 KPNA6 silencing leads to a lower replication of PRRSV.  A. KPNA6 protein level in the 
MARC-1 5 cells stab y tra sfected with KPNA6-shRNA. CT: control shRNA, K6: shRNA against 
KPNA6. The WB of KPNA6, KPNA1, and GAPDH was done. B. The relative viability of the 
shRNA-transfected MARC-145 cells. C. Lower PRRSV yield in the cells with KPNA6 silencing 
than in the control MARC-145 cells (**, P < 0.01). The MARC-145 cells were infected with 





minimal change in subcellular location of the other two proteins tested (Fig. 6.5C). This indicates that 
KPNA6 facilitates nsp1β nuclear translocation and may contribute to optimal virus replication.  
 
Fig. 5. KPNA6-knockout blocks nuclear  
 
Fig. 6.5 KPNA6-knockout blocks nuclear translocation of PRRSV nsp1β, and exogenous KPNA6 
expression restores its nuclear translocation. A. WB of KPNA6 protein in the KPNA6 knockout HeLa 
cells. CTRL: control cells stably transfected with empty vector with Cas9. KPNA6
-/-
: KPNA6-knockout 
HeLa cells. WB of KPNA6, KPNA2, and GAPDH was done. B. Relative cell viability of the KPNA6
-/-
 and 
CTRL HeLa cells. C. Confocal microscopy of the KPNA6
-/-
 and CTRL HeLa cells with transient 
expression of the PRRSV proteins. The cells were transfected with plasmids encoding HA-nsp1α, HA-
nsp1β, and N-YFP proteins. IFA with antibody against HA was done. The overlay IFA images show HA-
nsp1α and HA-nsp1β in red fluorescence, N-YFP in green fluorescence, and nuclear DNA staining with 
DAPI in blue. The bars in the low right of the images denote 10 µm. D. Transient exogenous expression of 
KPNA6 in KPNA6
-/-
 HeLa cells restores the nuclear translocation of PRRSV nsp1β. The cells were 
transfected with Myc-KPNA6 and HA-nsp1β plasmids. Empty vector (EV) was included as a control. IFA 
with antibodies against Myc and HA was done. Overlay of green and blue channels (Overlay (G+B)) are 






To exclude the possibility of off-target effect by sgRNA, we overexpressed KPNA6 and nsp1β 
plasmids into KPNA6-knockout HeLa cells to determine if exogenous restitution of KPNA6 would 
restore the nuclear localization of nsp1β. The results of confocal microscopy showed that restitution of 
KPNA6 restores the nuclear translocation of nsp1β completely (Fig. 6.5D). This result confirms that 
KPNA6 is required for nsp1β nuclear translocation. 
ZIKV infection induces KPNA6 elevation and requires KPNA6 for optimal replication  
PRRSV, a member of +ssRNA virus, replicates in the cytoplasm of infected cells. Nevertheless, 
KPNA6, a karyopherin, is responsible for the nucleocytoplasmic transportation of cellular proteins. To 
further test whether KPNA6 elevation is specific for PRRSV infection, we used another +ssRNA virus 
ZIKV and examined KPNA6 protein level. ZIKV also induced elevation of KPNA6 protein level 
compared to mock-infected cells (Fig. 6.6A). Effective ZIKV infection was confirmed by IFA detection 
of E protein using antibody against the flavivirus envelope protein (E) (Fig. 6.6A). Thus, KPNA6 
induction seems to be a common feature of the two +ssRNA viruses tested. 
To further confirm the role of KPNA6 in ZIKV replication, we established KPNA6-knockout 
Vero cells via CRISPR/Cas9 system. The empty vector containing Cas9 but no target gRNA was also 
used to establish stable Vero cells as controls. WB result showed significant reduction of KPNA6 in the 
stable KPNA6-/- Vero cells (Fig. 6.6B). The KPNA6 knockout had no detectable effect on the cell 
viability (Fig. 6.6C).  To test the effect of the KPNA6 knockout on virus replication, we infected the 
KPNA6-/- Vero and control Vero cells with ZIKV PRVABC59 strain. The KPNA6-/- Vero produced 
significantly lower ZIKV replication than control cells (Fig. 6.6D). These results demonstrate that 
KPNA6 is needed for ZIKV replication. 
Furthermore, we transfected KPNA6-/- Vero cells with KPNA6 plasmid and established stable 
cells for exogenous restitution of KPNA6 expression to exclude the off-target effect of CRISPR/Cas9 





Vero cells (Fig. 6.6E). To determine if the exogenous KPNA6 restitution could restore ZIKV replication 
in the KPNA6-/- Vero cells, we infected the cells with ZIKV PRVABC59 strain and harvested the cells 
at 24 hpi. The parental KPNA6-/- Vero and control cells were included as controls. The result of RT-
qPCR showed that expression of exogenous KPNA6 in the KPNA6-/- Vero cells could restore ZIKV 
replication (Fig. 6.6F). This result substantiates that KPNA6 is required for ZIKV replication.  
Fig. 6. ZIKV infection also increases  
 
Fig. 6.6 ZIKV infection also increases KPNA6 protein level and requires KPNA6 for efficient 
replication. A. KPNA6 increase in ZIKV-infected Vero cells. The cells were infected with ZIKV 
PRVABC59 strain at an MOI of 10 and harvested at 24 hpi. WB with antibodies against KPNA6, ZIKV E 
protein, and GAPDH was conducted. Relative level of KPNA6 is shown below the images. IFA with 
antibody against E protein was conducted. The image on right shows overlay of E in green and nuclear 
DNA staining with DAPI in blue. The bar in the low right of the image denotes 10 µm. B. KPNA6 
protein level in the KPNA6 knockout Vero cells. CTRL: control cells stably transfected with the empty 
vector, KPNA6
-/- 
: KPNA6-knockout Vero cells via CRISPR/Cas9 system. WB of KPNA6, KPNA2, and 
GAPDH was done. C. Relative cell viability of the CTRL and KPNA6
-/- 
Vero cells. D. ZIKV replication 
in the KPNA6
-/- 
Vero cells is significantly lower than that in the CTRL cells detected by RT-qPCR (***, 
P < 0.001). The CTRL and KPNA6
-/-
 Vero cells were infected with ZIKV PRVABC59 strain at an MOI 
of 0.1. RNA was isolated at 24 hpi and RT-qPCR was conducted to detect ZIKV RNA level. E. Stable 
expression of KPNA6 in KPNA6
-/-
 Vero cells restores KPNA6 protein level. F. Stable exogenous KPNA6 
expression in KPNA6
-/- 
Vero cells restores ZIKV replication level. The Vero cells were infected with 






Karyopherins are critical transport factors in canonical nucleocytoplasmic trafficking system, 
which is essential for the signal transduction of the host immune response. Accordingly, karyopherins 
have been found to be targeted by many viruses for an evasion of the host antiviral response, including 
Ebola virus (231, 232), HCV (298), Hepatitis B virus (HBV) (297), Poliovirus (389) and PRRSV (121). 
On the other hand, those viruses including DNA viruses (276), HIV (282) and influenza A virus (289) 
that replicate in the nucleus exploit karyopherins to translocate their proteins or genetic elements into the 
nucleus.  
In this study, we discovered that KPNA6 is required by two cytoplasmic +ssRNA viruses, 
PRRSV and ZIKV, to facilitate their replication. The viruses protected KPNA6 from the ubiquitin-
proteasome degradation. In addition, the KPNA6 knockdown or knockout impairs the viral replication. 
KPNA6 is involved in the nuclear translocation of PRRSV nsp1β. Notably, restitution of KPNA6 
expression in the KPNA6 knockout cells restores the nuclear translocation of PRRSV nsp1β and ZIKV 
replication. These data indicate that KPNA6 is a positive cellular factor for both PRRSV and ZIKV. 
Our data showed that both PRRSV and ZIKV led to the elevation of KPNA6 protein level. The 
KPNA6 transcript level had minimal change in the PRRSV-infected cells.  The KPNA6 elevation was 
dose-dependent on the PRRSV inoculum amount. The half-life of KPNA6 was extended from 12 h in 
the mock-infected cells to 32 h in the PRRSV-infected cells, which is consistent with the time kinetics of 
KPNA6 in the infected cells. The results suggest that the virus infection stabilizes the KPNA6 protein by 
protecting it from the ubiquitin-proteasome degradation. Consistent with this postulation, the MG132 
treatment increased the KPNA6 level. The KPNA6 poly-ubiquitination level in the virus-infected cells 
was significantly lower than mock-infected cells. The MG132 treatment lasted 6 hours in this 





critical role in flavivirus replication, and MG132, added before or soon after virus inoculation, was 
shown to strongly repress flavivirus RNA translation and replication (390).  
Among the PRRSV nsps tested, nsp1β, nsp7α, nsp7β, and nsp12 were found to induce the 
KPNA6 elevation when individually overexpressed. It is not known whether they work synergistically in 
PRRSV-infected cells to exert the effect on KPNA6 elevation. However, none of them is known to have 
a direct effect on the ubiquitin-proteasome pathway. Nsp1β antagonizes the host interferon induction 
and downstream JAK-STAT signaling (139). Nsp1β induces the degradation of KPNA1 to block 
STAT1 nuclear translocation. Interestingly, nsp1β can induce the elevation of KPNA6, a member of the 
same subfamily as KPNA1. The nsp1β dependence on KPNA6 for its nuclear translocation may account 
for the reason for the KPNA6 stabilization. Nsp7 is highly conserved and further cleaved into nsp7α and 
nsp7β, which are known to induce a strong humoral immune response in PRRSV-infected pigs (391). 
Nsp12 is reported to interact with many cellular proteins with high probability in a proteomic study 
(392). Among the cellular proteins, chaperone HSP70 is verified to interact with nsp12 and inhibition of 
HSP70 negatively affects PRRSV replication. Nsp12 induces Serine 727 phosphorylation of STAT1 to 
activate expression of inflammatory cytokines while having no effect on tyrosine 701 phosphorylation 
that is activated by interferons (393). The induction of S727 phosphorylation depends on the p38 
mitogen-activated protein kinase (MAPK) pathway. Our results confirmed that nsp12 induced the 
KPNA6 elevation in nsp12-stable HEK293 cells. Nsp12 might indirectly exert the effect, as no direct 
interaction between nsp12 and KPNA6 was detected in the co-IP. Further study is needed to delineate 
detail mechanisms on the viral interference with the KPNA6 turnover.  
KPNA6 silencing or knockout dramatically inhibits PRRSV and ZIKV replication, 
demonstrating that KPNA6 is required for the viral replication. Expression of exogenous KPNA6 in the 
KPNA6 knockout cells restores ZIKV replication, which substantiates the requirement of KPNA6 in the 





MARC-145 cells, we cannot exclusively exclude the possibility that the reduced PRRSV replication in 
KPNA6 knockdown cells could be in part due to off-target effects. Nevertheless, the restoration of 
ZIKV replication in KPNA6-knockout cells with expression of exogenous KPNA6 clearly demonstrates 
that KPNA6 is required for the viral replication.  PRRSV infection leads to heavy economic losses to the 
swine industry. ZIKV is a significant global public health problem. However, prevention and therapeutic 
strategies against these viral pathogens are either limited or unavailable. Our finding may facilitate the 
development of antiviral strategies by modulating KPNA6 or blocking the interaction of KPNA6 with 
the viral proteins.  
Even though +ssRNA viruses replicate in the cytoplasm, some viral proteins localize to the 
nucleus. Therefore, we speculated that KPNA6 might take charge of nuclear transport of some of the 
viral proteins. Indeed, PRRSV nsp1β was found to depend on KPNA6 for the nuclear translocation. This 
result was substantiated by the restoration of nsp1β nuclear translocation in KPNA6 knockout HeLa 
cells with expression of exogenous KPNA6. Our data suggest that nsp1β nuclear localization is 
important for PRRSV replication. Yet, we did not determine the nsp1β subcellular location in PRRSV-
infected MARC-145 cells with KPNA6 silencing due to lacking nsp1β antibody. However, our result 
does not exclude other potential mechanisms of KPNA6 to enhance the viral replication as for ZIKV, 
the nuclear translocation of ZIKV C and NS5 proteins were not affected by KPNA6 knockout (data not 
shown). Further studies to examine the mechanisms of KPNA6 on the replication of these +ssRNA 
viruses are warranted.  
In addition, elevation of KPNA6 protein level was also found in cells infected by other +ssRNA 
viruses, hepatitis C virus (HCV) and porcine epidemic diarrhea virus (PEDV) (data not shown). HCV, a 
member of the Hepacivirus genus of the Flaviviridae family (394), can cause liver disease upon 
infection, which could lead to cirrhosis and hepatocellular carcinoma; porcine epidemic diarrhea virus 





and highly contagious enteric disease in nursery piglets with the high mortality rate, which has led to 
tremendous economic losses in swine industry (396). Our data suggest that that KPNA6 might be a 
potential broad pro-viral protein for +ssRNA viruses. 
In conclusion, KPNA6 plays an important role in the replication of PRRSV and ZIKV. The virus 
infection protects KPNA6 from degradation via inhibition of KPNA6 poly-ubiquitination. RNAi-
mediated KPNA6 silencing or CRISPR/Cas9-knockout of KPNA6 leads to a significant reduction of 
PRRSV and ZIKV replication. KPNA6 is required for the nuclear translocation of PRRSV nsp1β. 
Notably, expression of exogenous KPNA6 in the KPNA6 knockout cells restores nsp1β nuclear 
translocation and ZIKV replication. These results suggest that KPNA6 is required for PRRSV and 
ZIKV, which modulate the KPNA6 turnover to facilitate the virus replication. This finding provides new 
insights on virus-cell interactions and may facilitate the development of antiviral therapeutics by 
blocking the viral manipulation of the cellular transport factor. 
 
Table 6.1 List of primers in Chapter 6  
Primera Sequences (5’ to 3’)b Target gene/use 
KPNA6F1 CCGAATTCGAGACCATGGCGAGCCCAGGG KPNA6 cloning 
KPNA6R1 GCCTCGAGTTATAGCTGGAAGCCCTCC KPNA6 cloning 
R-KPNA6-F1 GGAAGCCTATGGCTTGGATA KPNA6 real-time 
R-KPNA6-R1 CTGTTGCGTTTCATCGACTT KPNA6 real-time 
P7RF1 ATCGCTCACCAAAACCAGTCC PRRSV real-time 















CACCGAAGAGTGGTGGATCGGTTCG KPNA6 sgRNA 
KPNA6-
gRNA-p2tR 
AAACCGAACCGATCCACCACTCTTC KPNA6 sgRNA 
KPNA6-
gRNA-p2bF 







AAACATAGATGAAGTTATCAACAC KPNA6 sgRNA 
a. F: forward primer, R: reverse primer.  






Chapter 7: Conclusions and perspectives  
Since first reported in 1987, PRRS has been remaining one of the top challenges for swine 
industry across the world. The PRRSV infection is featured by prolonged viremia, persistent infection, 
and induction of weak protective immune response, which results in high PRRSV prevalence and big 
challenges for PRRS control. One of the possible reasons for the weak protective immune response is 
that PRRSV interferes with the innate immunity and cytokine signaling, including the JAK-STAT 
pathways. PRRSV inhibits IFN-activated JAK-STAT signaling by blocking the nuclear translocation of 
STAT1 and STAT2. In this dissertation research, PRRSV was found to antagonize JAK-STAT2 and 
JAK-STAT3 signaling and manipulate KPNA6 for viral replication.  The mechanisms of these 
interferences of cellular signaling have been characterized.  
In addition to the canonical IFN signaling, STAT2 is involved in non-canonical STAT1-
independent IFN signaling. In this alternative pathway, STAT2 interacts with IRF9 and other STAT 
proteins, but not STAT1, to form ISGF3-like complex, followed by driving a prolonged antiviral 
response. The PRRSV inhibition of this signaling is described in Chapter 4. PRRSV infection of 
MARC-145 cells and primary PAMs leads to significant reduction of STAT2 protein, whereas it has 
minimal effect on STAT1 protein level. Several strains of both genera of PRRSV induce a similar 
reduction of STAT2 protein level but have no effect on its transcript level. The STAT2 reduction is via 
ubiquitin-proteasome pathway as treatment of the PRRSV-infected cells with MG132, a proteasomal 
inhibitor, restores the STAT2 protein level. Notably, PRRSV nsp11 is responsible for STAT2 reduction 
through interaction. The aa 57-59 residues in nsp11 are critical for the interaction with and 
downregulation of STAT2. These results demonstrate that nsp11 might promote or provide a platform 
for the interaction between STAT2 and its ubiquitin E3 ligase. Further study will interrogate the E3 





perturbation of STAT1-independent IFN signaling, but also reveals another function of nsp11 in 
addition to its endoribonuclease activity.   
Among all the STAT proteins, STAT3 is known as highly pleiotropic in mediating the 
expression of a variety of genes in response to both cytokines and growth factors, and thus plays a 
pivotal role in numerous cellular processes including cell survival, proliferation, embryogenesis, and 
immune responses (202, 397). In this study, OSM, a member of the IL-6 family activating the JAK-
STAT3 signaling, has been found to inhibit PRRSV replication. To overcome the inhibition, PRRSV 
uses a strategy to reduce STAT3 protein level, which is described in Chapter 5. PRRSV induces STAT3 
reduction by increasing its polyubiquitination level and shortening its half-life. The hydrophobic 
transmembrane protein nsp5 is responsible for the STAT3 reduction. As a result, nsp5 inhibits the OSM-
activated STAT3 signaling. No direct interaction between nsp5 and STAT3 is found, which suggests 
that nsp5 might activate an E3 ligase of STAT3. Further study is needed to reveal the mechanism of the 
STAT3 degradation. Inhibition of the STAT3 signaling by PRRSV can lead to inhibition of a broad 
spectrum of cytokines and growth factors to thwart host antiviral responses and allow virus replication 
and spread in vivo. 
For JAK-STAT signaling, nuclear importins play indispensable roles in transporting the 
activated STAT complexes into the nucleus to activate the transcription and expression of downstream 
genes. KPNA1 and KPNA6 have been found to be mainly responsible for the translocation of STAT1/2 
and STAT3, respectively. PRRSV interrupts the nuclear import of STAT1/2 complex to prevent IFN 
signaling through nsp1β inducing KPNA1 degradation. However, we unexpectedly discovered that 
PRRSV could elevate KPNA6 protein level, elaborated in Chapter 6. PRRSV protects KPNA6 from 
degradation by blocking its poly-ubiquitination via nsp12. KPNA6 silencing suppresses PRRSV 
replication through blocking the nuclear translocation of nsp1β, which is a strong IFN antagonist. On the 





detrimental to ZIKV replication. These results indicate that KPNA6 is critical for the replication of 
PRRSV and ZIKV. However, the mechanism of KPNA6 required for ZIKV replication remains 
unknown.  
In this dissertation study, the mechanisms of PRRSV interference with STAT2 and STAT3 
signaling and manipulation of KPNA6 for viral replication have been elucidated. PRRSV nsp11, nsp5 
and nsp12 are responsible for STAT2 degradation, STAT3 reduction, and KPNA6 elevation, 
respectively. The critical amino acids of nsp11 for STAT2 reduction have been identified. Yet, the 
crucial amino acids of nsp5 and nsp12 for the observed effects in this study remain unknown. The 
identification of these key amino acid residues may be future research direction. Once these residues are 
identified, PRRSV infectious cDNA clone can be mutated in these residues for further functional study 
of these proteins in the context of whole virus infection and vaccine development to minimize the 
interference with the host cellular signaling and improve protective immune response. Moreover, any 
other PRRSV proteins interfering with host immune signaling may be considered for inclusion in the 
mutant infectious clone construction. Under this circumstance, one PRRSV strain with minimized 
capacity to antagonize host immune system might be recovered and will greatly facilitate the 
development of an improved vaccine against PRRS. A caveat is that mutation of multiple critical 
residues might be detrimental to the PRRSV viability and virus recovery might fail or, if successful, the 
recovered virus might have low titer due to poor replication. One possible alternative is generation of 
multiple clones with each carrying a limited number of mutations to avoid the detrimental effects and 
mix the recovered virus for vaccine application.  
On the other hand, this study reveals the role of KPNA6 in PRRSV and ZIKV replication. In 
addition, HCV and porcine epidemic diarrhea virus (PEDV) also induce KPNA6 elevation, and 
poliovirus replication is impaired by KPNA6 knockout. These results indicate that these +ssRNA 





mechanisms of the KPNA6 contribution to the viral replication. Several aspects can be investigated: 
KPNA6 subcellular location, KPNA6 functional domain, viral proteins interacting with KPNA6, and 
roles of other KPNAs in the viral replication of these +ssRNA viruses. These studies will provide much 
more insights into +ssRNA virus–host interactions, and facilitate the development of unique antiviral 
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